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1. IMPORTANCE OF LIPOPOLYSACCHARIDE IN BOVINE VETERINARY MEDICINE 
Lipopolysaccharide (LPS) is a structural part of the outer membrane of Gram-negative 
bacteria that is prerequisite for bacterial viability. The outer membrane acts as a protective 
barrier for the bacterium, with LPS contributing to this function. More specifically, 
phosphate diester bridges in the LPS-backbone are important in forming a cell surface 
structure, resistant to the penetration of harmful components such as penicillins (Tamaki et 
al., 1971). In an animal host, LPS is not toxic when incorporated in the cell wall of the 
microorganism. However, during bacterial proliferation or cell death with subsequent lysis, 
LPS is released from the outer membrane. As a result, its toxic moiety, lipid A, induces an 
inflammatory response through activation of the innate immune system (Van Amersfoort et 
al., 2003). From this point of view, the lipid A component of LPS is also referred to as 
endotoxin (Raetz and Whitfield, 2002). The innate immune system forms the first line of 
defence against microbial pathogens, with particularly blood monocytes, tissue 
macrophages and polymorphonuclear leukocytes contributing to this non-specific immune 
reaction (Miyake, 2004). 
In bovine veterinary medicine, LPS is responsible for important clinical entities, 
including endotoxemia and Gram-negative sepsis (Cullor, 1992; Olson et al., 1995). 
Endotoxemia refers to the presence of LPS in the circulation, whereas sepsis is defined as a 
combination of an infection and a systemic inflammatory response. With respect to sepsis, 
the infection source can be focal or generalized (Fecteau et al., 2009). Particularly in calves, 
Gram-negative bacteria play a crucial role in the most frequent and economically important 
calf diseases, namely neonatal diarrhea and bovine respiratory disease (Michaels and Banks, 
1988; Pardon et al., 2012b). In this respect, Escherichia coli, Mannheimia haemolytica and 
Pasteurella multocida are the most frequently involved pathogens (Confer et al., 1990; 
Constable, 2004; Harper et al., 2011). Also in septicemia, which continues to be a life-
threatening condition with high mortality risks – especially in calves with failure of passive 
transfer – the vast majority of isolates is Gram-negative (Fecteau et al., 2009). The former 
pathologies are responsible for the majority of deaths in live-born neonatal calves < 1 month 
of age, which have been reported to have a mortality risk of 15-30% (Lofstedt et al., 1999). 
Additionally, the prevalence and incidence risk for neonatal calf diarrhea has recently been 
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reported to be 19.1% and 21.2%, respectively (Bartels et al., 2010; Windeyer et al., 2014). 
The prevalence for bovine respiratory disease, on the other hand, depends on the 
production system, with particularly high incidences in white veal calves: 60% in the first 
three weeks after arrival at the farm (mean age at arrival: 17.4 ± 4.7 days) (Pardon et al., 
2012b; Pardon et al., 2015). Also in cows, approximately 40% of the clinical cases of mastitis 
are caused by Gram-negative bacteria, including E. coli, Klebsiella pneumoniae and various 
species of Enterobacter. From those cows with severe Gram-negative mastitis, nearly 25% 
will either die or be culled due to complications (Bannerman et al., 2003). Furthermore, LPS 
has been linked to infertility and subfertility, resulting from clinical or subclinical 
endometritis. This association can be attributed to the involvement of Gram-negative 
bacteria, including E. coli, in the pathogenesis of endometritis on the one hand, and to 
hormonal alterations induced by LPS on the other hand (Sheldon et al., 2009). Endotoxin can 
also induce pathophysiologic responses, irrespectively of systemic bacterial infections. 
Accordingly, large amounts of LPS, derived from the Gram-negative bacterial flora, can enter 
the blood stream through the intestine when the latter is compromised by ischemia or 
inflammation. This translocation can subsequently induce endotoxemia (Werling et al., 
1996). Additionally, systemic exposure to LPS has been associated with the development of 
non-infectious diseases, including laminitis and displaced abomasum (Andersen, 2003).  
The pathogenesis of Gram-negative bacterial infections is generally a fast process. In 
this respect, it should be remarked that, in contrast to bacterial exotoxins being toxic by 
killing host cells, the toxicity of LPS is mainly the consequence of the host’s reaction to LPS 
(Rietschel et al., 1994; Steiger et al., 1999). If the animal does not overcome the infection 
early in the disease process, the outcome may not be altered substantially by treatments 
applied too late in the process (Cullor, 1992). The latter can be attributed to the fast 
development of the inflammatory response (within hours) on the one hand, and the late 
recognition by farmers on the other hand.  
The former outlines the extensive involvement of this Gram-negative bacterial cell wall 
component in bovine veterinary medicine, and particularly in calves. In order to reduce 
morbidity and mortality, knowledge on the pathophysiologic changes induced by LPS is 
imperative.   
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2. LIPOPOLYSACCHARIDE SIGNALING  
2.1 CHEMICAL STRUCTURE OF LIPOPOLYSACCHARIDE 
Gram-negative bacteria typically contain a thin peptidoglycan cell wall, which itself is 
surrounded by an outer membrane (Fig. 1). LPS is the dominating component of this outer 
membrane, consisting of a hydrophilic heteropolysaccharide and the covalently bound toxic 
lipid A moiety (Rietschel et al., 1993) (Fig. 2). With respect to Enterobacteriaceae such as E. 
coli, the heteropolysaccharide component comprises two regions which differ in their 
genetic determination, biosynthetic pathways and chemical structure: the O-antigen and the 
core region. Additionally, the core segment can be formally subdivided into an outer and an 
inner portion (Rietschel et al., 1994). The lipid A domain anchors the LPS molecule to the 
outer membrane, whereas the O-antigen is exposed on the outer surface of the bacterium 
(Trent et al., 2006). 
 
Figure 1. Gram negative cell wall structure (adapted from Dahl, 2008) 
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Figure 2. Molecular structure of the LPS molecule  
(adapted from Maeshima and Fernandez, 2013) 
 
Among different bacterial strains, the LPS molecule exhibits a large variability, which 
can be attributed to the composition of the core region and the O-antigen. Particularly the 
latter shows a remarkable structural diversity, as more than 60 monosaccharides and 30 
different noncarbohydrate components have been recognized (Raetz and Whitfield, 2002). 
The lipid A moiety, on the other hand, is a highly conserved pattern among Gram-negative 
bacteria. In this respect, the host’s LPS receptors are targeted against the lipid A domain, 
whereas the O-antigen on the surface defines the serological specificity of the bacterium 
(Rietschel et al., 1994; Jerala, 2007). 
 
 
 
GENERAL INTRODUCTION 
 
 
11 
 
2.2. INNATE RECOGNITION OF LIPOPOLYSACCHARIDE 
The release of LPS from the bacterial surface results in the activation of the innate 
immune response, including blood monocytes, tissue macrophages and polymorphonuclear 
leukocytes (Miyake, 2004). The receptor that is responsible for delivering an LPS signal and 
that is expressed on the surface of these innate immune cells, has been identified as Toll-like 
receptor 4 (TLR4). In this context, three cooperating extracellular molecules are involved in 
the extracellular recognition of LPS: LPS-binding protein (LBP), cluster of differentiation 14 
(CD14) and myeloid differentiation protein (MD)-2. These proteins chaperone the LPS-
molecule from the bacterial membrane to the transmembranar TLR4 (Jerala, 2007) (Fig. 3). 
Briefly, the LBP first binds to the lipid A moiety of LPS. LBP then catalyses the transfer to 
either membrane-associated CD14 (mCD14), which is present on cells of the innate immune 
system, or to circulating soluble CD14 (sCD14). Subsequently, CD14 translocates LPS to MD-
2, an extracellular molecule that is associated with TLR4. The latter binding leads to the 
recruitment of adaptor proteins to the intracellular domain of TLR4, in this way triggering 
the intracellular signaling cascade (Miyake, 2004; Peri et al., 2010).  
 
2.3. INTRACELLULAR SIGNALING PATHWAY 
The intracellular signaling ultimately results in the activation of nuclear factor-κB (NF-
κB). NF-κB is the generic name of a family of transcription factors that regulate the 
expression of a large number of genes involved in immune and inflammatory processes. NF-
κB transcription factors are activated in response to various stimuli, including LPS. In this 
respect, two pathways are involved in TLR4 signaling: an early myeloid differentiation factor 
88 (MyD88)-dependent (Fig. 3) and a delayed MyD88-independent pathway. The first was 
shown to be responsible for pro-inflammatory cytokine expression, whereas the latter is 
rather linked to the induction of type I interferons (Lu et al., 2008; Verstrepen et al., 2008). 
Overall, these inflammatory mediators activate an assortment of inflammatory cascades, 
intending to control the Gram-negative bacterial infection. This predetermined and well-
orchestrated sequence of processes is referred to as the acute-phase response (Baumann 
and Gauldie, 1994; Wyns et al., 2015b).  
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Figure 3. Schematic overview of MyD88-dependent TLR4 activation  
(adapted from Brookes et al., 2009) 
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3. LIPOPOLYSACCHARIDE-INDUCED INFLAMMATION IN CATTLE 
The intravenous (IV) administration of purified standard reference LPS has been shown 
to induce an acute systemic inflammatory response, which in part corresponds to Gram-
negative sepsis. In this respect, the suitability of experimental endotoxemia models to study 
the pathophysiology of sepsis and septic shock has been suggested decades ago (Hoffman 
and Natanson, 1993; Remick and Ward, 2005; Andreasen et al., 2008). These models indeed 
provide several advantages regarding standardization and reproducibility. Nevertheless, 
counter-arguments are being reported as well, due to the lack of an infectious focus and a 
sepsis-induced immune reaction following an IV LPS challenge (Redl et al., 1993; Olson et al., 
1995; Remick and Ward, 2005). Despite this questioning, endotoxemia models have been 
confirmed to represent an adequate tool for understanding inflammatory processes and 
correlated non-specific symptoms (Poli-de-Figueiredo et al., 2008).  
Following an IV endotoxin challenge in cattle, LPS is cleared from the plasma within 15 
minutes (van Deventer et al., 1990; Redl et al., 1993; Ohtsuka et al., 1997a). As a result of 
the rapid response of the innate immune system, pro-inflammatory cytokines, such as tumor 
necrosis factor (TNF)-α, interleukin (IL)-1 and IL-6, and other inflammatory mediators, 
including prostaglandins (PGs) are released from cells of the monocytic lineage. These 
mediators subsequently trigger the acute-phase response, which is characterized by 
leukocyte activation, mobilization of phagocytes, altered plasma concentrations of zinc, iron, 
calcium and copper and the synthesis of acute-phase proteins by hepatocytes. Major acute-
phase proteins in cattle are serum amyloid A (SAA) and haptoglobin (Hp). Clinically, on the 
other hand, the acute-phase response is recognized by fever, tachycardia and behavioural 
changes such as depression, anorexia and hyperalgesia (Canning and Baker, 1990; 
Alsemgeest et al., 1994; Watkins et al., 1994; Van Miert, 1995; Paape et al., 2002; Borderas 
et al., 2008; Eckersall and Bell, 2010; Zebeli et al., 2010). In general, the acute-phase 
response is regarded to be beneficial, as it is important for providing protection to the 
animal, as well as to return the organism to normal function (Baumann and Gauldie, 1994; 
Carroll et al., 2009b). Nevertheless, when the reaction becomes dysregulated or excessive, it 
can result in life-threatening syndromes, such as sepsis and septic shock (Lillie, 1974; Peri et 
al., 2010). 
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Cattle, and in particular calves, have been shown to be extremely sensitive to LPS in 
comparison with other animal species (Michaels and Banks, 1988). In this respect, a study of 
Berczi et al. (1966) revealed a lethal dose of 0.025 mg/kg body weight (BW) of LPS (O78 E. 
coli strain) for calves following intraperitoneal (IP) administration, whereas for rabbits, dogs, 
swine and chickens, lethal doses of 3.0, 4.0, 5.0 and 50 mg/kg BW, respectively, were 
reported. Humans, on the other hand, are even more sensitive to endotoxin as a dose of 2-4 
ng/kg BW can be used to study the pathophysiology of sepsis (Suffredini et al., 1989). 
Additionally, doses as low as 0.06-0.2 ng/kg have been demonstrated to induce low-grade 
inflammation in humans (Starkie et al., 2003). 
 
3.1. IN VIVO BOVINE LIPOPOLYSACCHARIDE INFLAMMATION MODELS 
In order to study the bovine acute-phase response, various experimental designs have 
been reported in cattle. Overall, E. coli LPS is the most frequently applied type of endotoxin 
with respect to the induction of an inflammatory response. Table 1 provides a chronological 
overview of bovine E. coli LPS inflammation models, which were used to study the responses 
of cytokines and/or acute-phase proteins. As can be observed from this table, the IV 
administration of endotoxin is clearly the most common route of administration. 
Additionally, the selected E. coli serotype, dose, duration of administration and the 
techniques used for the determination of inflammatory mediators are included. Both the 
O55:B5 and O111:B4 serotypes are frequently applied in 61 and 33% of the studies, 
respectively. Particularly the earlier studies used the O55:B5 serotype, whereas the O111:B4 
serotype was selected more frequently in recent experiments. This evolution might be 
correlated with the not strictly reproducible inflammatory response following challenges 
using the O55:B5 serotype. Doses of LPS range from 0.01 to 25 µg/kg BW and 0.1 to 2.5 
µg/kg BW for the O55:B5 and O111:B4 serotype, respectively. Regarding the duration of 
administration, single LPS bolus doses and continuous infusions can be distinguished. 
Although it seems plausible that an infusion would mimic a clinical endotoxemia more 
closely, Carroll et al. (2009b) reported that this difference is rather theoretical than practical 
(Olson et al., 1995). This can be concluded from the study of Gerros et al. (1993) as well, 
since both an IV LPS bolus and an IV infusion resulted in the same sequence of mediator 
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release. The latter authors revealed that the duration and magnitude of the inflammatory 
response, on the other hand, can be related to the dose of endotoxin. Earlier studies 
generally used bioassays for analysis of mediators, whereas enzyme-linked immunosorbent 
assays (ELISAs) are currently regarded to be the gold standard (Elshal and McCoy, 2006). In 
this respect, ELISAs measure both free and receptor-bound cytokines, while bioassays only 
determine biologically active cytokines (Myers et al., 1999). Based on the advantages of 
multiplex flow cytometry assays, such techniques for the simultaneous detection of multiple 
inflammatory mediators are gaining popularity. More specifically, these techniques reduce 
the required sample volume and analysis time, and concurrently provide a wider dynamic 
range (Wyns et al., 2013). 
Regarding the research of Gram-negative mastitis in cows, the intramammary injection 
of E. coli LPS is a frequently applied method (Bannerman et al., 2003; Lehtolainen et al., 
2004; Vels et al., 2009). However, as this type of experiments diverges too much from 
systemic IV LPS challenges and were not the subject of this doctoral thesis, these studies 
were not included in Table 1.  
With respect to other types of LPS than E. coli, information is much more limited. The 
IV administration of endotoxin from a field isolate of P. multocida B:2 has been studied in 
buffalo calves by Horadagoda et al. (2002). This challenge resulted in peak values of TNF-α at 
1-2 h post LPS challenge (p.c.), as well as an increase of Hp concentrations. Additionally, 
Kwon et al. (2011) reported increased levels of Hp following the subcutaneous (SC) 
administration of Salmonella typhimurium LPS in 56-days-old calves.  
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Table 1. In vivo Escherichia coli LPS inflammation models in calves with respect to cytokines and acute-phase proteins. 
LPS Animals 
Time to maximal cytokine levels 
(h p.c.) 
Acute-phase proteins (APP) 
Technique for 
cytokine/APP analysis 
Reference 
Serotype 
Dose (µg/kg BW) 
(duration of infusion) 
N° Age (d) BW (kg) TNF-α IL-1β IL-6 SAA Hp 
Intravenous LPS administration 
O55:B5 
1.5 (0.5 h) 
0.5 (2.5 h) 
4 2-4 40.4-48.6 1-2 - - - - Bioassay Adams et al., 1990 
O55:B5 0.5 2 14-21 45-60 1-2 - - - - Radioimmunoassay Peel et al., 1990 
O55:B5 1.0 4* 100 90 2  - - - - Radioimmunoassay Kenison et al., 1991 
O55:B5 
Bolus: 
0.2; 2.0 or 20 
Infusion (0.83 h):  
0.2; 2.0 or 20  
25* 1 43.0 ± 6.1 1-1.5 3-3.5 - - - Bioassay Gerros et al., 1993 
O55:B5 
1.5 µg/kg/h (0.5 h) 
1 µg/kg/h (2.5 h) 
6* 1 32.7-53 2 - - - - Bioassay Semrad et al., 1993 
O55:B5 5 (0.17 h) 6* 7-8 46.5 1 - - - - Radioimmunoassay Kinsbergen et al., 1994 
O111:B4 2 (1.67 h) 6* - 346 ± 19 0.4-0.8 
Biphasic: 
0.67 / 5 
Biphasic: 
2 / 5.5 
Increase NI 
Bioassay/SAA: ELISA; 
Hp: Hb binding assay 
Werling et al., 1996 
O55:B5 25 5* - 60-180 1 - - - - Bioassay Ohtsuka et al., 1997a 
O26:B6 25 7* - 550-800 2 2 - - - Bioassay Ohtsuka et al., 1997b 
O111:B4 0.1 8 22 ± 2 46.7 ± 6.3 2 - - - - Bioassay Bieniek et al., 1998 
O111:B4 2 (1.67 h) 6* - 311 ± 5.1 1.5-2 - - - - Bioassay Steiger et al., 1999 
O55:B5 0.01; 0.1; 1 8 - 603 ± 59 - - - Increase Increase ELISA Jacobsen et al., 2004 
O55:B5 0.2 12 120-150 - 1 - - Increase Increase 
Radioimmunoassay/ 
ELISA 
Elsasser et al., 2005 
O55:B5 0.25 8 - 328 ± 6 1 - - Increase Increase 
Radioimmunoassay/ 
ELISA 
Kahl and Elsasser, 2006 
O55:B5 0.05 30 14 - 2 - - - Increase ELISA/ELISA Kushibiki et al., 2008 
O111:B4 1 18 - 233 ± 5 1.5 4.5-5 4-4.5 - NI ELISA/Hb binding assay Carroll et al., 2009a 
O111:B4 2.5 9 - 299 ± 5 1.4 3.0 4.3 Increase - ELISA/ELISA Carroll et al., 2009b 
O111:B4 0.5 21 - 310 1.5 - 3.5-4 - - ELISA Carroll et al., 2013 
Subcutaneous LPS administration 
O111:B4 4 42 9 ± 1 - - - - - Increase Hb binding assay Ballou, 2012 
BW: body weight; d: days; h p.c.: hours post LPS challenge; SAA: serum amyloid A; Hp: haptoglobin; Hb: haemoglobin; NI: no increase; -: not investigated; * studies including negative control 
calves (saline) 
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3.2. LIPOPOLYSACCHARIDE-INDUCED ACUTE-PHASE RESPONSE 
3.2.1. Inflammatory mediators  
As mentioned before, the acute-phase response is initiated by the release of several 
inflammatory mediators. Firstly, cytokines are characterized by functional pleiotropy and 
redundancy, which complicates the understanding of their hierarchal actions (Baumann and 
Gauldie, 1994). TNF-α has been put forward to be the principal mediator of acute 
inflammation in response to Gram-negative bacteria (Conti et al., 2004). As a result, this 
cytokine is the most frequently studied inflammatory mediator following endotoxin 
challenges. Table 1 demonstrates that this is also the case in cattle in in vivo E. coli LPS 
inflammation models. Peak levels of TNF-α were determined in all studies before 2 h p.c. 
Regarding the two related proteins IL-1α and IL-1β, only changes of IL-1β were reported. 
Nevertheless, analysis of IL-1β and IL-6 was performed less frequently, and maximal levels of 
these cytokines were recorded 1-4 h after the peak of TNF-α in all experiments. It should be 
mentioned, however, that different analytical techniques for cytokine determination may 
yield different results (bioassays/ELISAs).  
In addition to cytokines, eicosanoids such as prostaglandins, thromboxanes (TXs) and 
leukotrienes contribute to the acute-phase response. These lipid mediators are synthetized 
de novo from membrane phospholipids in response to trauma or inflammatory stimuli like 
LPS (Fig. 4). In this respect, a cascade of enzymes is involved, with phospholipase A2 (PLA2) 
coordinating the initial step: the release of arachidonic acid from membrane phospholipids 
(Henderson, 1994). Moreover, the upregulation of TLR4 has been demonstrated to lead to 
an excessive production of PLA2 (Jiang et al., 2003). Released arachidonic acid is the common 
precursor molecule of all eicosanoids, and is subsequently converted to prostaglandins and 
thromboxanes by the cyclooxygenase (COX) pathway and to leukotrienes by the 5-
lipoxygenase (LOX) pathway (Henderson, 1994). 
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Figure 4. The arachidonic acid pathway (based on Adams, 2001) 
  
All mentioned pro-inflammatory cytokines contribute to the induction of the hepatic 
synthesis of acute-phase proteins. Still, IL-6 has been reported to be the major mediator, in 
cooperation with glucocorticoids (Le and Vilcek, 1989; Gabay and Kushner, 1999; Petersen et 
al., 2004). Several review articles have gathered the current knowledge on these 
inflammatory parameters in cattle (Petersen et al., 2004; Gruys et al., 2005; Eckersall and 
Bell, 2010; Ceciliani et al., 2012). The general functions of acute-phase proteins include the 
elimination of pathogenic agents, tissue repair and restoring homeostasis (Ceciliani et al., 
2002). Depending on their respective increased or decreased plasma concentrations 
following an inflammatory response, acute-phase proteins are divided in positive and 
negative acute-phase proteins (Gabay and Kushner, 1999). As mentioned before, the major 
positive bovine acute-phase proteins are SAA and Hp (Ceciliani et al., 2012). Plasma 
concentrations of these proteins generally increase 10-100 fold during an acute phase 
response (Cray et al., 2009). The biological functions of SAA are far from elucidated. The 
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currently confirmed functions of this acute-phase protein include the transport of 
cholesterol from dying cells to hepatocytes and mediation of the migration, adhesion and 
tissue infiltration of monocytes and neutrophils (Badolato et al., 1994; Manley et al., 2006). 
Furthermore, SAA is an innate immune opsonin for Gram-negative bacteria and it has anti-
inflammatory properties, for instance through inhibition of the respiratory burst of 
leukocytes (Linke et al., 1991; Shah et al., 2006). The primary function of Hp covers the 
prevention of loss of iron through the formation of very stable complexes with free 
haemoglobin in the blood. In this way, Hp exerts a bacteriostatic effect by restricting the 
availability of iron for growing bacteria (Petersen et al., 2004). Similarly to SAA, Hp possesses 
anti-inflammatory capabilities, such as the inhibition of neutrophil respiratory burst activity, 
granulocyte chemotaxis and phagocytosis (Rossbacher et al., 1999). In contrast to the 
determination of pro-inflammatory cytokines following the IV administration of LPS in cattle, 
acute-phase proteins were not included in the majority of papers (Table 1). Nevertheless, 
both SAA and Hp plasma concentrations have been reported to increase. SAA levels 
increased significantly in all involved studies, whereas Werling et al. (1996) and Carroll et al. 
(2009a) detected no alterations in Hp levels. The latter may be explained by the limited 
sampling period (up to 6 and 8 h p.c., respectively), while maximal levels of acute-phase 
proteins are typically reached 24-48 h p.c. (Jacobsen et al., 2004; Kushibiki et al., 2008). 
Moderate positive acute phase proteins in cattle (≤ 10 fold increase) are α1-acid 
glycoprotein, LBP and fibrinogen (Cray et al., 2009; Ceciliani et al., 2012). Due to their rather 
subtle increases during an inflammatory response, it is advisable to combine the results of 
these moderate acute phase proteins with other parameters, including other (major) acute 
phase proteins and total leukocyte counts, in order to optimize the accuracy of the diagnosis 
(Ganheim et al., 2007). 
In response to the release of inflammatory mediators, a well-orchestrated series of 
clincial reactions is initiated (Fig. 5). In the following sections, these acute-phase response-
related clinical signs in cattle are illustrated more into detail: the pulmonary response, 
behavioural changes, fever and tachycardia. Additionally, the blood biochemical responses 
will be discussed briefly. 
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Figure 5. Overview of the release of inflammatory mediators and the induced clinical signs 
following an intravenous E. coli LPS challenge 
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3.2.2. Clinical signs 
3.2.2.1. Pulmonary response 
The lung has been described to be the target organ for endotoxin in cattle (Tikoff et al., 
1966). This finding can be related to the first clinical sign following an IV LPS challenge, being 
the occurrence of severe pulmonary distress. The latter is characterized by dyspnea, 
coughing and abnormal breathing sounds like stridor and stertor. These symptoms generally 
occur within 30 min p.c. (Kenison et al., 1991; Bieniek et al., 1998; Jacobsen et al., 2004). 
Nevertheless, higher doses of LPS seem to result in a faster appearance of respiratory 
distress (Tikoff et al., 1966; Ohtsuka et al., 1997b). In this respect, a direct toxic effect of LPS 
to bovine pulmonary endothelial cells can be hypothesized. Such an effect was previously 
confirmed for M. haemolytica endotoxin in an in vitro study (Paulsen et al., 1989). 
Additionally, pulmonary intravascular macrophages (PIMs), which are constitutively present 
in cattle, have been reported to be responsible for eliminating blood-borne toxins, including 
endotoxin (Winkler, 1988). The clearance of LPS by PIMs, however, results in the excessive 
release of eicosanoids. These mediators, and particularly TXA2, are regarded to play a role in 
the early hemodynamic effects of endotoxin, including a sharp rise in pulmonary arterial 
pressure (Tikoff et al., 1966; Olson and Brown, 1986). They are also involved in the increased 
pulmonary vascular resistance and decreased dynamic lung compliance, which coincide with 
the rise in pulmonary arterial pressure and contribute to the development of dyspnea 
(Esbenshade et al., 1982; Olson and Brown, 1986). Indeed, the presence of LPS in cytoplasm 
of PIMs was confirmed as soon as 8-10 min after the IV administration of 1 µg/kg BW E. coli 
LPS in sheep, with simultaneous development of pulmonary interstitial oedema (Singh and 
Atwal, 1997).  
 
3.2.2.2. Behavioural changes 
Following an LPS challenge, general depression and anorexia can be recognized in cattle 
(Borderas et al., 2008). Particularly IL-1β and TNF-α have been put forward with respect to 
these behavioural changes, due to depression of the central nervous system. As these 
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peripherally released cytokines cannot pass the blood-brain barrier passively, their actions 
on the brain involve two pathways: a fast neural transmission pathway through afferent 
nerves from the site of inflammation and a slower humoral transmission pathway which 
involves cytokine production in the choroid plexus and circumventricular organs, where the 
blood-brain barrier is deficient. Brain cytokines subsequently diffuse into the brain 
parenchyma by volume transmission, activating neurons and neural pathways relevant for 
expression of sickness behaviour (Konsman et al., 1999; Johnson, 2002; Dantzer, 2009). In 
both pathways, these cytokine actions can be mediated by prostaglandins, which are 
synthetized by endothelial cells of brain venules in response to circulating cytokines 
(Engblom et al., 2002).  
The systemic or central administration of IL-1β or TNF-α to rats and mice has been 
shown to induce the full spectrum of behavioural signs of sickness (depressed locomotor 
activity, decreased exploration of the physical and social environment, reduced food and 
water intake and impaired learning and memory), whereas IL-6 exerts no behavioural effects 
(Dantzer, 2001). Nevertheless, IL-6 potentiates the behaviourally depressing effects of IL-1β 
(Lenczowski et al., 1999). Particularly brain IL-1β has been reported to be potent at reducing 
appetite in mice (Layé et al., 2000). Most bovine studies indeed report a decrease in food 
intake following experimental endotoxemia, although it has been reported to be a dose-
dependent and short-lived effect (Kenison et al., 1991; Johnson and von Borell, 1994; 
Elander et al., 2007).  
The role of PGE2 in behavioural depression and anorexia has been confirmed repeatedly 
as well (Pecchi et al., 2009). Teeling et al. (2007) even demonstrated that low grade 
inflammation impacts on the brain independently of peripheral cytokine production, in this 
way suggesting a key role for prostaglandins. However, sub-pyrogenic doses of LPS were 
used in this murine study, and the effect on non-classic sickness behaviour was studied, 
including exploration and anxiety behaviour.  
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3.2.2.3. Fever 
The onset of fever is one of the most frequently studied effects following an endotoxin 
challenge. In cattle, maximal body temperatures are generally reached around 4-5 h p.c. 
(Kinsbergen et al., 1994; Steiger et al., 1999; Borderas et al., 2008; Carroll et al., 2009b). 
Fever is beneficial up to a certain point as it inhibits the growth of certain microorganisms 
and increases the rate of enzyme reactions. As a result, the body’s metabolism enhances, 
with stimulation of phagocytosis, immune responses, and tissue repair (Ceciliani et al., 
2002). In the course of time, the knowledge on fever development has evolved considerably. 
The “conventional view” states that the febrile response is initiated by the peripheral 
production of pyrogenic cytokines, TNF-α, IL-1β and IL-6 being the most relevant. In fact, IL-6 
appears to be the most prominent cytokine with respect to mediating fever (Conti et al., 
2004). As mentioned before, PGE2 synthesis in the brain will be induced next, where this 
lipid mediator will act on the thermoregulatory centre in the preoptic area of the anterior 
hypothalamus (Blatteis et al., 2005). As a result, the thermoregulatory set point will increase, 
leading simultaneously to increased heat production and decreased heat loss (Johnson, 
2002). This view was confirmed in calves as the IV administration of recombinant bovine 
TNF-α resulted in dose-dependent changes in the rectal body temperature (Kushibiki et al., 
2000). Also in adult cattle, recombinant bovine IL-1β induced the onset of fever, while the 
effect of recombinant bovine IL-6 has not been studied in this animal species (Goff et al., 
1992; Godson et al., 1995). The more recent insights in the course of fever development in 
humans and laboratory animals, on the other hand, emphasise that the onset of the febrile 
response precedes the systemic appearance of pyrogenic cytokines (Blatteis, 2007). Indeed, 
cytokines are not constitutively expressed in mononuclear phagocytes, and their de novo 
synthesis in response to pyrogenic stimuli requires some time, resulting in a more delayed 
PGE2 synthesis in the brain (Conti et al., 2004). Moreover, Steiner et al. (2006) demonstrated 
that circulating PGE2, released from macrophages within LPS-processing organs like the lung 
and liver, initiated fever in the early phase (0.5 h) of infection in rats. Similarly to PIMs, 
Kupffer cells in the liver contribute to the clearance of circulating endotoxin, yet to a larger 
extent in comparison with cattle since these are the primary LPS clearing cells in humans and 
laboratory animals (Blatteis, 2007). Besides the subsequent production of cytokines, the 
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transcription of inflammation-induced COX-2 is upregulated in Kupffer cells, leading to the 
activation of peripheral PGE2 synthesis (Li et al., 2006). The need for COX-2 transcription, 
however, might again lag the onset of the febrile response (Blatteis et al., 2005). 
Consequently, the immediate activation of the complement cascade by LPS has been 
hypothesized to be an important trigger of COX-1-induced PGE2 formation. This pathway 
implies the production of anaphylatoxin C5a, and its subsequent binding to its receptor on 
Kupffer cells, resulting in an early peripheral fever trigger through excitation of hepatic vagal 
afferents (Blatteis et al., 2005; Blatteis, 2007). In this respect, a similar pathway might be of 
importance in cattle, both in the liver and the lung. The ability of PGE2 to directly pass from 
the blood to the brain, on the other hand, has been questioned increasingly (Morimoto et 
al., 1992; Blatteis et al., 2005). 
 
3.2.2.4. Tachycardia 
Kinsbergen et al. (1994) and Bieniek et al. (1998) reported nearly coinciding maxima for 
body temperature and heart rate following an LPS challenge in calves. In this respect, it has 
been suggested that fever exerts a negative inotropic effect, with an increased heart rate 
compensating for the decreased contractility and the increased peripheral oxygen demand 
(Haupt and Rackow, 1983). Moreover, both central nervous system-mediated effects and 
cardiac-mediated mechanisms have been put forward with reference to the tachycardic 
effects of cytokines during fever and inflammation (Takayama et al., 2005; Nalivaiko, 2006). 
 
3.2.2.5. Blood biochemical responses 
An endotoxin challenge has been demonstrated to alter plasma concentrations of zinc, 
iron, calcium and copper (van Miert, 1995; Zebeli et al., 2010). Plasma zinc and iron levels 
decrease in response to the release of pro-inflammatory cytokines. More specifically, these 
cytokines induce the synthesis of metallothionein, which enhances the intracellular metal 
ion binding capacity (Gruys et al., 2005). As described for Hp, lower iron concentrations are 
beneficial to the host, as iron is essential for microbial growth. Additionally, decreased 
serum zinc values are beneficial during an inflammatory response, since increased zinc levels 
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have been shown to impair phagocytic functions (Sugarman, 1983). Regarding the decreased 
levels of calcium following LPS administration, on the other hand, it remains unclear whether 
this is associated with the detoxification of endotoxin or with impaired calcium mobilization 
(Zaloga et al., 1992; Garidel et al., 2005; Zebeli et al., 2010). In contrast to the lower plasma 
concentrations of zinc, iron and calcium during an inflammatory condition, plasma levels of 
copper increase, enhancing the host’s antimicrobial responses (Hodgkinson and Petris, 
2012). These elevated levels can be partially attributed to increased serum concentrations of 
the copper-binding protein, ceruloplasmin (Erskine and Bartlett, 1993).  
 
3.3. COMPARISON WITH BACTERIAL INFECTIONS IN CATTLE 
In addition to endotoxin challenges, experimental infections with Gram-negative 
bacteria have been frequently applied in cattle in view of the study of the acute-phase 
response. In this respect, experiments using E. coli, S. typhimurium, P. multocida, M. 
haemolytica and Histophilus somni have been performed, based on the similarity with 
natural occurring diseases in cattle, including mastitis, enteritis and bovine respiratory 
disease. Due to multifactoriality, these experimental bacterial infections generally result in 
higher inter-animal variations compared with the administration of LPS, both with respect to 
fever development and plasma concentrations of inflammatory mediators (Horadagoda et 
al., 2002).  
Regarding the profile of pro-inflammatory cytokines following non-intramammary 
experimental bacterial infections in cattle, data are limited to TNF-α. More specifically, 
elevated plasma concentrations of this cytokine were only demonstrated in two studies, 
applying an intra-tracheal inoculation with M. haemolytica (Pace et al., 1993; Horadagoda et 
al., 1994). The inoculum used by Horadagoda et al. (1994) contained a higher number of 
colony forming units than the inoculum of Pace et al. (1993) (4 x 1010 and 3.5 x 107, 
respectively). In this respect, the first study reported maximal levels of TNF-α already 2 h 
after inoculation, whereas in the second study, peak concentrations were measured at 8 h 
post inoculation. The oral inoculation of calves with S. typhimurium, on the other hand, did 
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not result in increased levels of TNF-α (Peel et al., 1990). It should be mentioned, however, 
that blood collection in this study was limited to a once-daily sampling.  
In contrast with the assessment of cytokine profiles, acute-phase proteins have been 
evaluated more frequently following experimental infections. The underlying idea here is the 
possibility to use acute-phase proteins as biomarkers of infection and inflammation 
(Eckersall and Bell, 2010). Additionally, these inflammatory mediators show a more 
prolonged presence in plasma compared to cytokines. Table 2 provides a brief overview of 
the published studies investigating acute-phase proteins in calves in experimental models of 
bacterial respiratory infections. 
 
Table 2. Experimental models exploring the effect of a bacterial respiratory infection on 
serum amyloid A (SAA) and haptoglobin (Hp) in calves. 
 
Bacterium SAA Hp Reference 
Mannheimia haemolytica - Increase Conner et al., 1989 
 Increase Slow increase Horadagoda et al., 1994 
 Increase - Yamamoto et al., 1998 
 - Increase Schroedl et al., 2001 
 Increase Increase Ganheim et al., 2003 
 - Increase Corrigan et al., 2007 
Pasteurella multocida Increase Increase Dowling et al., 2002 
Histophilus somni - Increase McNair et al., 1997 
-: not investigated
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4. IMMUNOMODULATION BY DRUGS IN BOVINE VETERINARY MEDICINE 
Immunopharmacology is a relatively recent research field that aims to manipulate the 
immune system by modifying the endogenous immune responses to the benefit of the host 
in the treatment of diseases (Hadden and Kishimoto, 1993). One of its subdisciplines studies 
the influence of pharmacological agents on the innate immune response. Particularly in 
human medicine, the first reports on such beneficial effects of drugs have initiated intensive 
research regarding immunomodulatory drugs. Additionally, the indication that certain 
antimicrobial agents can exert immunomodulatory properties has led to high prospects of 
this topic. Labro (2000) even described these antibiotics as “a therapeutic need for the third 
millennium” with stress on the use in immunocompromised patients. However, it should be 
remarked that immunomodulation differs from immunosuppression or anti-inflammation 
and that it does not strictly refer to beneficial effects (Hamilton-Miller, 2001; Kanoh and 
Rubin, 2010). Van Vlem et al. (1996) distinguished immuno-enhancing antibiotics from 
immuno-depressing antibiotics. During this classification, one of the major problems 
regarding immunopharmacology was observed: the inconsistency of results. One of the 
causes, contributing to these inconsistencies, is the diversity of methods used to assess 
immunomodulatory effects. In this respect, methods ranging from in vitro and ex vivo 
studies on the alteration of the phagocytic function of leukocytes to the in vivo evaluation of 
the influence on the release of pro-inflammatory cytokines have been applied.  
In veterinary medicine, the choice of a pharmacological agent remains nowadays 
mainly based on its direct activity. Nevertheless, the immunomodulatory properties of drugs 
could provide an added value in the treatment of an animal. Mulcahy and Quinn (1986) 
reviewed the application of immunomodulators in veterinary medicine in the 1980s. Based 
on more recent data, an overview of the current knowledge on immunomodulatory drugs 
will be provided, with emphasis on bovine veterinary medicine. In this respect, bovine in 
vitro, ex vivo and in vivo studies using antimicrobial drugs, non-steroidal anti-inflammatory 
drugs (NSAIDs) and corticosteroids were taken into account. 
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4.1. BOVINE IN VITRO STUDIES WITH RESPECT TO IMMUNOMODULATORY DRUGS 
In vitro studies generally focus on the following endpoints to study immunomodulatory 
properties of drugs: phagocytosis, respiratory burst, transcription and/or release of 
inflammatory mediators and neutrophil recruitment and apoptosis. These parts of the innate 
immune response are highly important in the defence against invading micro-organisms, and 
the subsequent initiation of the acute-phase response.   
 The main phagocytic cells include neutrophils and monocytes/macrophages. Due to 
their rapid and abundant recruitment, neutrophils act as the first line of defence in case of 
an inflammatory event. During such an insult, local resident macrophages produce multiple 
factors of inflammation, including cytokines and chemokines. These products stimulate the 
adhesion of phagocytes to endothelial cells. The adhesion is initiated by a weak selectin-
mediated interaction between both cell types, resulting in rolling of neutrophils. Subsequent 
presentation of chemokines on the endothelial cell surface will induce neutrophil integrin 
activation. The consequence of this inside-out signaling, is a firm phagocyte adhesion to the 
endothelium (Kinashi, 2005). Diapedesis is the next step in the neutrophil recruitment, and is 
mainly characterized by paracellular migration of phagocytes through the vascular 
endothelium (Muller, 2003). This is followed by the migration towards the inflammatory site 
under the influence of a chemotactic gradient, which consists of microbial components and 
endogenous chemoattractants, including complement factor 5a, leukotriene B4 (LTB4), 
platelet activating factor and neutrophil-active chemokines, such as IL-8. Due to the 
concurrent exposure to priming agents, neutrophil functions are potentiated, which include 
the manifestation of powerful antimicrobial activities. Monocytes are concomitantly 
recruited by chemotaxis, yet not as fast and extensively as neutrophils (Silva, 2010).  
Both types of leukocytes then continue their phagocytic activities by the recognition of 
their targets through multiple ligand-receptor interactions. Various opsonins, including 
immunoglobulins, collectins and complement components are involved in opsonin-
dependent phagocytosis, while direct target recognition (opsonin-independent 
phagocytosis) is another possible trigger of engulfment (van Lookeren et al., 2007). The 
internalized particle is subsequently delivered to the phagosome, which matures into a 
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phagolysosome through vesicle-mediated delivery (degranulation process) of various 
antimicrobial effectors, including proteases, antimicrobial peptides and lysozyme (Garin et 
al., 2001). This phagolysosome is the ultimate location of killing of pathogens and in this 
respect, two different, yet synergistically acting mechanisms can be distinguished. The first 
mechanism – the oxygen-independent – covers a broad array of antimicrobial proteins and 
peptides including bactericidal/permeability-increasing protein, lactoferrin, lysozyme, and 
defensins. The oxygen-dependent mechanism – the respiratory burst – on the other hand, 
refers to the assemblage of the NADPH-oxidase complex, resulting in its activation. 
Accordingly, the phagocytes’ oxygen consumption increases with simultaneous generation 
of superoxide anion radicals (O2
‒●) and hydrogen peroxide (H2O2). In the presence of 
myeloperoxidase, which is released during the degranulation process, hypochloric acid 
(HOCl) and chloramines are generated. Another antimicrobial system of phagocytic cells is 
the inducible nitric oxide synthase (iNOS) pathway, which generates nitric oxide (NO) 
radicals. Both the NADPH-oxidase and the iNOS pathway occur in both types of phagocytes, 
although the first pathway is more pronounced in neutrophils, and the latter in macrophages 
(Nathan and Shiloh, 2000). The final step of the phagocytosis process is the digestion of the 
debris by hydrolases and other lytic enzymes present in the phagolysosome. 
Phagocytosis-induced reactive oxygen species (ROS) are highly antimicrobial, but can 
also damage the surrounding tissue, resulting in an amplification of the inflammatory 
reaction. Additionally, the release of proteolytic compounds from necrotic neutrophils can 
contribute to self-perpetuating inflammatory injury (Buret, 2010). During neutrophil 
apoptosis, on the other hand, the integrity of the membrane and the organelles remains 
preserved. Overall, the following immunomodulatory effects of drugs are regarded to be 
beneficial: stimulation of phagocytosis, inhibition of the respiratory burst and ROS, 
downregulation of pro-inflammatory cytokines, prevention of excessive neutrophil 
infiltration (reduced chemotaxis, LTB4 and IL-8) and induction of neutrophil apoptosis. With 
respect to the determination of these properties for different drugs, several in vitro studies 
using bovine cells from healthy animals have been performed. The underlying mechanisms, 
on the other hand, remain largely unknown. Table 3 provides an overview of the findings 
regarding antimicrobial drugs, NSAIDs, corticosteroids and miscellaneous drugs.  
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As can be concluded from Table 3, particularly antimicrobial drugs were studied in 
vitro (63% of the reported drugs: 36 antibiotics, belonging to 9 classes). Indeed, therapeutic 
compounds that generate both anti-bacterial as well as immunomodulatory effects are of 
great interest for the treatment of bacteria-induced inflammatory diseases (Buret, 2010). 
Conversely, several antibiotics have been reported to reduce phagocytic and bactericidal 
activities of neutrophils, in this way impairing the host’s defence mechanism. Knowledge on 
the effect of an antibiotic on the innate immune response can consequently serve as a 
secondary aid in the selection of an antibiotic for antimicrobial therapy (Paape et al., 1991). 
In this respect, it should also be kept in mind that antimicrobial drugs that are effective 
against the bacterial cell wall (like penicillins and cephalosporins) result in a greater release 
of LPS than those that affect microbial protein synthesis (such as macrolides) (Bentley et al., 
2002).  
Besides antibiotics, several anti-inflammatory drugs were evaluated with respect to 
their immunomodulatory properties (NSAIDs and corticosteroids: 14 and 12% of the drugs 
included in Table 3, respectively). The reported effects occur independently of their direct 
anti-inflammatory actions, which encompass the inhibition of COX by NSAIDs and of PLA2 by 
glucocorticoids, with subsequent blocking of prostaglandins, thromboxanes and/or 
leukotrienes (Fig. 6). Their immunomodulatory effects, on the other hand, include the 
inhibition of NF-κB-related gene transcription (Brattsand and Linden, 1996; Tegeder et al., 
2001). This was indeed confirmed in vitro for acetylsalicylic acid, flunixin meglumine and 
dexamethasone (Table 3) (Kiku et al., 2002; Malazdrewich et al., 2004a; Myers et al., 2010). 
  
 
Table 3. Evaluation of in vitro immunomodulatory effects of antimicrobial drugs, NSAIDs, corticosteroids and miscellaneous drugs using bovine cells. 
Blank cells represent non-investigated effects.  
 
  EFFECTS  
Drug Cell type Phagocytosis 
Respiratory 
burst (RB) and 
reactive oxygen 
species (ROS) 
Pro-inflammatory 
cytokines 
Chemotaxis, LTB4 
and IL-8 
Apoptosis Reference 
ANTIMICROBIAL DRUGS       
Aminoglycosides        
Amikacin Milk neutrophil Decrease     Paape et al., 1991 
Dihydrostreptomycin Blood neutrophil  NE    Hoeben et al., 1998a 
Gentamycin Milk neutrophil Decrease     Paape et al., 1991 
Neomycin Blood neutrophil  NE    Hoeben et al., 1998a 
Spectinomycin Milk neutrophil NE     Paape et al., 1991 
Streptomycin Milk neutrophil NE     Paape et al., 1991 
Tobramycin Milk neutrophil Decrease     Paape et al., 1991 
Β-lactam antibiotics        
Ampicillin Milk neutrophil NE     Paape et al., 1991 
 Blood neutrophil  Increase ROS 
scavenging 
   
Hoeben et al., 1998a 
Benzylpenicillin Milk neutrophil  Decrease RB    Hoeben et al., 1997a 
 Blood neutrophil  Decrease RB – 
Increase ROS 
scavenging 
   
Hoeben et al., 1998a 
Carfecillin Milk neutrophil Decrease     Paape et al., 1991 
Ceftiofur Milk neutrophil  Increase RB    Hoeben et al., 1997a   
 Blood neutrophil  Increase RB – 
Increase ROS 
scavenging 
  
 
 
 
NE 
Hoeben et al., 1998a  
 
 
Fischer et al., 2011 
Cephacetrile  Milk neutrophil Decrease     Paape et al., 1991 
Cephapirin  Milk neutrophil Decrease     Paape et al., 1991 
 Blood neutrophil NE Decrease RB
a
 – 
Increase ROS 
scavenging
a
 
   
Dosogne et al., 1998 
Cloxacillin Milk neutrophil NE     Paape et al., 1991 
 Blood neutrophil  NE    Hoeben et al., 1998a 
Mecillinam Blood neutrophil NE Decrease RB
a
 – 
Increase ROS 
scavenging
a
 
   
Dosogne et al., 1998 
  
 
 
Drug Cell type Phagocytosis RB and ROS Cytokines Chemotaxis Apoptosis Reference 
Nafcillin Milk neutrophil NE     Paape et al., 1991 
Penicillin Milk neutrophil NE     Paape et al., 1991 
 Blood neutrophil     NE Fischer et al., 2011 
Chloramphenicol and analogs       
Chloramphenicol  Milk neutrophil Decrease  
Decrease RB 
   
Paape et al., 1990   
Hoeben et al., 1997a 
 Blood neutrophil Decrease Decrease RB    Hoeben et al., 1997b 
Florfenicol Milk neutrophil NE     Paape et al., 1990 
Thiamphenicol Milk neutrophil NE     Paape et al., 1990 
Fluoroquinolones        
Ciprofloxacin Milk neutrophil NE     Paape et al., 1991 
Danofloxacin Milk neutrophil  Decrease RB    Hoeben et al., 1997a 
 Blood neutrophil  Increase ROS 
scavenging 
   
Hoeben et al., 1997b 
Enrofloxacin Milk neutrophil  Increase RB    Hoeben et al., 1997a 
 Blood neutrophil  Increase RB    Hoeben et al., 1997b 
Flumequine Milk neutrophil NE     Paape et al., 1991 
Lincosamides        
Lincomycin Blood neutrophil  NE    Hoeben et al., 1998a 
Macrolides        
Erythromycin Milk neutrophil NE  
NE 
   
Paape et al., 1991   
Hoeben et al., 1997a 
 Blood neutrophil Decrease NE    Hoeben et al., 1997b 
Oleandomycin Blood neutrophil  NE    Hoeben et al., 1998a 
Spiramycin Milk neutrophil NE  
NE 
   
Paape et al., 1991   
Hoeben et al., 1997a 
 Blood neutrophil Decrease NE    Hoeben et al., 1997b 
Tilmicosin Alveolar macrophage NE   NE on chemotaxis  Brumbaugh et al., 2002 
 Blood neutrophil   
 
 
Decrease LTB4 
synthesis 
Induction 
Induction 
Chin et al., 2000 
Lee et al., 2004 
 Macrophage Increase 
efferocytosis 
 
 
  
 
 
NE 
Chin et al., 2000 
 
Lee et al., 2004 
Tulathromycin Blood neutrophil   Decrease NF-κB 
activation 
 
Decrease IL-8 mRNA 
 
Decrease LTB4 
secretion 
Induction 
 
 
Fischer et al., 2011   
 
Fischer et al., 2014 
 Macrophage  
Increase 
efferocytosis 
   
Decrease IL-8 
secretion 
NE 
Induction 
Fischer et al., 2011  
Fischer et al., 2013 
  
 
Drug Cell type Phagocytosis RB and ROS Cytokines Chemotaxis Apoptosis Reference 
Tylosin Milk neutrophil NE     Paape et al., 1991 
 BME-UV cell line   Downregulation IL-1 
Downregulation IL-6 
NE  on TNF-α 
NE on IL-8  Mazzilli and Zecconi, 2010 
Polymyxins        
Polymyxin B Alveolar macrophage   Decrease TNF-α 
Decrease IL-1β 
Decrease TNF-α mRNA 
Decrease IL-1β mRNA 
  Yoo et al., 1995 
Sulphonamides        
Sulphadiazine Milk neutrophil  NE    Hoeben et al., 1997a 
 Blood neutrophil  NE    Hoeben et al., 1997b 
Tetracyclines        
Doxycycline Milk neutrophil Decrease     Paape et al., 1991 
 Blood neutrophil  Decrease RB – 
Increase ROS 
scavenging 
   Hoeben et al., 1998a 
Minocycline Milk neutrophil Decrease     Paape et al., 1991  
Oxytetracycline Milk neutrophil NE  
NE 
   Paape et al., 1991  
Hoeben et al., 1997a 
 Blood neutrophil  
Decrease 
Increase RB
a
  
NE 
 
   
 
NE 
Myers et al., 1995   
Hoeben et al., 1997b 
Fischer et al., 2011 
NSAIDs        
Acetominophen Milk neutrophil Decrease     Paape et al., 1991 
Acetylsalicylic acid Milk neutrophil Increase     Paape et al., 1991 
 Whole blood   Decrease TNF-α mRNA   Myers et al., 2010 
Centrophenoxine Milk neutrophil Increase     Paape et al., 1991 
Flunixin meglumine Whole blood   Decrease TNF-α mRNA   Myers et al., 2010 
Ibuprofen Milk neutrophil Decrease     Paape et al., 1991 
Indomethacin Milk neutrophil Decrease     Paape et al., 1991 
 Milk macrophage    NE on chemotaxis  Politis et al., 1991 
 Whole blood   NE on TNF-α mRNA   Myers et al., 2010 
Phenylbutazone Milk neutrophil Decrease     Paape et al., 1991 
PTPBS
b
 Whole blood   Decrease TNF-α mRNA   Myers et al., 2010 
CORTICOSTEROIDS        
6α-methylprednisolone Blood neutrophil  NE    Hoeben et al., 1998b 
Betamethasone Blood neutrophil  NE    Hoeben et al., 1998b 
Cortisone Blood neutrophil  NE    Hoeben et al., 1998b 
  
NE: no effect; 
a
: only at high concentrations; 
b
: 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzene sulfonamide (a specific COX-2 inhibitor); 
c
: peripheral blood 
mononuclear cells; 
d
: a bicyclic imidazole 
 
 
Drug Cell type Phagocytosis RB and ROS Cytokines Chemotaxis Apoptosis Reference 
Dexamethasone Blood neutrophil Decrease  
NE 
   
 
NE 
Ohman et al., 1987 
Hoeben et al., 1998b  
Chin et al., 2000 
 PBMC
c
   Decrease TNF-α mRNA 
Decrease IL-1β mRNA 
Decrease IL-6 mRNA 
  Kiku et al., 2002 
 Blood neutrophil     Decrease Chang et al., 2004 
 Alveolar macrophage   Decrease TNF-α  
Decrease IL-1β  
Decrease TNF-α mRNA 
Decrease IL-1β mRNA 
Decrease IL-8 
Decrease IL-8 mRNA 
 Malazdrewich et al., 2004a 
 Whole blood   NE on TNF-α mRNA   Myers et al., 2010 
Hydrocortisone Blood neutrophil  NE    Hoeben et al., 1998b 
Prednisolone Blood neutrophil  NE    Hoeben et al., 1998b 
OTHERS        
Chlorpromazine PBMC
c
  
 
Decrease TNF-α mRNA 
Decrease IL-1β mRNA 
NE on IL-6 mRNA 
 
 
Kiku et al., 2002 
Pentoxifylline PBMC
c
  
 
NE on TNF-α mRNA 
NE on IL-1β mRNA 
NE on IL-6 mRNA 
 
 
Kiku et al., 2002 
 Alveolar macrophage  
 
Decrease TNF-α  
Decrease IL-1β  
Decrease TNF-α mRNA 
NE on IL-1β mRNA 
Decrease IL-8 
NE on IL-8 mRNA 
 
Malazdrewich et al., 2004a 
Rolipram Alveolar macrophage  
 
Decrease TNF-α  
Decrease IL-1β  
NE on TNF-α mRNA 
NE on IL-1β mRNA 
NE on IL-8  
NE on IL-8 mRNA 
 
Malazdrewich et al., 2004a 
SB203580
d
 Alveolar macrophage  
 
Decrease TNF-α  
NE on IL-1β  
NE on TNF-α mRNA 
NE on IL-1β mRNA 
Decrease IL-8 
NE on IL-8 mRNA 
 
Malazdrewich et al., 2004a 
Tetrahydropapaveroline Alveolar macrophage  
 
Decrease TNF-α  
Decrease IL-1β  
Decrease TNF-α mRNA 
Decrease IL-1β mRNA 
Decrease IL-8 
Decrease IL-8 mRNA 
 
Malazdrewich et al., 2004a 
Thalidomide Alveolar macrophage  
 
NE on TNF-α  
NE on IL-1β  
NE on TNF-α mRNA 
NE on IL-1β mRNA 
NE on IL-8  
NE on IL-8 mRNA 
 
 
Malazdrewich et al., 2004a 
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Figure 6. Direct anti-inflammatory actions of NSAIDs and corticosteroids:  
inhibition of the enzymatic production of eicosanoids (based on Adams, 2001) 
 
In addition to antibiotics, NSAIDs and corticosteroids, a number of drugs belonging to 
miscellaneous classes were also studied with respect to their immunomodulatory properties 
(11% of the reported drugs in Table 3). The choice of these drugs was based on conclusions 
from earlier studies. Chlorpromazine, for example, is a psychotropic drug that has been 
demonstrated to inhibit TNF-α release in mice (Gadina et al., 1991). Additionally, the 
hemorrheologic agent pentoxifylline, the antidepressant rolipram, the imidazole SB203580, 
the antioxidant tetrahydropapaveroline and the sedative thalidomide have been mentioned 
in this context (Sampaio et al., 1991; Eugui et al., 1994; Lundblad et al., 1995; Badger et al., 
1996; Korhonen et al., 2013). In vitro studies using bovine cells indeed established the 
inhibition of pro-inflammatory cytokines by the former drugs, with the exception of 
thalidomide (Kiku et al., 2002; Malazdrewich et al., 2004a). Their application in bovine 
veterinary medicine, on the other hand, is rather questionable and even unlikely. 
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 Regarding the applied cell types, milk and blood derived neutrophils are clearly the 
most frequently studied leukocytes. Accordingly, neutrophils have been reported to be a key 
player in the pathogenesis of for instance bovine respiratory disease and mastitis, based on 
their role in the production of inflammatory mediators, recruitment of other leukocytes and 
tissue damage (Aulik et al., 2010; Buret, 2010).   
As can be concluded from Table 3, several drugs inhibit the phagocytic properties of 
bovine leukocytes. This refers to the formerly mentioned distinction between immuno-
enhancing and immuno-depressing drugs by Van Vlem et al. (1996). Only the NSAIDs 
acetylsalicylic acid and centrophenoxine have been confirmed to increase phagocytosis in 
bovine neutrophils. In human medicine, on the other hand, several antimicrobial drugs such 
as erythromycin, chloramphenicol and nafcillin have been reported to stimulate the 
phagocytic function (Labro et al., 2000). With respect to efferocytosis – the clearance of 
apoptotic neutrophils by macrophages – both tilmicosin and tulathromycin have been 
demonstrated to exert an enhancing effect (Chin et al., 2000; Fischer et al., 2013). As 
mentioned before, such inconsistencies in in vitro results are highly frequent in 
immunopharmacology. Many controversies arise from the use of non-standardised 
techniques, cells obtained from various origins or various cell subsets (Labro, 1993). This is 
also clear from Table 3, as cephapirin, for example, decreased phagocytosis in milk 
neutrophils, while it had no effect in blood derived neutrophils. Additionally, Fischer et al. 
(2011) reported no influence of tulathromycin on apoptosis of macrophages, whereas in a 
more recent study (2013), these authors did observe the induction of apoptosis in 
macrophages by tulathromycin. The experimental protocols used to assess the 
immunomodulatory properties of the drugs listed in Table 3 were indeed rather diverse. For 
instance, most studies applied higher concentrations than achievable in the animal, while 
others evaluated therapeutic doses (Paape et al., 1991; Hoeben et al., 1997a, 1997b, 1998; 
Fajt et al., 2000). Nevertheless, authors using high drug concentrations claim that after local 
and repeated treatment much higher concentrations can be achieved in certain body 
compartments such as the udder. As a result, the influence of concentrations even up to 
1000 µg/mL (unachievable in vivo) were frequently tested (Hoeben et al., 1997b). It should 
be mentioned, however, that high drug concentrations can result in a reduced viability of 
cells as well, as reported for oxytetracycline by Hoeben et al. (1997b). 
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Regarding the influence of antimicrobial drugs on the transcription and/or release of 
pro-inflammatory cytokines, only data for one macrolide (tylosin) and polymyxin B are 
available from bovine in vitro studies (Yoo et al., 1995; Mazzilli and Zecconi, 2010). The 
choice of the former class can be related to the results from in vitro experiments using 
innate immune cells from humans and laboratory animals (Khan et al., 1999; Araujo et al., 
2002; Cao et al., 2006). More specifically, these studies demonstrated an inhibition of TNF-α, 
IL-1β and IL-6 by azithromycin, clarithromycin, telithromycin, tilmicosin and/or tylosin. In this 
context, the involvement of NF-κB inactivation by macrolides has been suggested 
(Giamarellos-Bourboulis, 2008). Besides the impact on cytokines, an influence on neutrophil 
function, migration, infiltration and accumulation as well as on mucus (hyper)secretion and 
bacterial biofilm formation and quorum sensing has been reported for macrolides in humans 
and other animal species (Čulić et al., 2001; Parnham, 2005; Ou et al., 2008). The effect of 
polymyxin B was evaluated since this antimicrobial drug interacts with the lipid A component 
of LPS, ultimately resulting in a reduced production of pro-inflammatory cytokines (Coyne 
and Fenwick, 1993). This hypothesis was indeed confirmed by Yoo et al. (1995) using bovine 
alveolar macrophages. The systemic administration of polymyxin B in the animal, on the 
other hand, is rather controversial, due to its nephrotoxic and neurotoxic side effects at 
antibacterial doses (Kelmer, 2009). Nevertheless, in vivo studies in goats and horses 
demonstrated that lower doses can effectively reduce clinical signs of experimentally 
induced endotoxemia, as well as TNF-α and/or IL-6 concentrations (van Miert et al., 1997; 
Morresey and Mackay, 2006). In this respect, a cautious approach for the treatment of 
animals in the clinical setting is highly recommended.  
The corticosteroid dexamethasone was studied by different research groups. From the 
results of these in vitro studies, it can be concluded that dexamethasone is a positive control 
immunomodulatory drug with respect to the transcription and release of pro-inflammatory 
cytokines (Kiku et al., 2002; Malazdrewich et al., 2004a). Myers et al. (2010), on the other 
hand, did not detect any effect of dexamethasone on TNF-α mRNA expression. This 
unexpected observation could be attributed to the use of a rather low dose of the 
corticosteroid for whole blood cultures, in contrast to doses applied in experiments with 
purified innate immune cells. 
GENERAL INTRODUCTION 
 
  
38 
 
4.2. BOVINE EX VIVO STUDIES WITH RESPECT TO IMMUNOMODULATORY DRUGS 
Ex vivo studies with respect to immunomodulatory drugs refer to the in vivo treatment 
of healthy animals, followed by the collection of selected cell types and subsequent in vitro 
experiments. As a consequence, the ability of therapeutic drug doses to modulate innate 
immune functions is studied, instead of empirically selected – often supratherapeutic – 
doses. Table 4 gives an overview of such ex vivo bovine experiments, applied to evaluate the 
immunomodulatory properties of antibiotics, NSAIDs and corticosteroids. It is clear that ex 
vivo studies have been performed notably less frequent in comparison with in vitro studies. 
Only Donalisio et al. (2013) studied the effect of flunixin meglumine and ketoprofen on TNF-
α production, which was inhibited by these NSAIDs. Nevertheless, in addition to the ex vivo 
studies in healthy animals, other authors based their research on experimentally infected 
animals that received an in vivo treatment post infection (Goubau and Buret, 2000; Fajt et 
al., 2003). Such studies were not included in Table 4, as distinguishing between a bacterial 
effect and an influence of the drug on the immune function is not possible in these settings. 
From this point of view, the experimental protocol applied by Bednarek et al. (1999) might 
provide more advantages. More specifically, these authors induced local lung inflammation 
in calves by the injection of sterile mineral oil into the diaphragmatic lobus of the right lung. 
The calves then received a treatment with either the NSAID meloxicam or the corticosteroid 
flumethasone, after which blood samples were collected to evaluate the ex vivo ability of 
innate immune cells to produce TNF-α. The results of this study showed that both 
meloxicam and flumethasone significantly inhibited this cytokine’s release. Additionally, 
both drugs had no effect on the phagocytic activity of blood phagocytes (Bednarek et al., 
1999). 
  
 
Table 4. Evaluation of ex vivo immunomodulatory effects of antimicrobial drugs, NSAIDs and corticosteroids using samples derived from 
healthy bovines. 
 DRUG   EFFECTS  
Drug 
Dose 
(mg/kg 
BW) 
TOA (h) ROA TBC (h) Cell type Phagocytosis 
Respira-
tory burst 
Pro-
inflammatory 
cytokines 
Chemotaxis, 
LTB4 and  
IL-8 
Apoptosis Reference 
Antimicrobial drugs           
Fluoroquinolones            
Danofloxacin 6 0 SC 12; 26; 60 Blood 
neutrophil 
NE NE  NE on 
chemotaxis 
- Fajt et al., 2000 
Marbofloxacin 2 0; 24; 48; 
72; 96 
SC 120 Whole 
blood 
- Decrease - - - Spehner et al., 1996 
Macrolides            
Tilmicosin 10 0 SC 12; 26; 60 Blood 
neutrophil 
NE NE - NE on 
chemotaxis 
- Fajt et al., 2000 
NSAIDs            
Flunixin meglumine 2.2 0; 12; 36; 60 IV 1; 13; 37; 61; 
85 
Whole 
blood 
- - Decrease TNF-α NE on LTB4 
Decrease IL-8 
- Donalisio et al., 2013 
Ketoprofen 3 0; 12; 36; 60 IV 1; 13; 37; 61; 
85 
Whole 
blood 
- - Decrease TNF-α NE on LTB4 
Decrease IL-8 
- Donalisio et al., 2013 
Corticosteroids            
Dexamethasone SA
a
: 0.08 
LA
b
: 0.25 
0 
37 
IM 
IM 
13; 37; 61; 
109; 181; 253 
Blood 
neutrophil 
- - - Increase 
chemotaxis 
- Anderson et al., 1999 
 0.1 G1
c
: 0 
G2
c
: 0 
G3
c
: 0; 6 
G4
c
: 0; 6; 12 
IM G1: 3 
G2: 6 
G3: 12 
G4: 24 
Blood 
neutrophil 
- - - - Decrease Chang et al., 2004 
TOA: time(s) of administration; ROA: route of administration; TBC: time of blood collection relative to the first drug administration; SC: subcutaneous; IV: intravenous; IM: 
intramuscular; NE: no effect; -: not investigated; 
a
: short acting; 
b
: long acting; 
c
: group 
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4.3. BOVINE IN VIVO STUDIES ON IMMUNOMODULATORY DRUGS USING LPS INFLAMMATION MODELS 
As in vitro and ex vivo studies with experimentally fixed systems do not truly reflect the 
dynamics and multiple interactions that occur in vivo, inflammation models in the absence of 
active bacteria can provide more information on the immunomodulatory properties of drugs 
(Labro, 1993; Bednarek et al., 2003; Buret, 2010). In this respect, LPS-induced inflammation 
models can be put forward and could be advisable. An overview of such bovine in vivo 
studies concerning the effects of drugs on body temperature, pulmonary response, clinical 
score and levels of cytokines and acute-phase proteins following an LPS challenge is 
provided in Table 5. Similarly to Table 4, the results of studies with natural or experimentally 
induced infections are not included in Table 5, since the presence of actively invading and 
growing microorganisms complicates the interpretation of the effect of immunomodulatory 
drugs. In comparison with in vitro studies, it is clear that the number of drugs evaluated in 
vivo is again remarkably lower. Moreover, emphasis was rather placed on the clinical 
outcome. With respect to antimicrobial drugs, only the immunomodulatory effect of 
tilmicosin was studied in cattle by Reuter et al. (2008). It should be mentioned, however, 
that the main aim of these authors was to evaluate the effects of the dietary energy source 
and level on the immune function, and that the influence of tilmicosin was only assessed 
additionally. The decrease of SAA concentrations, for example, was merely observed in the 
group receiving a restricted amount of a 70% concentrate diet. Also in other animal species, 
data from in vivo studies on the modulation of pro-inflammatory cytokine release by 
antimicrobial drugs are rather scarce, and principally limited to mice and rats (Ianaro et al., 
2000; Tkalcevic et al., 2006; Leiva et al., 2007; Wyns et al., 2015b). 
Regarding NSAIDs and corticosteroids, mostly commonly used drugs were studied. 
Overall, the anti-inflammatory drugs decreased the clinical score following the LPS challenge. 
This clinical score generally encompassed the occurrence of depression and anorexia, as 
these are important signs in the early detection of illness. Regarding the influence on body 
temperature and pulmonary response, the evaluated drugs had nearly no effect. With 
respect to the studies of Semrad (1993a, 1993b), this might be related to the administration 
of the drug 15 min after the IV LPS bolus, since an inflammatory reaction is already initiated 
at this time. The administration of dexamethasone prior to the challenge indeed resulted in 
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a more pronounced effect, including a reduction of the pulmonary response (Olson and 
Brown, 1986; Ohtsuka et al., 1997a). It can therefore be concluded that the time of drug 
administration is of major importance with respect to the effect on the clinical outcome. Pre-
treatment of calves with dexamethasone did not affect the body temperature, which might 
be attributed to the rather slow action of corticosteroids, due to the need for lipocortin 
synthesis (Hirata, 1983; Ohtsuka et al., 1997a). Nevertheless, the results of the study of 
Ohtsuka et al. (1997a) concerning TNF-α inhibition confirm our previous conclusion from 
bovine in vitro studies regarding dexamethasone being a positive control 
immunomodulatory drug. 
Similarly to the in vitro studies, a number of drugs belonging to miscellaneous classes 
were studied in vivo with respect to their immunomodulatory properties. Besides 
chlorpromazine and pentoxifylline, also dimethyl sulfoxide (DMSO) and two lazaroids 
(U74389F and tirilazad mesylate) were evaluated. The anti-inflammatory compound DMSO 
was selected by Semrad (1993b) based on its antithrombogenic, endothelial sparing and free 
radical scavenging capabilities. The lazaroids, on the other hand, are antioxidants that 
combine certain properties of NSAIDs and corticosteroids, without the side effects of the 
latter. Moreover, tirilazad mesylate was evaluated by Rose and Semrad (1992) as this drug 
for the treatment of central nervous system trauma would have the capacity to mitigate the 
adverse reactions induced by the entrance of endotoxin into the circulation. Surprisingly, 
from these five drugs, chlorpromazine had the most pronounced influence on the LPS-
induced inflammatory reaction (Ohtsuka et al., 1997a). More specifically, the body 
temperature, pulmonary response, clinical score and TNF-α levels were all significantly 
decreased by this psychotropic drug. Nevertheless, its side effects, including tachycardia, 
hypothermia and sedation, cannot be neglected. It should also be mentioned that Semrad 
(1993b) did not report the effects of all drugs on the studied parameters, which complicates 
the interpretation of this experiment (i.e. NR or not reported in Table 5).  
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Table 5. Bovine in vivo studies using LPS-induced inflammation to evaluate the immunomodulatory properties of antimicrobial drugs, NSAIDs, 
corticosteroids and miscellaneous drugs. 
 DRUG  EFFECTS  
Drug 
Bolus 
(mg/kg 
BW) 
Infusion 
(duration) 
ROA TOA (h) 
 
Body 
temperature 
Pulmonary 
response 
Clinical 
score 
TNF-α IL-6 SAA Reference 
Antimicrobial drugs            
Macrolides             
Tilmicosin 10  SC -48  NE - - Trend to 
increase 
NE Decrease
a
 Reuter et al., 2008 
NSAIDs             
Flunixin meglumine 1.1  IV +0.25  NE NE Decrease - - - Semrad, 1993a 
Flunixin meglumine 1.1  IV +0.25  NR NR Decrease - - - Semrad, 1993b 
Ketoprofen 2.2  IV +0.25  NE NE Decrease - - - Semrad, 1993a 
Ketorolac 1.1  IV +0.25  NE NE Decrease - - - Semrad, 1993a 
Corticosteroids             
Dexamethasone 5 5 mg/kg BW  
(5 h: during 
endotoxemia) 
IV Bolus:  
-18; -1 
 - Decrease - - - - Olson and Brown, 1986 
 0.3  IV -1  NE Decrease Decrease Decrease - - Ohtsuka et al., 1997a 
Prednisolone 1.1  IV +0.25  NR NR Decrease - - - Semrad, 1993b 
Others             
Chlorpromazine 4  IV -1  Decrease Decrease Decrease Decrease - - Ohtsuka et al., 1997a 
DMSO  0.5 g/kg BW 
(1.25 h) 
IV +0.25  NE NR Increase - - - Semrad, 1993b 
Pentoxifylline 20  IV -1  NE NE NE NE - - Ohtsuka et al., 1997a 
Tirilazad mesylate  1.5 mg/kg BW 
(0.08 h) 
IV G1
c
: -1 
G2
c
: +1 
 NE 
 
NE 
 
Decrease 
 
Decrease 
 
- - Rose and Semrad, 1992 
& Semrad et al., 1993 
U74389F
b
 1.5  IV +0.25  NR NE NE - - - Semrad, 1993b 
ROA: route of administration; TOA: time of administration relative to LPS challenge; SC: subcutaneous; IV: intravenous; NE: no effect; NR: not reported; -: not investigated; 
a
: in case of a specific diet; 
b
: a lazaroid; 
c
: group 
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5. RELEVANCE OF LIPOPOLYSACCHARIDE INFLAMMATION MODELS AND THE SELECTED DRUGS 
FOR BOVINE VETERINARY MEDICINE 
The IV administration of LPS results in a series of clinical signs, which are rather non-
specific: depression, anorexia and fever. As these signs are part of several bovine diseases, 
including pneumonia, septicemia and neonatal diarrhea, the possible contributing role of LPS 
in the development of these clinical entities can be put forward. The former sections are 
consequently not limited to fundamental research, as the use of LPS inflammation models 
with respect to the study of immunomodulatory drugs can provide valuable information for 
cattle practice. More specifically, such information can contribute to improved treatment 
strategies for LPS-associated diseases, resulting in economic, public and animal benefits.  
Since immunopharmacology aims to manipulate the immune system to the benefit of 
the host, immunomodulatory drugs would ideally induce a more rapid and improved clinical 
recovery, resulting in enhanced animal welfare and better production results (Hadden and 
Kishimoto, 1993). In this context, drugs that exert both anti-bacterial as well as anti-
inflammatory effects have been suggested to be most effective in treating bacteria-induced 
inflammatory diseases (Buret, 2010). Nevertheless, antimicrobial resistance is currently one 
of the leading health concerns in human and veterinary medicine (Pardon et al., 2012a). 
Rational use of this class of drugs is therefore highly recommended. In this respect, the 
concomitant use of an antibiotic and an anti-inflammatory drug can provide synergistic or 
additive benefits. The choice between a corticosteroid and a NSAID, however, remains a 
controversial topic in bovine veterinary medicine (Lekeux and Van de Weerdt, 1997). More 
specifically, despite the side effects of corticosteroids, including suppression of the immune 
system and the adrenal gland, these drugs are still commonly preferred to NSAIDs by 
practitioners for their potential pharmacodynamic action.  
In the present thesis, one drug of each class was selected to be evaluated with respect 
to its immunomodulatory properties. Firstly, gamithromycin was chosen since macrolides 
have been suggested to be the most promising antimicrobial drugs regarding 
immunomodulation. This 15-membered semi-synthetic azalide is registered in view of the 
therapeutic and preventive treatment of bovine respiratory disease, associated with M. 
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haemolytica, P. multocida and H. somni. The superior characteristics of this drug are its 
potency, as well as in its long half-life of elimination (51 h), which is reflected by the ease of 
use, as only a single SC administration is needed (Huang et al., 2010).  
Secondly, the corticosteroid dexamethasone was selected as a positive control 
immunomodulatory drug, based on the reported results from several bovine studies 
(Ohtsuka et al., 1997a; Kiku et al., 2002; Malazdrewich et al., 2004a). As previously 
mentioned, veterinarians frequently decide on using this anti-inflammatory drug to elicit a 
fast clinical response in acute inflammatory diseases. Moreover, corticosteroids can be 
administered exclusively by veterinarians in Belgium. 
 Lastly, the NSAID ketoprofen was included for its previously reported beneficial 
effects in cattle (Semrad, 1993a; Donalisio et al., 2013). Additionally, according to a study of 
Pardon et al. (2012a), ketoprofen is the most frequently used NSAID in Belgian white veal 
calves.  
To the best of our knowledge, comparative in vivo studies regarding the 
immunomodulatory properties of antimicrobials drugs, corticosteroids and NSAIDs have not 
yet been performed in cattle. Moreover, LPS inflammation models to study these effects are 
currently rather limited and poorly standardized (Table 5).  
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The first reports suggesting beneficial effects of certain antimicrobial and (non)-
steroidal anti-inflammatory drugs ((N)SAIDs) on the innate immune system have led to high 
prospects of the research field of immunomodulation. In this respect, the need for bovine 
inflammation models in the absence of active bacteria has been put forward repeatedly. 
Consequently, an LPS inflammation model in calves can be used to investigate the influence 
of drugs on the release of pro-inflammatory cytokines and acute-phase proteins, as well as 
on the induced clinical signs. Irrespective of clinical settings, it has been demonstrated that 
pre-treatment is necessary in in vivo experiments to elicit a maximum effect of the drug on 
the immune response. 
Macrolides have been suggested to be the most promising antimicrobial drugs with 
respect to immunomodulation in humans and animals. The second generation macrolide 
gamithromycin (GAM) has been registered for the treatment of bovine respiratory disease, 
whereas data on its immunomodulatory properties are currently lacking. With respect to the 
use of anti-inflammatory drugs as ancillary therapy to bovine respiratory disease, the 
corticosteroid dexamethasone (DEX) and the NSAID ketoprofen (KETO) are frequently 
administered, irrespectively of the controversy regarding the choice between these drug 
classes. To date, it is insufficiently known to what extent DEX and KETO or their combination 
with GAM (GAM-DEX and GAM-KETO) can modulate the acute-phase response.  
Therefore, the GENERAL AIM of this doctoral thesis was to evaluate the 
immunomodulatory properties of GAM, DEX and KETO alone, as well as their two-drug 
combinations in a standardized LPS inflammation model in calves. This information 
contributes to an improved, evidence-based treatment strategy, with respect to production 
results, animal welfare and responsible drug use. 
In order to realize the general aim, the following SPECIFIC AIMS were postulated: 
1) To develop and characterize an LPS inflammation model in calves with emphasis on 
inflammatory mediators and the appearance of different clinical signs (Chapter 1). 
2) To determine the pharmacokinetic properties of KETO following intramuscular 
administration in calves, in order to optimize the study design (Chapter 2). 
3) To assess the pharmacodynamic effects of GAM, DEX and KETO in the previously 
developed inflammation model (Chapter 3). 
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CHAPTER 1 
Development of an intravenous lipopolysaccharide inflammation 
model in calves 
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Adapted from  
Plessers, E., Wyns, H., Watteyn, A., Pardon, B., De Backer, P., Croubels, S., 2015. 
Characterization of an intravenous lipopolysaccharide inflammation model in calves with 
respect to the acute-phase response. Veterinary Immunology and Immunopathology 163, 
46-56. 
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Abstract 
Our objective was to develop an LPS inflammation model in calves to evaluate the 
acute-phase response with respect to the release of pro-inflammatory cytokines and acute-
phase proteins, fever development and sickness behaviour. Fourteen 4-week-old male 
Holstein Friesian calves were included and randomly assigned to a negative control group (n 
= 3) and an LPS challenged group (n = 11). The latter received an intravenous bolus injection 
of 0.5 µg of LPS/kg body weight. Blood collection and clinical scoring were performed at 0, 
0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 28, 32, 48, 54 and 72 h post LPC challenge 
(p.c.). In the LPS group, the following clinical signs were observed successively: tachypnea 
(on average 18 min p.c.), decubitus (29 min p.c.), general depression (1.75 h p.c.), fever (5 h 
p.c.) and tachycardia (5 h p.c.). Subsequent to the recovery from respiratory distress, general 
depression was prominent, which deteriorated when fever increased. One animal did not 
survive LPS administration, whereas the other animals recovered on average within 6.1 h 
p.c. Moreover, the challenge significantly increased plasma concentrations of TNF-α, IL-6, 
SAA and Hp, with peaking levels at 1 h, 3.5 h, 24 h and 18 h p.c., respectively. The present 
LPS model was practical and reproducible, caused obvious clinical signs related to 
endotoxemia and a marked change in the studied inflammatory mediators, making it a 
suitable model to study the immunomodulatory properties of drugs in future research. 
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1. Introduction 
As a part of the outer membrane of Gram-negative bacteria, LPS or endotoxin is 
involved in many infectious bovine diseases, including neonatal diarrhea and respiratory 
disease (Radostitis et al., 2007; Pardon et al., 2012b). Intravascular or peripheral exposure of 
host cells to LPS is a possible trigger of a complex series of non-specific, predetermined and 
well-orchestrated reactions, intending to control the Gram-negative bacterial infection 
(Conner et al., 1989; Baumann and Gauldie, 1994): the acute-phase response. Nevertheless, 
the response can be excessive and subsequently result in detrimental effects to the host, like 
sepsis and septic shock (Peri et al., 2010). 
As a consequence of the marked similarity between the systemic effects of Gram-
negative bacterial infections and those provoked by an exogenous LPS challenge, endotoxin 
models have been widely applied in veterinary research to study diverse aspects of the 
acute-phase response (Lillie, 1974; Redl et al., 1993; Hodgson, 2006). More specifically, 
various experimental designs using different serotypes of LPS, ranging from high-dosed IV 
bolus injections to low-dose infusions over several hours, have been reported in calves (< 6 
months) (Adams et al., 1990; Kenison et al., 1991; Gerros et al., 1993; Semrad et al., 1993; 
Kinsbergen et al., 1994; Bieniek et al., 1998; Kushibiki et al., 2008). On the whole, data on 
the development of fever and the increased plasma concentrations of TNF-α are clear, 
emphasising the impact of contact with LPS. The duration and magnitude of the response, 
on the other hand, has been described to be related to the amount of circulating LPS (Gerros 
et al., 1993). Remarkably, data on the release of IL-1β, IL-6 and acute-phase proteins are 
either lacking or less frequently reported in young calves following experimental 
endotoxemia. Also regarding sickness behaviour in these animals, limited information is 
available (Borderas et al., 2008). 
Therefore, our first objective was to develop an LPS inflammation model in 4-week-old 
calves, with inclusion of TNF-α, IL-1β, IL-6, SAA and Hp, which could be applied in further 
research regarding the immunomodulatory properties of (N)SAIDs and antimicrobials. 
Secondly, through applying this model, the authors attempted to design a clinical scoring 
system for the early detection of illness. 
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2. Materials and methods 
2.1. Experimental animals 
Fourteen healthy male Holstein Friesian calves were conveniently selected from local 
farms shortly after birth. The calves were conventionally reared on the farm, generally 
through separation from the mother and subsequent housing in individual pens. All animals 
received an oral treatment with paromomycin sulphate (100 mg/kg BW, sid, 10 days) 
(Gabbrovet® 70, Ceva Santé Animale, Brussels, Belgium) on the farm of origin, in order to 
reduce cryptosporidiosis related symptoms (Grinberg et al., 2002). One week before the 
start of the experiment, at an average age of 22.6 ± 4.2 days, the calves were transferred to 
the Faculty of Veterinary Medicine. Upon arrival, the calves received a single treatment with 
5 mg/kg BW enrofloxacin (Floxadil® 50 mg/ml, Emdoka, Hoogstraten, Belgium) s.c., to limit 
the spread of respiratory infections. During the acclimatization period, the animals were 
housed in individual pens on straw with ad libitum access to hay and fresh water. The calves 
were fed milk replacer three times a day, receiving a total of 5 L daily. After the morning 
feeding, 50 g of starter mix was given to the calves.  
The animals’ clinical condition was evaluated twice a day, including the determination 
of the rectal body temperature and visual inspection of the faeces. Analysis of faecal 
samples (Easy-Digest, Bio K 151, Bio-X, Jemelle, Belgium) revealed the presence of antigen of 
rotavirus, E. coli and Cryptosporidium parvum in a number of calves (36%, 21% and 29%, 
respectively). However, in order to avoid interference with the experiment, the calves were 
not treated pharmacologically during the week of acclimatization. In case of diarrhoea, the 
calves would receive electrolyte therapy. If illness would require an antimicrobial and/or an 
anti-inflammatory treatment, the calf would be excluded from the experiment.  
At the end of the study, the calves were introduced in the teaching or experimental 
herd of our faculty. 
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2.2. Study protocol and sample collection 
The day before the experiment, the calves were weighed (54.8 ± 7.0 kg), after which a 
14 G indwelling catheter (Cavafix, B. Braun, Diegem, Belgium) was placed aseptically in the 
right jugular vein. A recovery period of at least 12 h was respected. After this period, the 
calves were randomly divided in two groups (average age 29.6 ± 4.2 days): a negative control 
group (CONTR; n = 3) and an LPS treated group (LPS; n = 11). The clinical condition at 0h was 
evaluated and a rectal body temperature ≥ 40 °C was handled as an exclusion criterion at 
this time.  
Reference venous blood samples (0 h) for cytokines and acute-phase proteins were 
collected from the catheter and transferred into tubes containing EDTA. The calves in the 
LPS-group were subsequently challenged IV with 0.5 µg/kg BW ultrapure LPS (500 units/kg 
BW, E. coli serotype O111:B4, LPS-EB Ultrapure, InvivoGen, Toulouse, France) via the 
catheter, while the CONTR calves received a similar volume of saline. Blood samples for 
cytokines and acute-phase proteins analyses were collected at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 
6, 8, 12, 18, 24, 28, 32, 48, 54 and 72 h p.c. At all mentioned sampling points, rectal body 
temperature, respiratory rate and heart rate were recorded. The respiratory rate was 
assessed first, before entry of the pens. Subsequently, the rectal body temperature was 
measured using a digital thermometer, followed by heart rate determination. Animals were 
also clinically scored by a qualified veterinarian during the first 9 h of the experiment, 
including the evaluation of the presence of dyspnea, coughing, breathing sounds, mental 
state, position and appetite. If systemic shock symptoms would occur, the respective calf 
would be humanely euthanized, and subsequently necropsied. The investigators were not 
blinded to the treatment groups. 
All blood samples were centrifuged at 1,000 × g for 15 min, after which the plasma 
was harvested and stored in aliquots at ≤ -70 °C for future analysis, with a maximum of 8 
months. 
All procedures were approved by the Ethical Committee of the Faculty of Veterinary 
Medicine (Ghent University) (EC 2009/153 and EC 2011/148). 
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2.3. Sample analyses for cytokines and acute-phase proteins 
All plasma samples were analysed in duplicate for cytokines and acute-phase proteins 
using commercially available ELISAs. The assays for cytokines were validated prior to use, as 
suitability for plasma samples was not guaranteed by the manufacturer. The validation 
procedure consisted of the determination of imprecision parameters (intra- and inter-assay 
coefficients of variation (CV)) as well as method inaccuracies by evaluation of the linearity 
under dilution (Maddens et al., 2010). Intra- and inter-assay CV values < 10% and < 15%, 
respectively, were assessed to be acceptable. For the evaluation of the inaccuracy, a 
recovery range of 80-120% for the linear dilutions was postulated. Additionally, the limit of 
quantification (LOQ) was calculated for these assays. To this end, the lowest cytokine 
concentration within the linear range of the standard curve was determined by evaluation of 
five standard curves for each cytokine.  
Following the manufacturer’s protocol for the Bovine TNF-α DuoSet (R&D Systems 
Europe, Abingdon, UK), an intra- and inter-assay CV of 5% and 8%, respectively, were 
obtained from the validation. The LOQ was set at 196 pg/mL. The validation procedure of 
the Bovine IL-1β and IL-6 Screening Sets (Thermo Fisher Scientific, Rockford, IL, USA), on the 
other hand, revealed the necessity of minor adjustments to the manufacturer’s protocol. 
These adjustments implied a replacement of the suggested reagent diluent (4% bovine 
serum albumin in Dulbecco’s phosphate buffered saline) by 5% Tween 20 in Dulbecco’s 
phosphate buffered saline, an additional wash procedure after coating (three washes), an 
additional wash step after blocking (one wash), and an increased number of washes for the 
subsequent three wash steps (from three to five washes). By applying these modifications, 
the intra- and inter-assay CV of the IL-1β Screening Set were 8% and 12%, respectively, 
whereas for the IL-6 Screening Set these values were 7% and 11%, respectively. An LOQ of 
125 and 286 pg/mL was calculated for IL-1β and IL-6, respectively. 
The SAA (Phase SAA Assay, Tridelta Development Ltd., Maynooth, Ireland) and Hp 
(Haptoglobin Bovine ELISA, Alpco, Salem, NH, USA) assays were performed according to the 
manufacturer’s protocol. The intra- and inter-assay CVs reported for the SAA ELISA were 
7.5% and 12%, respectively, whereas for the Hp assay, both CVs were described to be < 10%. 
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The analytical sensitivities, calculated by the manufacturers, were 1.5 µg/mL and 3.64 ng/mL 
for the SAA and Hp assay, respectively.  
  
2.4. Statistical analysis 
The results are presented as means (± SD). All given parameters were compared 
between the CONTR group and the LPS group using repeated measures analysis of variance 
(ANOVA). In this model, the effect of the group and time p.c., as well as the interaction of 
group and time p.c. were assessed. Differences were considered significant at P < 0.05. All 
analyses were performed in SPSS Statistics version 22 (IBM Corp., Armonk, NY, USA). 
 
3. Results  
The eventual number of animals in the LPS group was reduced from 11 to 9. The 
clinical condition at 0 h led to the exclusion of one calf, due to the presence of fever (40.7 
°C). The second calf was euthanized 50 min p.c. because of the appearance of severe shock 
symptoms. The necropsy and histological examination revealed acute diffuse alveolar 
damage, as well as compensatory changes of the myocardium. More specifically, the lung 
lesions included general congestion and oedema, multiple haemorrhages, multifocal alveolar 
emphysema and hyaline membrane formation. Infiltration of macrophages and neutrophils 
in the alveolar septa was observed, while inter-alveolar macrophages and neutrophils were 
less frequent. The myocardial changes, on the other hand, were indicative of an earlier 
injury, and might have enhanced the sensitivity to LPS. 
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3.1. Clinical signs 
The CONTR group showed no changes in rectal body temperature, respiratory rate and 
heart rate during the experiment, with mean values being 38.5 ± 0.2 °C, 30 ± 3 bpm and 73 ± 
5 bpm, respectively. Following the LPS challenge, all parameters altered significantly, 
whereas normalization was established within 24 h p.c. (Fig. 1.1-1.2). The mean rectal body 
temperature increased gradually in the LPS group and reached a maximum of 39.4 °C at 4-5 
h p.c., after which a slow decrease was initiated (Fig. 1.1; Table 1.1). However, two different 
visual trends were observed regarding the course of the rectal body temperature in this 
group: five calves showed an early rise in rectal body temperature (≤ 5 h p.c.), whereas the 
remaining four calves presented a more delayed development of fever (≥ 6 h p.c.), which 
was preceded by a slight drop in the body temperature at 3h p.c. (Fig. 1.1). The respiratory 
rate rose sharply in all calves after LPS administration, reaching a peak at 0.5 h p.c. (92 ± 24 
bpm), followed by a rather fast decline in the next hour (Fig. 1.2A). Regarding the heart rate 
in the LPS group, a subdivision was made, based on the different rectal body temperature 
trends (Fig. 1.2B). In the early responding rectal body temperature group (n = 5), the heart 
rate demonstrated a quite similar profile as for rectal body temperature, with a maximum at 
5 h p.c. (118 ± 12 bpm). The delayed responding rectal body temperature group (n = 4), on 
the other hand, showed a biphasic heart rate course, reaching a first peak at 3.5 h p.c. and a 
second peak at 8 h p.c. 
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Figure 1.1. Time course of the mean rectal body temperature following an IV bolus injection 
of either 0.5 µg/kg BW lipopolysaccharide (LPS; n = 9) (full line, closed triangle) or a similar 
volume of saline (CONTR; n = 3) (full line, open circle). The dash lines (open triangles) result 
from the subdivision of the calves in the LPS group in an early (n = 5) (short dashes) and a 
delayed responding group (n = 4) (long dashes), based on the time of maximal rectal body 
temperature (≤ 5 h or ≥ 6 h p.c.). For clarity of presentation, SDs are not included in this 
figure. However, Table 1.1 gives an overview of the full data set. 
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Figure 1.2. (A) Mean (+SD) respiratory rate following an IV bolus injection of either 0.5 µg/kg 
BW lipopolysaccharide (LPS; n = 9) (closed triangle) or a similar volume of saline (CONTR; n = 
3) (open circle). (B) Mean heart rate following an IV bolus injection of either 0.5 µg/kg BW 
lipopolysaccharide (LPS; n = 9) (full line, closed triangle) or a similar volume of saline 
(CONTR; n = 3; mean (‒SD)) (full line, open circle). The dash lines (open triangles) result from 
the subdivision of the calves in the LPS group in an early (n = 5; mean (‒SD)) (short dashes) 
and a delayed responding group (n = 4; mean (+SD)) (long dashes) with respect to fever 
development (≤ 5 h or ≥ 6 h p.c.). 
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Table 1.1. Mean (± SD) rectal body temperature following an i.v. bolus injection of either 0.5 µg/kg BW lipopolysaccharide (LPS; n = 9) or a 
similar volume of saline (CONTR; n = 3). The additional subdivision of the LPS group in an early (n = 5) and a delayed responding group (n = 4) is 
related to the time of maximal rectal body temperature (≤ 5 h or ≥ 6 h p.c.).  
 
Time p.c. (h) 0 0.5 1 1.5 2 2.5 3 3.5 4 5 6 8 12 18 24 
                 
CONTR 
(°C) 
 
 38.5 
(0.6) 
38.4 
(0.4) 
38.7 
(0.2) 
38.5 
(0.3) 
38.5 
(0.3) 
38.4 
(0.2) 
38.7 
(0.2) 
38.5 
(0.4) 
38.6 
(0.5) 
38.7 
(0.3) 
38.4 
(0.3) 
38.6 
(0.4) 
38.6 
(0.1) 
38.6 
(0.3) 
38.6 
(0.1) 
LPS  
Total 
(°C) 
 
 38.7 
(0.4) 
38.7 
(0.3) 
38.9 
(0.2) 
38.9 
(0.3) 
38.9 
(0.3) 
38.9 
(0.4) 
39.0 
(0.5) 
39.2 
(0.6) 
39.4 
(0.5) 
39.4 
(0.2) 
39.3 
(0.5) 
39.2 
(0.5) 
39.2 
(0.6) 
38.9 
(0.4) 
38.8 
(0.2) 
 LPS  
Early 
(°C) 
 
38.5 
(0.4) 
38.6 
(0.2) 
38.9 
(0.2) 
38.9 
(0.2) 
38.9 
(0.2) 
39.1 
(0.2) 
39.3 
(0.3) 
39.7 
(0.4) 
39.8 
(0.2) 
39.5 
(0.1) 
39.0 
(0.5) 
38.9 
(0.5) 
38.9 
(0.5) 
38.7 
(0.3) 
38.7 
(0.3) 
 LPS  
Delayed 
(°C) 
 
39.0 
(0.3) 
38.9 
(0.4) 
39.0 
(0.2) 
38.9 
(0.4) 
38.9 
(0.5) 
38.7 
(0.5) 
38.7 
(0.4) 
38.7 
(0.4) 
 
38.9 
(0.4) 
39.3 
(0.3) 
39.6 
(0.1) 
39.6 
(0.2) 
39.6 
(0.3) 
39.2 
(0.2) 
38.9 
(0.1) 
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Regarding the clinical signs and changes in mental state, position and appetite 
following the LPS challenge, three behavioural phases could be identified in the first 9 h of 
the experiment. All calves passed through these three phases, even though the intensity and 
duration of each phase varied among the animals (Fig. 1.3). None of the calves showed any 
interest in starter mix, hay or water during the three phases. The first phase was clearly 
associated with LPS administration, and was initiated at 17.9 ± 3.1 min p.c. by an anxious 
impression of the calves and the onset of dyspnea, which was characterized by an increased 
respiratory effort and tachypnea (respiratory rate > 80 bpm) (respiratory phase). In addition, 
two calves showed open-mouth breathing, which started at 22.5 ± 3.5 min p.c. One calf, on 
the other hand, only showed a moderate increase in respiratory rate. The onset of 
respiratory distress was marked by the appearance of coughing in six out of nine calves. 
Stridor in consequence of dyspnea occurred in four calves, independent of the incidence of 
coughing. Most of the animals lay down quickly, with the mean time to lie down being 29 ± 
18 min p.c. The calves that remained standing after the start of respiratory distress adopted 
a pose with extended neck and lowered head (n = 3). Most animals lay in sternal position, 
with their head and neck contacting the floor, whereas two of the calves demonstrated 
lateral decubitus immediately after lying down. None of the calves showed any interest in 
the environment during this phase, which continued up to the moment of recovery from 
respiratory distress (1.75 ± 0.9 h p.c.). The second phase was characterized by moderate 
depression that deteriorated again while fever developed (depression phase). Six calves 
showed lateral decubitus over a certain period in this phase. Finally, the last phase was 
distinguished by general recovery of the animals and could be recognized by regained 
alertness and vitality (recovery phase). Depression diminished after 5.0 ± 1.9 h, with 
adoption of a sternal position. The mean time at which the calves got up for the first time 
after the LPS challenge was 6.1 ± 1.1 h p.c., and was regarded as an indication of full 
recovery. Most calves drank water shortly after standing up. Milk (1 L) was first presented 7 
h p.c., and was refused by one calf at that moment. At 13 h p.c., none of the calves remained 
anorexic, as the supplied 2 L of milk and a handful of starter mix were consumed easily.  
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Figure 1.3. Time course of the three behavioural phases in the calves following an IV bolus 
injection of 0.5 µg/kg BW lipopolysaccharide (n = 9), based on scoring of the animals’ clinical 
condition during the first nine hours of the experiment. The boxes present the mean 
duration of the different phases, whereas the vertical lines indicate the minimum and 
maximum points in time at which the respective phase starts and ends, within a certain calf. 
The start of the respiratory phase is characterized by the onset of dyspnea. Recovery from 
respiratory distress, on the other hand, displays the end of this first phase, and 
simultaneously indicates the start of the depression phase. The latter ends when alertness is 
regained, while this observation initiates the recovery phase. The time at which the calf 
stands up is referred to as the end of this last phase, and consequently indicates full 
recovery of the calf.  
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3.2. Inflammatory mediators 
As can be observed from Fig. 1.4 and 1.5, the CONTR group presented no detectable or 
only basal concentrations of TNF-α, IL-6, SAA and Hp during the course of the experiment. 
Following the LPS challenge, on the other hand, plasma concentrations of these 
inflammatory mediators increased significantly. Cytokine levels normalized within 8 h p.c., 
whereas the acute-phase proteins returned to pre-challenge concentrations within 54 h p.c. 
TNF-α levels increased dramatically in the LPS group, reaching a peak as soon as 1 h p.c. (Fig. 
1.4A). Maximal IL-6 concentrations were recorded at a later time, namely at 3.5 h p.c. (Fig. 
1.4B). For IL-1β, on the other hand, only very low concentrations were measured in the LPS 
group following a 1/2 plasma dilution. However, as the validation procedure revealed a 
minimal dilution factor of 1/5 for plasma, no IL-1β levels could be demonstrated following 
LPS administration. As shown in Fig. 1.5A, the LPS group reached peak SAA plasma 
concentrations at 24 h p.c. Maximal Hp levels were determined prior to the SAA peak, 
namely at 18 h p.c. (Fig. 1.5B).  
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Figure 1.4. Mean (+SD) plasma concentrations of TNF-α (A) and IL-6 (B) following an IV bolus 
injection of either 0.5 µg/kg BW lipopolysaccharide (LPS; n = 9) (closed triangle) or a similar 
volume of saline (CONTR; n = 3) (open circle). 
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Figure 1.5. Mean (+SD) plasma concentrations of SAA (A) and Hp (B) following an IV bolus 
injection of either 0.5 µg/kg BW lipopolysaccharide (LPS; n = 9) (closed triangle) or a similar 
volume of saline (CONTR; n = 3) (open circle). 
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4. Discussion 
The present study demonstrates the feasibility of this LPS inflammation model to 
mimic the acute-phase response in calves. Besides a significant alteration of cytokine and 
acute-phase protein concentrations, non-specific symptoms of sickness were induced, 
including fever and depression. Furthermore, this is the first inflammation model in calves (< 
6 months) reporting increased plasma concentrations of IL-6, as well as of both SAA and Hp. 
The results of this study can serve as a basis to define the immunomodulatory properties of 
(N)SAIDs and antimicrobial drugs at different levels of the acute-phase response. 
Several research groups use neonatal calves for their experiments, which are obtained 
from local farms within 6 h of birth (Adams et al., 1990; Gerros et al., 1993; Rose and 
Semrad, 1992; Semrad et al., 1993). Upon arrival at the experimental site, these colostrum-
deprived calves receive pooled colostrum. Calves with negative results of a faecal screening 
test for K-99 antigen and positive results of a zinc sulphate turbidity test for colostral 
antibodies subsequently enter the study between 24 and 36 hours of age. Bieniek et al. 
(1998), on the other hand, obtained calves from local farms that were raised for a minimum 
of 19 days with their mother. Given the fact the mentioned studies in neonatal calves are 
not straightforward with respect to fever development, the present study applied a method 
of animal collection quite similar to that of Bieniek et al. (1998).  
Although calves are less sensitive to handling stress than for example pigs, three 
control animals were included in the present study. Stress can induce elevated cortisol 
concentrations, which in turn can result in the release of IL-6 (Cooke and Bohnert, 2011). 
Nevertheless, the calves in the present study were habituated to human presence and 
contact, as well as to experimental manipulations during the acclimatisation period. The 
indwelling catheter for blood collection was an additional measure to reduce stress. Indeed, 
the CONTR animals demonstrated no changes in their clinical condition, nor in cytokine or 
acute-phase protein concentrations. Therefore, we agree with the statement of Carroll et al. 
(2009b) that control treatments may not be necessary in these kind of experiments. Instead, 
animal-specific pre-challenge values could serve as an adequate control. For this reason, 
repeated measures ANOVA was selected as statistical test. 
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LPS exerts its effect through binding to Toll-like receptor 4 (TLR4), expressed on the 
surface of innate immune cells. As a consequence, an intracellular signaling pathway is 
initiated, which ultimately results in the activation of NF-κB. The latter stimulates the 
transcription of genes coding for pro-inflammatory cytokines and mediators, which play a 
key role in triggering the acute-phase response. The generally applied E. coli serotypes in 
bovine endotoxemia studies are O55:B5 and O111:B4. Since reports on the development of 
fever were not straightforward following the administration of serotype O55:B5, we selected 
the O111:B4 serotype for the present study (Kenison et al., 1991; Rose and Semrad, 1992). 
Additionally, Carroll et al. (2009b) demonstrated that this serotype resulted in the onset of 
fever, as well as in elevated concentrations of all studied pro-inflammatory cytokines and 
SAA in steers. In contrast with previous studies using the O111:B4 serotype, we administered 
a highly purified and well-characterized LPS batch. It was confirmed by the manufacturer 
that this type of ultrapure LPS only activates the TLR4 pathway. Most LPS preparations, on 
the other hand, are contaminated by other bacterial components, in this way activating both 
TLR4 and TLR2 signaling (Rutledge et al., 2012). The applied dose of 0.5 µg/kg BW (500 
units/kg BW) was carefully selected based on the different doses used in the studies of 
Werling et al. (1996), Bieniek et al. (1998) and Carroll et al. (2009b), in heifers, calves and 
steers, respectively. Since calves are physiologically extremely sensitive to LPS, the doses 
used in older animals were thought to be too high (Michaels and Banks, 1988). Bieniek et al. 
(1998), on the other hand, described their dose of 0.1 µg/kg BW to be low. For this reason, 
an intermediate amount of endotoxin was applied in the present study. Except for 
occurrence of shock symptoms in one animal, this was indeed found to be a suitable dose 
with respect to the aims of our research. The postulated exclusion criterion (rectal body 
temperature ≥ 40 °C), on the other hand, might have been too high. Therefore, in our 
opinion, this criterion should be adapted to at least 39.5 °C for future experiments.  
TNF-α has been put forward to be the principal mediator of acute inflammation in 
response to Gram-negative bacteria (Conti et al., 2004). The profile of our TNF-α plasma 
concentration-time curve showed a marked similarity to previously reported experiments: a 
sharp increase with a peak at 1 h p.c., followed by a rather fast decline, and a nearly 
complete normalization by 4 h p.c. The early peak was confirmed by previous endotoxin 
challenges in young calves (< 6 months) (Adams et al., 1990; Gerros et al., 1993; Kinsbergen 
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et al., 1994), although other authors reported maximal levels at 2 h p.c. (Kenison et al., 1991; 
Semrad et al., 1993; Bieniek et al., 1998; Kushibiki et al., 2008). Nevertheless, in the study of 
Kushibiki et al. (2008) blood sampling at 1 h p.c. was not included in the experimental 
design. Furthermore, no influence of age, the administered dose or serotype or method of 
administration (bolus or infusion) was observed. Plasma concentrations of IL-1β were very 
low in the LPS group of our experiment and could not be quantified due to the required 
dilution factor. In contrast to the frequent determination of TNF-α, only one study in calves 
reported increased activity of IL-1β in response to an endotoxin challenge, with maximal 
values at 3-3.5 h p.c. (Gerros et al., 1993). Research in older animals demonstrated maximal, 
yet low plasma concentrations of IL-1β at 3 h p.c. as well (Carroll et al., 2009b). These 
findings might be attributed to the rather low efficiency of IL-1β mRNA translation (Bailly et 
al., 1994). The present study is the first to report IL-6 levels in LPS-treated calves. Maximal 
concentrations were observed 3.5 h p.c., which is considerably later than the peak of TNF-α. 
This is in accordance to the findings of Carroll et al. (2009b) in steers, with a recorded peak 
of IL-6 at 3 h p.c. In our research, this cytokine’s plasma concentration-time curve had a 
rather symmetric shape, indicating a more gradual increase and decrease in comparison with 
TNF-α. Carroll et al. (2009b), on the other hand, still detected high levels of IL-6 at their final 
sampling time (8 h p.c.). 
Once released, these pro-inflammatory cytokines initiate the acute-phase response in 
collaboration with other peripheral inflammatory mediators, such as arachidonic acid 
metabolites, ROS and NO. Interestingly, the first clinical symptoms following LPS 
administration (17.9 ± 3.1 min p.c.), including dyspnea, coughing and stridor, preceded the 
increasing levels of pro-inflammatory cytokines. This early onset of the respiratory phase 
might be explained by the role of the lung as the major target organ for endotoxin in cattle, 
rapidly resulting in an increased respiratory drive, dyspnea, diffuse pulmonary oedema and 
congestion, as well as airway haemorrhages (Tikoff et al., 1966; Ohtsuka et al., 1997b; Preas 
et al., 2001). These lesions were confirmed by the histological examination of the lungs of 
the euthanized calf in our experiment at 50 min p.c. The open-mouth breathing, observed in 
two of the calves in our experiment, reflects the occurrence of severe respiratory distress 
and hypoxemia (Constable et al., 1991).  
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Reports on the course of the respiratory rate following LPS challenges in calves are not 
straightforward. In our experiment, the respiratory rate clearly peaked during the 
respiratory phase, with a maximal rate determined at the first sampling point (0.5 h p.c.). 
This early peak was confirmed by Constable et al. (1991) and Bieniek et al. (1998), while 
Borderas et al. (2008) and Kinsbergen et al. (1994) observed maximal frequencies only 3 h 
and 4 h p.c., respectively. Rose and Semrad (1992), on the other hand, reported no 
significant increase in respiratory rate following experimental endotoxemia in neonatal 
calves. In this respect, differences related to the administered dose, method of 
administration and age of the calves have been suggested to be of importance (Bieniek et 
al., 1998; Borderas et al., 2008). However, no trend could be observed depending on these 
factors, nor an effect of the specific LPS serotype selected for the challenge.  
During the respiratory phase, the calves were severely depressed, although respiratory 
symptoms predominated. The depression phase, on the other hand, resembled more to the 
development of naturally occurring illness, with anorexia and deteriorating depression while 
fever developed. In this regard, cytokines (particularly IL-1β and TNF-α) and prostaglandins 
play a pivotal role, inducing non-specific symptoms of illness following an LPS challenge 
(Johnson, 2002; Conti et al., 2004; Dantzer; 2009; Pecchi et al., 2009). Simultaneously with 
the induction of sickness behaviour, IL-1β and IL-6 stimulate the hypothalamic-pituitary-
adrenal axis and the subsequent production of adrenocorticotropic hormone and 
glucocorticoids (Werling et al., 1996; Carroll et al., 2009b). As a result, further cytokine gene-
expression is inhibited through a negative feedback mechanism (Baybutt and Holsboer, 
1990; Turnbull and Rivier, 1999). 
The onset of fever might be the most frequently studied effect following an LPS 
challenge. Both pyrogenic cytokines (TNF-α, IL-1β and IL-6 being the most relevant) and 
PGE2 have been reported to be of importance in fever development (Godson et al., 1995; 
Kushibiki et al., 2000; Conti et al. 2004; Blatteis, 2007). Also in the present study, a distinct 
effect of endotoxin on the body temperature was observed in calves. The occurrence of 
lateral decubitus during this febrile response is thought to be a form of thermoregulatory 
behaviour, increasing heat loss (Borderas et al., 2008). The rectal body temperature 
increased in our experiment from 1 h and up to 4-5 h p.c., which fairly corresponds to the 
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observations of Semrad (1993a), Kinsbergen et al. (1994), Bieniek et al. (1998) and Borderas 
et al. (2008) in young calves. Kenison et al. (1991), on the other hand, did not attain a well-
defined fever response in 3-month-old calves. In this respect, the authors suggested that the 
applied dose of 1 µg/kg BW of LPS might have been too low. Rose and Semrad (1992) 
reported a non-responding rectal body temperature as well following a 3-h-lasting IV 
endotoxin infusion of 3.25 µg/kg BW in neonatal calves. Nevertheless, the lowest dose 
studied in calves (0.025 µg/kg BW) already resulted in a marked increase in rectal body 
temperature (Borderas et al., 2008). The age of the calves in the latter study (3 weeks old) 
might have been of importance, although calves are considered immunocompetent at birth 
(Buddle et al., 2003). The degree of fever development is difficult to compare between 
different experiments, as many factors can interfere, including the administered dose, 
method of administration, method of body temperature determination, environmental 
temperature and breed (Johnson and von Borell, 1994; Carroll et al., 2013). Concerning the 
effect of the administered dose, Jacobsen et al. (2005) made a remarkable conclusion in 
adult cows: increasing doses of LPS (10 – 100 – 1000 ng/kg BW) resulted in a mono-, bi-, and 
triphasic pattern of the rectal body temperature, respectively. Different “waves” of PGE2 
synthesis might be of importance here (Blatteis et al., 2005; Blatteis, 2007). Furthermore, 
these authors reported an inverse relationship between the dose of endotoxin and the rectal 
body temperature, which could be attributed to a pre-shock effect in response to higher 
doses (Lohuis et al., 1988). This pre-shock effect might be an explanation for the two 
different rectal body temperature trends observed in our experiment. More specifically, the 
delayed responding rectal body temperature group showed a slight decline in rectal body 
temperature shortly after the LPS-challenge (2.5 h p.c.), whereas the early responding rectal 
body temperature group presented increasing values at this time. In this respect, we can 
conclude that individual variations in LPS-induced responses cannot be neglected. Several 
devices have been used in cattle to determine the body temperature. The rectal application 
of a digital thermometer is overall the most frequently reported method (Werling et al., 
1996; Borderas et al., 2008). Nevertheless, the accuracy of this measurement can be 
influenced by several factors, including defecation and repeated insertions of the 
thermometer (Burfeind et al., 2013). The use of an automatic rectal body temperature 
monitoring device might therefore be an interesting solution (Carroll et al., 2009b; Reuter et 
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al., 2010). Besides the decreased labour for researchers and the absence of handling stress 
in the animals, this device is able to record at 1 minute intervals. However, its suitability for 
rectal body temperature determination in young calves has not been evaluated. Carroll et al. 
(2009b) also determined the skin surface temperature in their endotoxin experiment. More 
specifically, shaved surfaces of the shoulder, rump and ear were recorded using an infrared 
thermometer. Although skin temperatures at the shoulder and rump increased following the 
endotoxin challenge, this was not as closely related to the LPS challenge as the rectal body 
temperature. Moreover, the ear skin temperature decreased dramatically during the 
experiment. Another method to evaluate the body temperature in older animals is by a 
temperature-sensitive bolus, which is placed in the rumen (Carroll et al., 2009b). Still, Reuter 
et al. (2010) reported that the LPS challenge affected the rectal body temperature more 
significantly than the ruminal temperature.  
Simultaneously with the onset of fever, the heart rate increased in the present study. 
The first peak in the biphasic heart rate profile of the delayed responding rectal body 
temperature group (3.5 h p.c.) might be attributed to the previously mentioned pre-shock 
effect. As for the respiratory rate, reports on the course of the heart rate from other 
experiments are not completely straightforward. Kinsbergen et al. (1994) and Bieniek et al. 
(1998) both confirm our findings, with nearly coinciding maxima for the heart rate and rectal 
body temperature. Kenison et al. (1991), on the other hand, recorded rapid heart rates 
already during the initial reaction to endotoxin. Interestingly, Borderas et al. (2008) reported 
no differences between HRs in LPS and saline challenged calves, not even around the time of 
maximum rectal body temperature.  
The acute-phase response is generally regarded to be beneficial to the organism, as it 
is important for providing protection to the animal, as well as for initiating events to restore 
the animal to a homeostatic condition (Carroll et al., 2009b). Nevertheless, when the 
reaction becomes dysregulated or excessive, it can result in life-threatening syndromes, such 
as sepsis and septic shock (Lillie, 1974; Peri at al., 2010). The slight decline in rectal body 
temperature shortly after the LPS challenge in the delayed responding group was previously 
linked to a pre-shock effect (Lillie, 1974). In human medicine, it has been described that 
hypothermic patients with septic shock have a significantly higher mortality than febrile 
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septic shock patients (Marik and Zaloga, 2000). Indeed, the calves in the early responding 
rectal body temperature group generally recovered faster from the challenge in comparison 
with the animals in the delayed responding group. Concerning the occurrence of shock, TNF-
α has been reported to be an important mediator (Beutler, 1985). In this respect, the over-
stimulation of TNF-α production by large amounts of endotoxin may result in intravascular 
coagulation, hypotension and shock (Rietschel and Brade, 1992). NO, which is released from 
endothelial cells immediately following an endotoxin challenge, contributes to shock 
development as well (Salvemini et al., 1990). During sepsis, both TNF-α and NO induce 
vascular dilatation, causing a large decrease in systemic vascular resistance. This situation 
can lead to distributive or vasodilatory (septic) shock, characterized by a hyperdynamic 
phase with increased heart rate and cardiac ouput (Klosterhalfen et al., 1992). This early 
hyperdynamic phase can evolve to a late hypodynamic phase, with a low cardiac output and 
a high systemic vascular resistance, accompanied by cold extremities (Garrido et al., 2004; 
Carroll et al., 2009b). Nevertheless, as mentioned before, endotoxin models do not 
accurately mimic patients with sepsis (Remick and Ward, 2005). Septic shock, for example, is 
often the result of vascular invasion by bacteria, which is consequently lacking following an 
LPS challenge (Fink and Heard, 1990). In this respect, Garrido et al. (2004) described in their 
review article that lower doses of LPS seem to result in the hyperdynamic phase of shock, 
whereas larger endotoxin doses induce the hypodynamic phase, resulting in rapid circulatory 
collapse and death. From this point of view, we can state that the dose of LPS applied in the 
present study rather induced a hypodynamic circulatory pattern. More specifically, the shock 
symptoms in the euthanized calf included tachycardia, tachypnea, lateral decubitus, pale 
mucosae, slow capillary refill and cold extremities.  
Besides the occurrence of non-specific symptoms of sickness, the acute-phase 
response is characterized by the hepatic synthesis of acute-phase proteins. Our LPS 
challenge induced increasing levels of both SAA and Hp, reaching maximal plasma 
concentrations at 24 and 18 h p.c., respectively. These findings emphasise the importance of 
a prolonged sampling period following an endotoxin challenge with respect to the study of 
acute-phase proteins. Reports on acute-phase proteins following experimental endotoxemia 
are clearly less frequent in calves in comparison with reports on cytokines. Kushibiki et al. 
(2008) reported maximal Hp levels at 24 h p.c., whereas Conner et al. (1989), remarkably, 
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observed peak Hp concentrations only 5 days p.c. In older calves (5-12 months), Elsasser et 
al. (2005) demonstrated increased levels of both acute-phase proteins following an LPS 
challenge. However, no conclusions on the sequence of appearance could be drawn from 
this study as only three sampling points were included (0, 7 and 24 h p.c.). The results of two 
studies in heifers and steers are rather controversial, as the sampling period only lasted for 6 
and 8 h, respectively (Werling et al., 1996; Carroll et al., 2009b). The observations of the 
present study do not correspond to the conclusions of studies applying experimental 
infections. More specifically, the latter generally report SAA to be a more rapidly reacting 
acute-phase protein than Hp (Horadagoda et al., 1994; Ganheim et al., 2003). In this respect, 
Horadagoda et al. (1999) even concluded that SAA and Hp may be used to discriminate 
between acute and chronic inflammatory conditions in cattle. This discrepancy, however, 
might be associated with the administration of merely endotoxin in the present study.  
All plasma analyses for cytokines and acute-phase proteins in the present study were 
performed by ELISAs. These assays are highly specific and sensitive, and are still considered 
as the gold standard today (Elshal and McCoy, 2006). Nevertheless, the authors strongly 
advise to run analyses within one specific batch, as we stated rather large differences 
between the results of assays from different lots for certain parameters. In this respect, the 
development of a multiplex assay might be of interest as well, as ELISAs are rather time and 
sample-consuming (Dernfalk et al., 2007; Wyns et al., 2013). 
The clinical scoring in the present study was performed by direct observation of the 
animals. Borderas et al. (2008), on the other hand, recorded the calves before and after the 
LPS challenge using video cameras. Subsequently, the behaviour of the animals was scored 
minutely by a single observer. This enabled the authors to formulate extensive reports 
regarding the behaviour of the animals following experimental endotoxemia, including the 
duration of standing, lying sternally and lying laterally. However, such reports were not the 
objective of the present study. The course of the depression phase, on the other hand, was 
of major interest for us, as one of our aims encompassed the development of a clinical 
scoring system for the early detection of illness. Indeed, the early symptoms during the 
respiratory phase do not correspond to naturally occurring illness, but the fact that 
depression deteriorated while fever developed was an important finding. Once the maximal 
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rectal body temperature was passed in each of the calves, alertness and appetite were 
gradually regained. In this respect, depression among a group of calves might be indicative 
of a developing infection. Contradictorily, an increased respiratory rate and fever were 
reported to be the early signs of pneumonia in calves, while depression only developed later 
(Lorenz et al., 2011). This statement might, however, depend on the observational skills of 
the animal keeper, with severe depression being secondary to fever in pneumonic calves. 
Accordingly, Apley (2006) emphasises the importance of detecting the earliest signs of 
depression with respect to the chance of success of bovine respiratory disease therapy. This 
author even suggests treating on the basis of depression with undifferentiated fever. To 
further define “depression” in calves, we can conclude from our study that anorexia and 
depression, characterized by sustained (lateral) decubitus, were omnipresent during the 
depression phase. In addition, Borderas et al. (2008) observed reduced self-grooming, 
rumination and ingestion of hay, as well as an increase in time spent lying and standing 
inactive. Rumination was not assessed in the present study, as only a few calves developed 
this behaviour during the acclimatization period. In older animals, ruminal hypomotility has 
indeed been established to be a good parameter for evaluating sickness behaviour (Jacobsen 
et al., 2005).  
 
5. Conclusion 
We developed and characterized a reliable LPS inflammation model in calves, clearly 
inducing all aspects of the acute-phase response. In this respect, the release of pro-
inflammatory cytokines and acute-phase proteins was significantly enhanced, and non-
specific symptoms of sickness appeared following the endotoxin challenge. Regarding the 
latter, we recorded deteriorating depression while fever developed. This observation 
emphasises the importance of the recognition of depression in the early detection of illness.  
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Determination of the pharmacokinetic parameters of R(‒) and S(+) 
ketoprofen in calves following intramuscular administration of a 
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Abstract  
The pharmacokinetic properties of ketoprofen (KETO) were determined in 4-week-old 
calves after intramuscular (IM) injection of a racemic mixture at a dose of 3 mg/kg body 
weight. Due to possible enantioselective disposition kinetics and chiral inversion, the plasma 
concentrations of the R(‒) and S(+) enantiomer were quantified separately, using a 
stereospecific validated high-performance liquid chromatography (HPLC) assay with 
ultraviolet (UV) detection. A distinct predominance of the S(+) enantiomer was observed, as 
well as significantly different pharmacokinetic parameters between  R(‒) and S(+) KETO. 
More in specific, a greater value for the mean area under the plasma concentration-time 
curve (AUC0→∞) (46.92 ± 7.75 and 11.13 ± 2.18 µg.h/mL for the S(+) and R(‒) enantiomer, 
respectively), a lower apparent clearance (Cl/F) (32.8 ± 5.7 and 139.0 ± 25.1 mL/h.kg for the 
S(+) and R(‒) enantiomer, respectively) and a lower apparent volume of distribution (Vd/F) 
(139 ± 14.7 and 496 ± 139.4 mL/kg for the S(+) and R(‒) enantiomer, respectively) were 
calculated for the S(+) enantiomer, indicating enantioselective pharmacokinetics for KETO in 
calves following IM administration.  
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1. Introduction 
KETO (Fig. 2.1) or 2-(phenyl 3-benzoyl) propionic acid is a non-steroidal anti-
inflammatory drug (NSAID) that is still commonly used in a wide range of indications in 
human and veterinary medicine for anti-inflammatory, antipyretic and analgesic purposes 
(Hersh et al., 2000; Lees et al., 2004; Pardon et al., 2012a). KETO is a chiral compound and 
veterinary formulations are racemic mixtures, containing both enantiomers in equal 
amounts. The S(+) enantiomer has been generally accepted to be pharmacologically active, 
through inhibition of COX (Cabré et al., 1998). R(‒) KETO, on the other hand, is a weak COX 
inhibitor, whereas the analgesic effect of KETO has been associated with this enantiomer 
(Cooper et al., 1998; Ghezzi et al., 1998).  
 
 
 
Figure 2.1. Chemical structure of R(‒) ketoprofen (A) and S(+) ketoprofen (B) 
 
As a result of the highly chiral environment of the body, the pharmacokinetic (PK) and 
pharmacodynamic (PD) properties can significantly differ between both KETO enantiomers. 
The species-specific differences in PK may be attributed to enantioselectivity in each of the 
pharmacokinetic processes, including chiral conversion from R(‒) to S(+) KETO (Landoni and 
Soraci, 2001). The IV or extravascular administration of racemic KETO demonstrated 
enantioselective PK in sheep, camels, pigs, horses, dogs, cats and poultry, with a 
A 
B 
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predominance of the S(+) enantiomer in plasma of most species, except for sheep, camels 
and poultry, in which R(‒) KETO predominated (Delatour et al., 1993; Jaussaud et al., 1993; 
Landoni and Lees, 1995a; Landoni et al., 1999; Al Katheeri et al., 2000; Arifah et al., 2001; 
Lees et al., 2003; Fosse et al., 2011; Neirinckx et al., 2011a; Mustonen et al., 2012). In 
contrast, the IV administration of the racemate in calves revealed no enantioselectivity 
(Landoni et al., 1995). Besides stereoselective PK, chiral conversion of R(‒) to S(+) KETO has 
been confirmed in calves, cows, sheep, goats, pigs, horses, dogs, cats, rabbits and humans 
following the administration of R(‒) KETO (Jaussaud et al., 1993; Aberg et al., 1995; Landoni 
and Lees, 1995b, 1996; Rudy et al., 1998; Landoni et al., 1999; Arifah et al., 2001, 2003; 
Igarza et al., 2002; Lees et al., 2003; Neirinckx et al., 2011b). Hence, the plasma 
concentrations of both enantiomers are similar in calves despite the occurrence of chiral 
conversion, which corresponds to the observations in goats and humans. 
Notwithstanding the fact that the IM administration of KETO is highly frequent in 
calves, to the authors’ knowledge, no data on the enantioselective behaviour of KETO 
following this route of administration have been reported in calves. Therefore, the aim of 
this study was to determine and compare the PK of the R(‒) and the S(+) enantiomer after 
IM administration of the drug racemate. Additionally, these characteristics will be applied in 
further research on the immunomodulatory properties of KETO, either alone or in 
combination with antimicrobial drugs, in our previously developed LPS inflammation model 
in calves. 
 
2. Materials and methods 
Eight male 4-week-old Holstein Friesian calves, with an average BW of 53.9 ± 5.8 kg, 
were obtained from local farms. During an acclimatization period of one week, the animals 
were housed in individual pens on straw with ad libitum access to hay and fresh water. The 
calves were fed milk replacer three times a day, receiving a total of 5 L daily. One day before 
the start of the experiment, a 14G indwelling catheter (Cavafix, B. Braun, Diegem, Belgium) 
was placed in the jugular vein.  
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Racemic KETO (Ketofen® 10%, Merial, Diegem, Belgium) was administered IM in the 
left neck region (cervical ventral serratus muscle) at a dose of 3 mg/kg BW, as recommended 
by the manufacturer. Blood samples were drawn from the catheter and transferred to EDTA 
tubes (Vacutest Kima, Piove di Sacco, PD, Italy) just before administration and at 0.25, 0.5, 
0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 20 and 24 h post-administration (p.a.). Blood 
samples were centrifuged at 1,500 x g for 15 min at 4 °C and plasma was stored at ≤ -20 °C 
until analysis, for a maximum of 2 months. All procedures were approved by the Ethical 
Committee of the Faculty of Veterinary Medicine (Ghent University) (EC 2013/28). 
Plasma concentrations of R(‒) and S(+) KETO were quantified by a validated HPLC-UV 
method, preceded by derivatization of both enantiomers. Both the racemic KETO standard 
and the racemic internal standard, fenoprofen, were obtained from Sigma-Aldrich. First, 
plasma samples (500 µL) were spiked with internal standard, acidified using 200 µL HCl (1 
mol/L), extracted with 5 mL of isooctane-isopropanol (95:5, v/v), and subsequently, the 
organic phase was evaporated under a stream of nitrogen at 40 °C. The derivatization of 
KETO and fenoprofen was then performed using L-leucinamide, principally according to the 
method described by Foster and Jamali (1987). L-leucinamide converts the enantiomers into 
their diastereomers, which potentiates their separation on a conventional HPLC reversed-
phase column. Subsequently, a 20 µL aliquot of the sample was injected onto a Thermo 
Separation Products (Fremont, CA, USA) HPLC system consisting of a P-4000 pump, an AS 
3000 autosampler and a Spectra Focus Forward scanning UV-detector set at 260 nm. The R(‒
) fenoprofen peak was used as internal standard. 
The PK parameters were calculated by means of the WinNonlin software program, 
version 6.3 (Pharsight Corporation, Mountain View, CA, USA), using a non-compartmental 
and a one-compartmental method for R(‒) and S(+) KETO, respectively. The model with the 
best fit was selected after visual inspection of the fitted curve. Values below the limit of 
quantification of 0.05 µg/mL were excluded from the PK analysis. The area under the plasma 
concentration-time curve (AUC0→∞) was calculated using the trapezoidal method with 
extrapolation to infinity. The elimination rate constant (λz) was deduced from the lower part 
of the plasma concentration-time curve for the R(‒) enantiomer. Data are expressed as 
means ± standard deviation (SD) and were statistically analysed by means of a Mann-
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Whitney U test, using SPSS 21.0 software for Windows (IBM Corp., Armonk, NY, USA). 
Differences were considered significant at P < 0.05. 
 
3. Results 
Semi-logarithmic plots of the mean R(‒) and S(+) KETO plasma concentration versus 
time curves after IM administration of the racemic mixture are presented in Figure 2.2. 
Quantifiable concentrations of R(‒) and S(+) KETO were measured until 10 h and 20 h p.a., 
respectively. The mean calculated PK parameters for both enantiomers are summarized in 
Table 2.1, indicating that most parameters differ significantly between R(‒) and S(+) KETO. 
 
 
Figure 2.2. Mean (± SD) plasma concentration-time profiles of R(‒) and (S+) KETO after a 
single IM administration of 3 mg/kg BW of the racemic mixture in calves (n = 8).  
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Table 2.1. Pharmacokinetic parameters (mean ± SD) of R(‒) and S(+) KETO in calves after a 
single IM administration of 3 mg/kg BW of the racemic mixture, using a non-compartmental 
and a one-compartmental method for R(‒) and S(+) KETO, respectively (n = 8). 
 
 
AUC0→∞, area under the plasma concentration-time curve, extrapolated to infinity; kel, elimination 
rate constant; t1/2el, half-life of elimination; tmax, time to maximum plasma concentration; Cmax, 
maximum plasma concentration; Cl/F, total clearance not corrected for bioavailability; Vd/F, volume 
of distribution not corrected for bioavailability; MRT, mean residence time. 
Different letters within a row indicate significant differences between the enantiomers. 
 
4. Discussion 
The present study is the first to describe the PK of R(‒) and S(+) KETO after IM 
administration of a racemic mixture in calves. Similar to most of the animal species 
mentioned above, a predominance of the S(+) enantiomer was determined at all sampling 
points. In this context, a lower apparent clearance (Cl/F) and a greater AUC0→∞ value were 
calculated for this enantiomer, as well as a lower apparent volume of distribution (Vd/F). 
However, the identification of the processes involved in the observed enantioselectivity 
could not be determined due to the experimental design.  
In calves, only the chiral conversion metabolic phenomenon, which occurs 
predominantly in the liver, has been reported as a factor possibly contributing to 
stereoselective PK (Mehvar and Jamali, 1988; Landoni and Lees, 1995b; Igarza et al., 2002). 
The extent of chiral conversion is highly species specific, ranging from 5% in sheep to 51% in 
Parameter Units R(‒) KETO S(+) KETO 
AUC0→∞ µg.h/mL 11.13 ± 2.18
a 46.92 ± 7.75b 
kel /h 0.29 ± 0.06 0.24 ± 0.05 
t1/2el h 2.45 ± 0.48 3.02 ± 0.60 
tmax h 0.50 ± 0.23
a 0.98 ± 0.18b 
Cmax µg/mL 5.40 ± 1.41
a 8.56 ± 0.80b 
Cl/F mL/h.kg 139.0 ± 25.1a 32.8 ± 5.7b 
Vd/F mL/kg 496 ± 139.4
a 139 ± 14.7b 
MRT h 2.30 ± 0.33 ‒ 
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newborn calves (Landoni et al., 1999; Igarza et al., 2002). However, as mentioned earlier, 
enantioselectivity in each of the pharmacokinetic processes can also be involved. As drugs 
are generally absorbed through passive non-ionic diffusion, and absorption by active 
processes is not reported for KETO, stereospecificity is not expected in this phase. 
Differences between the enantiomers regarding their distribution, on the other hand, can be 
the result of enantioselective binding to plasma or tissues proteins (Tucker and Lennard, 
1990). As with other NSAIDs, KETO is very highly bound to plasma proteins, resulting in low 
Vd values (Vd/F in the present study was 496 ± 139.4 mL/kg and 139 ± 14.7 mL/kg for R(‒) 
and S(+) KETO, respectively) (Lees et al., 2004). In cattle, 97% protein binding has been 
reported for KETO, while data on binding of the respective enantiomers in calves are lacking 
(EMA, 1995). Still, the extent of protein binding differed significantly between the 
enantiomers in female camels and humans, although drug and protein concentrations as 
well as differences in protein configuration might be of importance (Dubois et al., 1993; Al 
Katheeri et al., 2000). The higher plasma protein binding of R(‒) KETO compared to S(+) 
KETO in camels was reflected by both a higher Vd and a higher Cl for the S(+) enantiomer. 
However, a higher Cl for one enantiomer could also be attributed to enantioselectivity in 
elimination. For example, stereoselective glucuronidation has been stated for KETO in 
rabbits, which partially contributed to the faster clearance of the R(‒) enantiomer (Abas and 
Meffin, 1987). In vitro studies using canine liver microsomes, on the other hand, 
demonstrated a formation ratio of S(+) to R(‒)-glucuronides of 4.5 (Chakir et al., 1994). 
Besides this enantioselectivity in biotransformation, biliary and urinary excretion have been 
reported to be stereoselective as well. A preferential biliary excretion of the S(+) enantiomer 
in rats, followed by an enantioselective enterohepatic circulation in favour of S(+) KETO, 
resulted in a significantly longer half-life of elimination (t1/2el) for this enantiomer (Menzel et 
al., 1993). In addition, Foster et al. (1988) recorded a higher recovery of S(+) KETO in urine of 
humans after the administration of a racemic mixture. Stereoselectivity in the renal 
processes of active secretion and, yet less likely, active reabsorption have been suggested in 
this context (Tucker and Lennard, 1990).  
The present study demonstrated significant differences between the enantiomers 
regarding the maximum plasma concentration (Cmax) and the time to maximum plasma 
concentration (tmax). These two parameters have been reported to be indirect measures of 
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rate of drug absorption, although their reliability has been questioned repeatedly (Endrenyi 
et al., 1991; Lacey et al., 1994). In this respect, Lacey et al. (1994) established that 
Cmax/AUC0→∞ is a more sensitive and powerful indirect measure for estimation of absorption 
rate. The application of this metric on our data revealed a ratio of 0.48 ± 0.05 and 0.19 ± 
0.02 for R(‒) and S(+) KETO, respectively, indeed reflecting a significant difference in rate of 
absorption between the enantiomers. Accordingly, a PK study following IM administration of 
the enantiomers individually could further elucidate this observation, and could reveal 
whether chiral inversion is a contributing factor.  
In contrast to the results of the present study in 4-week-old calves, enantioselective PK 
of KETO were not reported after IV administration of the same dose of the racemic mixture 
in 20-week-old ruminating calves, with a mean BW of 119 kg (Landoni et al., 1995). These 
authors observed nearly identical values for AUC and Cl for both enantiomers. Moreover, 
after administration of this 3 mg/kg BW dose, the values for AUC0→∞ and half-life of 
elimination (t1/2el) were found to be remarkably higher in the present study using IM 
administration in 4-week-old calves compared to IV administration in 20-week-old calves (for 
S(+) KETO, 46.92 and 9.94 µg.h/mL for AUC and 3.02 and 0.42 h for t1/2el, respectively) 
(Landoni et al., 1995). This finding can be explained by a ten-fold lower Cl/F in 4-week-old 
calves in comparison with 20-week-old calves (for S(+) KETO, 32.8 and 330 mL/h.kg, 
respectively). As glucuronidation to an acyl-glucuronide has been reported to be the major 
biotransformation process in most animal species, the lower Cl/F might be the result of an 
immature hepatic capacity for metabolizing drugs in young, mainly milk-fed calves (Shoaf et 
al., 1987; Kawalek and El Said, 1994; Mauleón et al., 1996; Igarza et al., 2004).  
Unlike the observations of Landoni et al. (1995), the IV administration of the 
enantiomers individually demonstrated enantioselective differences in ruminating calves 
weighing on average 113 kg (Landoni and Lees, 1995b), as well as in newborn calves (Igarza 
et al., 2002, 2004), which corresponds to our findings. Landoni and Lees (1995b) observed 
31% of inversion from R(‒) to S(+) KETO, combined with a longer t1/2el for S(+) KETO. Igarza et 
al. (2002, 2004) reported a higher percentage of inversion in newborn calves (51%), as well 
as significantly different values for AUC and Cl between the enantiomers. Nevertheless, 
enantioselectivity in more than one PK process may be compensatory and in that way result 
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in similar AUC values for individual enantiomers after the administration of the drug 
racemate (Evans, 1992). In this respect, further research could elucidate the processes 
contributing to the observed differences, including possible age- or diet-related factors. 
In conclusion, plasma concentrations of S(+) KETO predominated over R(‒) KETO 
subsequent to the IM administration of racemic KETO in calves. In contrast with the 
previously reported PK observed after IV administration of the drug racemate, the results of 
the present study demonstrate distinct enantioselective differences between the PK 
properties of R(‒) and S(+) KETO. This emphasizes the importance of enantioselective PK 
studies in comparison to total drug analyses, with respect to the understanding of 
pharmacological and toxicological consequences, as well as for the prediction of potential 
drug interactions and influences of the inflammatory state.  
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of veterinary drugs with respect to the acute-phase response 
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CHAPTER 3.1 
Study of the immunomodulatory properties of gamithromycin and 
dexamethasone in lipopolysaccharide-challenged calves 
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Abstract 
The aim of this study was to define the in vivo immunomodulatory properties of the 
macrolide antibiotic gamithromycin (GAM) in calves, with respect to the acute-phase 
response. Additionally, the corticosteroid dexamethasone (DEX) was included as a positive 
control immunomodulatory drug. Both drugs, as well as their combination, were studied in a 
previously developed inflammation model, which was initiated by an IV LPS challenge (0.5 
µg/kg body weight). The results were compared to those obtained previously in calves that 
received no pharmacological treatment (LPS-group; n = 9). In the present experiment, 
eighteen 4-week-old male Holstein Friesian calves were treated with GAM (n = 6), DEX (n = 
6) or their combination (n = 6) 1 h prior to LPS administration. Blood collection and clinical 
scoring were performed at regular time points until 72 h p.c. Plasma concentrations of 
selected cytokines (TNF-α and IL-6) and acute-phase proteins (SAA and Hp) were 
subsequently determined. GAM did not have any effect on the LPS-induced clinical signs 
(dyspnea, fever, anorexia and depression), nor on the studied inflammatory mediators. In 
the DEX and combination group, the occurrence of dyspnea and fever was not prominently 
influenced, although the calves recovered significantly faster from the challenge. Moreover, 
DEX significantly inhibited the levels of TNF-α and IL-6, suggesting a key role for these 
cytokines in sickness behaviour. In conclusion, unlike DEX, GAM did not directly reduce 
cytokine release in an LPS inflammation model in calves.  
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1. Introduction 
Acute inflammatory diseases in cattle, like bovine respiratory disease and mastitis, can 
evolve to dysregulated or excessive immune reactions, consequently impairing animal 
welfare (Bradley, 2002; Snowder et al., 2007; Peri et al., 2010). In this respect, the first 
reports suggesting beneficial effects of certain antimicrobial and (N)SAIDs on the innate 
immune system have led to high prospects of the research field of immunomodulation, 
particularly in regard to the treatment of endotoxemic or septicemic patients (Labro, 2000; 
Christaki et al., 2011). Also the need for bovine inflammation models in the absence of active 
bacteria has been put forward repeatedly in view of the study of the immunomodulatory 
properties of antibiotics and anti-inflammatory drugs in cattle (Bednarek et al., 2003; Buret, 
2010). In this respect, an LPS-induced acute-phase response in calves can serve as a model to 
investigate the influence of drugs on the release of pro-inflammatory cytokines and acute-
phase proteins, as well as on the clinical signs, including dyspnea, fever, anorexia and 
depression (Semrad, 1993a; Ohtsuka et al., 1997a; EMA, 2001; Plessers et al., 2015b). 
Moreover, this information could contribute to the development of improved treatment 
strategies, with emphasis on animal welfare (Zarogoulidis et al., 2012). 
Macrolide antibiotics have been demonstrated to possess immunomodulatory 
properties, independently of their antimicrobial actions (Labro, 2000; Giamarellos-
Bourboulis, 2008; Kanoh and Rubin, 2010). In this respect, modulation of the release of pro-
inflammatory cytokines and alteration of neutrophil functions are frequently reported 
effects. In cattle, both in vitro and in vivo studies have confirmed several immunomodulatory 
actions of tilmicosin and tulathromycin, including the induction of apoptosis in pulmonary 
neutrophils and the subsequent reduction of interleukin (IL)-8 and leukotriene B4 synthesis 
(Buret, 2010; Fischer et al., 2013). For the relatively recent azalide GAM (Fig. 3.1.1), on the 
other hand, data regarding its immunomodulatory behaviour are lacking (Huang et al., 
2010). 
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Figure 3.1.1. Chemical structure of gamithromycin (GAM) 
 
Despite the immunosuppressive effect of corticosteroids, these drugs are frequently 
used in the treatment of acute inflammatory processes in cattle, based on their good short-
term effects (Lekeux and Van de Weerdt, 1997). Accordingly, corticosteroids inhibit various 
components of the acute-phase response, including the onset of fever and the release of 
pro-inflammatory cytokines (Coelho et al., 1995; Brattsand and Linden, 1996). In calves, 
Ohtsuka et al. (1997a) indeed demonstrated an inhibitory effect of DEX (Fig. 3.1.2) on LPS-
induced TNF-α serum levels. From this point of view, DEX can be referred to as a positive 
control immunomodulatory drug.  
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Figure 3.1.2. Chemical structure of dexamethasone (DEX) 
 
The aim of this research was to study the immunomodulatory properties of GAM and 
DEX, as well as the combination of both drugs, in our previously developed in vivo LPS 
inflammation model in calves (Plessers et al., 2015b). More specifically, emphasis was placed 
on the pro-inflammatory cytokines TNF-α and IL-6, the acute-phase proteins SAA and Hp, 
and the clinical signs following endotoxin challenge. 
  
2. Materials and methods 
2.1. Animal experiment 
In order to evaluate the effects of the different pharmacological treatments, the 
results of the present study were compared to those obtained in a previous experiment, 
which was performed in a similar time frame (Plessers et al., 2015b). The aim of the former 
study was to develop a reproducible inflammation model in 4-week-old calves, using nine 
animals, which were not treated pharmacologically prior to the LPS challenge (LPS group; n = 
9). Furthermore, the effects of the challenge on the release of pro-inflammatory cytokines 
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(TNF-α and IL-6), acute-phase proteins (SAA and Hp), fever development and sickness 
behaviour were extensively described in this paper. 
With respect to the present study, eighteen healthy male Holstein Friesian calves, with 
a mean age of 21.3 ± 5.8 days, were obtained from local farms. Upon arrival at the Faculty of 
Veterinary Medicine, the calves were housed and treated following a similar protocol as 
described in Plessers et al. (2015b). Briefly, the animals were housed in individual pens on 
straw with ad libitum access to hay and fresh water. The calves were fed milk replacer three 
times a day, receiving a total of 5 L daily. After the morning feeding, 50 g of starter mix was 
given to the calves. In order to evaluate the animals’ clinical condition and to habituate the 
animals to human presence and contact, as well as to experimental manipulations, a one-
week acclimatisation period was set. The day before the start of the experiment, the calves 
were weighed (56.8 ± 6.1 kg) after which a 14 G indwelling catheter (Cavafix, B. Braun, 
Diegem, Belgium) was placed aseptically in the right jugular vein, in order to facilitate serial 
blood collection. A recovery period of at least 12 h was respected. After this period, the 4-
week-old calves were randomly divided into three groups: a GAM group (n = 6), a DEX group 
(n = 6) and a GAM-DEX group (n = 6). The clinical condition at 0 h was evaluated by 
determination of the rectal body temperature and visual inspection of the faeces. A rectal 
body temperature ≥ 39.5 °C was handled as an exclusion criterion at this time. 
Reference venous blood samples (0 h) for cytokines and acute-phase proteins were 
collected from the catheter and transferred into EDTA-containing tubes. According to the 
group, the calves were subsequently treated with either 6 mg/kg BW GAM (Zactran®, Merial, 
Diegem, Belgium) subcutaneously (SC) in the neck region, 0.3 mg/kg BW DEX (Dexa® 0.2%, 
Kela Laboratoria, Hoogstraten, Belgium) IM in the neck region (cervical ventral serratus 
muscle), or the combination of both drugs (6 mg/kg BW GAM SC and 0.3 mg/kg BW DEX IM). 
One hour after drug administration, all calves were IV challenged with 0.5 µg/kg BW 
ultrapure LPS (500 units/kg BW, E. coli serotype O111:B4, LPS-EB Ultrapure, InvivoGen, 
Toulouse, France) via the catheter. Blood samples for cytokines and acute-phase proteins 
analyses were collected at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 28, 32, 48, 54 and 72 
h p.c. At all mentioned sampling points, rectal body temperature (RT), respiratory rate (RR) 
and heart rate (HR) were recorded as well. Additionally, animals were clinically scored during 
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the first 9 h of the experiment, including the evaluation of the presence of dyspnea, 
coughing, breathing sounds, mental state, position and appetite. Based on these 
observations, the appearance of the three behavioural phases (respiratory, depression and 
recovery phase) following LPS administration was recorded (Plessers et al., 2015b). If clinical 
signs of systemic shock would occur during the experiment, the respective calf would be 
humanely euthanased, and subsequently submitted for post-mortem examination. The 
investigators were not blinded to the treatment groups. 
All blood samples were centrifuged at 1,000 x g for 15 min, after which plasma was 
harvested and stored in aliquots at ≤ -70 °C until analysis, with a maximum of 6 months. 
All procedures were approved by the Ethical Committee of the Faculty of Veterinary 
Medicine of Ghent University (EC 2011/057). 
 
2.2. Sample analyses for cytokines and acute-phase proteins 
Plasma samples were analysed in duplicate for cytokines and acute-phase proteins 
using commercially available ELISAs. As their suitability for plasma samples was not 
guaranteed by the manufacturer, the assays for cytokines (Bovine TNF-α DuoSet, R&D 
Systems Europe, Abingdon, UK; and Bovine IL-6 Screening Set, Thermo Fisher Scientific, 
Rockford, IL, USA) were validated prior to use (Plessers et al., 2015b). The SAA (Phase SAA 
Assay, Tridelta Development Ltd., Maynooth, Ireland) and Hp (Haptoglobin Bovine ELISA, 
Alpco, Salem, NH, USA) assays were performed according to the manufacturer’s protocol.  
 
2.3. Statistical analysis 
The results are presented as means (± SD or + SD). The effect of the LPS challenge 
within the different groups was assessed using repeated measures ANOVA. Additionally, 
area under the curve (AUC0→t) values for the time course of RT (AUC0→24h), RR (AUC0→6h), HR 
(AUC0→24h) as well as TNF-α (AUC0→6h), IL-6 (AUC0→8h), SAA (AUC0→72h) and Hp (AUC0→72h) 
plasma concentrations were calculated, and subsequently analysed by single factor ANOVA 
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(Altan et al., 2010). Pairwise comparisons of the mean AUC values of the different groups 
were performed using the Bonferroni test. For those parameters that were not normally 
distributed, the Kruskal-Wallis ANOVA by ranks was applied. Parameters that were only 
recorded once (including the occurrence of coughing, abnormal breathing sounds, open 
mouth breathing and the time of full recovery) were analysed using single factor ANOVA 
with Bonferroni-corrected pairwise comparisons. Differences were considered significant at 
P < 0.05. All analyses were performed in SPSS Statistics version 22 (IBM Corp., Armonk, NY, 
USA). 
 
3. Results 
3.1. Clinical signs 
Mean pre-LPS-challenge values for rectal body temperature, respiratory rate and heart 
rate among the different groups were 38.8 ± 0.2 °C, 35 ± 3 bpm and 75 ± 14 bpm, 
respectively. As can be observed from Table 3.1.1, Fig. 3.1.3 and Fig. 3.1.4, the effect of LPS 
was present in all groups, since these parameters altered significantly in time within each of 
the groups following LPS challenge (P < 0.05). Conversely, no significant differences were 
observed between the groups (Table 3.1.2). Normalization of the clinical signs was generally 
established within 24 h p.c. Two different visual trends regarding the course of the rectal 
body temperature were present in the LPS group, i.e. an early (n = 5) and delayed (n = 4) 
responding group, with a peak in rectal body temperature ≤ 5 h p.c. and ≥ 6 h p.c., 
respectively (Fig. 3.1.3). The DEX and GAM-DEX group showed a rectal body temperature 
course similar to the early responding LPS group, while the GAM group rather corresponded 
to the delayed responding LPS group. The respiratory rate raised sharply in all groups after 
LPS administration, reaching a peak at 0.5 h p.c., followed by a rather fast decline in the next 
hour (Fig. 3.1.4A). Regarding the heart rate, a consistent increase was observed within each 
of the groups (Fig. 3.1.4B), although the time of maximal heart rate differed among the 
groups. 
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Table 3.1.1. Mean (± SD) rectal body temperature (°C) after an IV bolus injection of 0.5 µg/kg BW lipopolysaccharide, either not preceded by 
drug administration (LPS; n = 9) or following a pre-treatment with gamithromycin (GAM; n = 6), dexamethasone (DEX; n = 6) or the combination 
of both drugs (GAM-DEX; n = 6). The additional subdivision of the LPS group in an early (n = 5) and a delayed responding group (n = 4) is related 
to the time of maximal rectal body temperature (≤ 5 h or ≥ 6 h p.c.). 
 
 
Time p.c. (h) 0 0.5 1 1.5 2 2.5 3 3.5 4 5 6 8 12 18 24 
                 
LPS  
Total 
 
 38.7 
(0.4) 
38.7 
(0.3) 
38.9 
(0.2) 
38.9 
(0.3) 
38.9 
(0.3) 
38.9 
(0.4) 
39.0 
(0.5) 
39.2 
(0.6) 
39.4 
(0.5) 
39.4 
(0.2) 
39.3 
(0.5) 
39.2 
(0.5) 
39.2 
(0.6) 
38.9 
(0.4) 
38.8 
(0.2) 
 LPS  
Early 
 
38.5 
(0.4) 
38.6 
(0.2) 
38.9 
(0.2) 
38.9 
(0.2) 
38.9 
(0.2) 
39.1 
(0.2) 
39.3 
(0.3) 
39.7 
(0.4) 
39.8 
(0.2) 
39.5 
(0.1) 
39.0 
(0.5) 
38.9 
(0.5) 
38.9 
(0.5) 
38.7 
(0.3) 
38.7 
(0.3) 
 LPS  
Delayed 
 
39.0 
(0.3) 
38.9 
(0.4) 
39.0 
(0.2) 
38.9 
(0.4) 
38.9 
(0.5) 
38.7 
(0.5) 
38.7 
(0.4) 
38.7 
(0.4) 
 
38.9 
(0.4) 
39.3 
(0.3) 
39.6 
(0.1) 
39.6 
(0.2) 
39.6 
(0.3) 
39.2 
(0.2) 
38.9 
(0.1) 
GAM 
 
 
 38.8 
(0.2) 
39.0 
(0.3) 
38.8 
(0.3) 
38.7 
(0.3) 
38.8 
(0.5) 
38.7 
(0.5) 
38.8 
(0.7) 
39.0 
(0.7) 
39.0 
(0.8) 
39.1 
(0.7) 
39.2 
(0.5) 
39.2 
(0.3) 
39.6 
(0.6) 
39.4 
(0.5) 
39.0 
(0.3) 
DEX 
 
 
 38.8 
(0.2) 
39.0 
(0.2) 
39.0 
(0.4) 
39.1 
(0.3) 
39.3 
(0.4) 
39.6 
(0.6) 
39.8 
(0.6) 
39.9 
(0.4) 
39.9 
(0.4) 
39.4 
(0.2) 
39.1 
(0.2) 
38.9 
(0.2) 
39.0 
(0.2) 
38.9 
(0.1) 
38.6 
(0.1) 
GAM-DEX 
 
 38.7 
(0.1) 
38.9 
(0.3) 
39.1 
(0.3) 
 
39.1 
(0.3) 
39.3 
(0.4) 
39.6 
(0.4) 
39.8 
(0.4) 
39.8 
(0.4) 
39.7 
(0.4) 
39.1 
(0.2) 
39.0 
(0.3) 
38.9 
(0.4) 
39.0 
(0.4) 
38.8 
(0.3) 
38.7 
(0.3) 
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Figure 3.1.3. Time course of the mean rectal body temperature in 4-week-old calves after an 
IV bolus injection of 0.5 µg/kg BW lipopolysaccharide, either not preceded by drug 
administration (LPS – Early responding group (n = 5) and LPS – Delayed responding group (n 
= 4)) or following pre-treatment with gamithromycin (GAM; n = 6), dexamethasone (DEX; n = 
6) or the combination of both drugs (GAM-DEX; n = 6). For clarity of presentation, SDs are 
not included in this figure. However, Table 3.1.1 gives an overview of the full data set. 
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Figure 3.1.4. Mean (+SD) respiratory rate (A) and heart rate (B) in 4-week-old calves after an 
IV bolus injection of 0.5 µg/kg BW lipopolysaccharide, either not preceded by drug 
administration (LPS; n = 9) or following pre-treatment with gamithromycin (GAM; n = 6), 
dexamethasone (DEX; n = 6) or the combination of both drugs (GAM-DEX; n = 6).  
0
20
40
60
80
100
120
140
0 0.5 1 1.5 2 2.5 3 3.5 4 5 6
R
e
sp
ir
at
o
ry
 r
at
e
 (
b
p
m
)
Time p.c. (h)
LPS
GAM
DEX
GAM-DEX
0
20
40
60
80
100
120
140
160
180
0 1 2 3 4 5 6 8 12 18 24
H
e
ar
t 
ra
te
 (
b
p
m
)
Time p.c. (h)
LPS
GAM
DEX
GAM-DEX
A 
B
A 
 103 
 
Table 3.1.2. Mean (± SD) area under the curve (AUC0→t) values for the time course of the rectal body temperature (RT), the respiratory rate 
(RR), the heart rate (HR),  and TNF-α, IL-6, SAA and Hp plasma concentrations following an IV bolus injection of 0.5 µg/kg BW 
lipopolysaccharide, either not preceded by drug administration (LPS; n = 9) or following a pre-treatment with gamithromycin (GAM; n = 6), 
dexamethasone (DEX; n = 6) or the combination of both drugs (GAM-DEX; n = 6). Within a parameter, groups sharing a superscript letter do not 
differ from one another at the 5% global significance level. 
 
 
 
RT 
AUC0→24h 
(°C x h) 
RR 
AUC0→6h 
(bpm x h) 
HR 
AUC0→24h 
(bpm x h) 
TNF-α 
AUC0→6h 
(ng/mL x h) 
IL-6 
AUC0→8h 
(ng/mL x h) 
SAA 
AUC0→72h 
(mg/mL x h) 
Hp 
AUC0→72h 
(mg/mL x h) 
        
LPS 937a 
(7) 
310a 
(83) 
2448a 
(332) 
25.9a 
(4.3) 
60.1a 
(32.1) 
12.6a 
(4.2) 
5.3a 
(3.6) 
GAM 942a 
(6) 
313a 
(86) 
2853a 
(503) 
33.5a 
(14.4) 
79.6ab 
(64.5) 
12.8a 
(4.9) 
11.3a 
(10.8) 
DEX 936a 
(2) 
281a 
(62) 
2125a 
(423) 
7.8b 
(5.4) 
17.8bc 
(8.7) 
10.3a 
(2.2) 
21.1a 
(22.8) 
GAM-DEX 935a 
(7) 
294a 
(50) 
2647a 
(369) 
7.1b 
(6.6) 
13.0c 
(9.0) 
9.7a 
(2.7) 
24.3a 
(18.9) 
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The LPS and GAM group demonstrated a rather similar course of the three successive 
behavioural phases, even though the intensity and duration of each phase varied among the 
individual animals (Fig. 3.1.5). None of the calves in these two groups showed any interest in 
starter mix, hay or water before the end of the recovery phase was reached. The calves in 
the DEX and GAM-DEX group, on the other hand, presented a number of remarkable 
deviations, including the absence of the depression phase and a faster recovery from the 
challenge.  
 
 
Figure 3.1.5. Time course of the three behavioural phases (respiratory, depression and 
recovery phase) in 4-week-old calves after an IV bolus injection of 0.5 µg/kg BW 
lipopolysaccharide, either not preceded by drug administration (LPS; n = 9) or following pre-
treatment with gamithromycin (GAM; n = 6), dexamethasone (DEX; n = 6) or the 
combination of both drugs (GAM-DEX; n = 6). This figure is based on scoring of the animals’ 
clinical condition during the first nine hours of the experiment. In general, the boxes 
represent the mean duration of the different phases, whereas the vertical lines indicate the 
minimum and maximum points in time at which the respective phase starts and ends, within 
a certain calf. The squares in the DEX and GAM-DEX group indicate an exception as they 
represent the mean time at which alertness was regained. Hence, the depression phase was 
absent in these groups, as the calves became alert already during the respiratory phase.  
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During the respiratory phase, the calves were severely depressed, although respiratory 
symptoms predominated. Even though two and three calves of the DEX and GAM-DEX 
group, respectively, only showed moderate tachypnea (> 45 and ≤ 80 bpm), the occurrence 
of coughing (67-83%) and open-mouth breathing (17-33%) during the respiratory phase did 
not differ significantly among the four studied groups. Nevertheless, abnormal breathing 
sounds like stridor and stertor were absent in the DEX and GAM-DEX group, while in the 
remaining two groups, audible respiration occurred in approximately 50% of the animals. 
Most calves lay in sternal position, with their head and neck contacting the floor. Two calves 
in the LPS group and one calf in the GAM group already demonstrated lateral decubitus 
during this phase. Remarkably, alertness was regained prior to the recovery from respiratory 
distress in the DEX and GAM-DEX group (squares in Fig. 3.1.5).  
For the calves in the LPS and GAM group, the depression phase was characterized by 
moderate depression that deteriorated while fever developed. During this phase, 67 and 
33% of the calves in the LPS and GAM group, respectively, showed lateral decubitus over a 
certain period. Due to the early regained alertness of the calves in the DEX and GAM-DEX 
group (squares in Fig. 3.1.5), the depression phase was absent in these groups. Moreover, 
half of the DEX-treated calves already ate a small amount of starter mix prior to the fever 
peak (at approximately 2 h p.c.). 
Since the depression phase was lacking following DEX administration, the calves in the 
DEX and GAM-DEX group recovered significantly faster than the calves in the LPS and GAM 
group. Full recovery, which was recognized by the moment at which the calf stands up, was 
observed in the LPS, GAM, DEX and GAM-DEX group at a mean time of 6.1, 5.9, 2.5 and 3.7 h 
p.c., respectively. Milk (1 L) was first presented 7 h p.c., and was refused by one calf in the 
LPS group and two calves in the GAM group at this time. At 13 h p.c., all calves easily 
consumed the supplied 2 L of milk and a handful (50 g) of starter mix. 
 
 
 
 
CHAPTER 3.1 
 
 
106 
 
3.2. Inflammatory mediators 
Maximal levels of TNF-α, IL-6, SAA and Hp were attained at 1, 2.5-3.5, 24 and 18-28 h 
p.c., respectively, in all groups (Fig. 3.1.6 and 3.1.7). Nevertheless, cytokine concentrations 
were clearly reduced in the DEX and GAM-DEX group. For TNF-α, these declines were 
significant in comparison with both the LPS and the GAM group (Fig. 3.1.6A; Table 3.1.2). 
Also regarding IL-6, this overall lower trend following DEX pre-treatment persisted, although 
a significant difference could not be demonstrated between the GAM and the DEX group 
(Fig. 3.1.6B; Table 3.1.2). As described previously, IL-1β levels could not be determined due 
to the low concentrations and the required dilution factor for this assay (Plessers et al., 
2015b). With respect to SAA, DEX did not induce significant decreases, even though a slight 
inhibition of SAA-levels was perceived (Fig. 3.1.7A; Table 3.1.2). Regarding Hp, on the other 
hand, no stable trends could be observed among the DEX-treated groups, nor any significant 
differences between the groups (Fig. 3.1.7B; Table 3.1.2).  
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Figure 3.1.6. Mean (+SD) plasma concentrations of TNF-α (A) and IL-6 (B) in 4-week-old calves after 
an IV bolus injection of 0.5 µg/kg BW lipopolysaccharide, either not preceded by drug administration 
(LPS; n = 9) or following pre-treatment with gamithromycin (GAM; n = 6), dexamethasone (DEX; n = 
6) or the combination of both drugs (GAM-DEX; n = 6). 
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Figure 3.1.7. Mean (+SD) plasma concentrations of SAA (A) and Hp (B) in 4-week-old calves after an 
IV bolus injection of 0.5 µg/kg BW lipopolysaccharide, either not preceded by drug administration 
(LPS; n = 9) or following pre-treatment with gamithromycin (GAM; n = 6), dexamethasone (DEX; n = 
6) or the combination of both drugs (GAM-DEX; n = 6). 
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4. Discussion 
In order to elicit a maximal effect of the drug on the innate immune response, all drugs 
were administered 1 h prior to LPS administration. This interval corresponds to the time of 
maximum plasma concentration of GAM (Huang et al., 2010), as well as to the interval 
applied by Ohtsuka et al. (1997a) between DEX administration and the IV LPS bolus. 
Regarding GAM, the dose recommended by the manufacturer was applied, whereas for DEX, 
the dose used by Ohtsuka et al. (1997a) was administered, as the latter authors reported a 
clear influence of this dose on TNF-α release in calves. 
The main objective of this study was to evaluate whether GAM, a second generation 
macrolide, indeed exerts immunomodulatory properties in calves. Drugs that exert both 
anti-bacterial as well as anti-inflammatory effects have been suggested to be most effective 
in treating bacteria-induced inflammatory diseases (Buret et al., 2010). Nevertheless, in the 
present study, the administration of GAM had no influence on the LPS-induced clinical signs, 
nor on the studied inflammatory mediators. Similarly to the LPS group, depression 
deteriorated in the GAM group while the rectal body temperature increased. This group 
even demonstrated a rectal body temperature profile, more or less analogous to that of the 
delayed responding LPS group. A delayed rectal body temperature response was previously 
associated with a pre-shock effect in certain calves, consequently suggesting that GAM 
induced a more pronounced inflammatory reaction in comparison with the average of the 
LPS group (Lohuis et al., 1988; Plessers et al., 2015b). These findings do not correspond to 
previous reports on other macrolide antibiotics in cattle (Buret, 2010; Mazzilli and Zecconi, 
2010; Fischer et al., 2011). More specifically, tilmicosin, tylosin and tulathromcyin have all 
been confirmed to exert certain immunomodulatory actions in bovine in vitro and/or in vivo 
studies. Although the underlying mechanisms have yet to be fully characterized, the ability 
of tilmicosin and tulathromycin to induce neutrophil apoptosis is a recurrently reported 
effect (Chin et al., 1998; Lee et al., 2004; Fisher et al., 2011). This is a highly important 
finding, as the production of pro-inflammatory mediators is inhibited in apoptotic cells. 
Nonetheless, the influence of macrolide antibiotics on the release of pro-inflammatory 
cytokines in cattle is a less explored research field. Besides the in vitro inhibition of 
transcription and secretion of the neutrophil attractant IL-8 by tulathromycin in LPS-
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stimulated neutrophils and macrophages, only the downregulation of IL-1 and IL-6 by tylosin 
was reported in a Staphylococcus aureus challenged bovine cell line (Mazzilli and Zecconi, 
2010; Fischer et al., 2011, 2013). Also in other animal species, data from in vivo macrolide 
studies on the modulation of pro-inflammatory cytokine release are rather scarce, and 
principally limited to mice and rats (Ianaro et al., 2000; Tkalcevic et al., 2006; Leiva et al., 
2007). However, when interpreting the results of the GAM group of the present study, it 
should be kept in mind that a bacterial infection was lacking in the present study, and that 
this may also affect the clinical significance. From this point of view, the evaluation of GAM 
in a bacterial infection model could provide additional insights regarding its 
immunomodulatory properties.  
In the present study, the potent long-acting corticosteroid DEX was selected as a 
positive control immunomodulatory drug. This choice was based on reports in cattle, 
confirming the capacity of DEX to inhibit the endotoxin-induced cardiopulmonary response, 
fever development and pro-inflammatory cytokine release (Olson and Brown, 1986; Lohuis 
et al., 1989; Ohtsuka et al., 1997a). The effects on the lung and rectal body temperature are 
generally attributed to the lipocortin-mediated inhibition of the formation of arachidonic 
acid metabolites, including TXA2 and PGE2 (Coelho et al., 1995). The influence on the release 
of pro-inflammatory cytokines, on the other hand, is rather associated with repression of 
transcription factor NF-κB, which plays a key role in the activation of immunoregulatory 
genes in response to inflammatory stimuli (Auphan et al., 1995; Smoak and Cidlowski, 2004). 
Nevertheless, the results from the present experiment did not correspond entirely to the 
previously mentioned studies, since respiratory distress and fever development following 
LPS challenge were not prominently influenced by pre-treatment with DEX. Still, DEX had a 
clear positive influence on recovery from the challenge, as the depression phase was absent 
in the DEX-treated groups. Also regarding TNF-α and IL-6, a marked inhibition was evoked by 
DEX, subsequently resulting in lower SAA levels. From this point of view, it can be put 
forward that depression is associated with cytokine release (particularly TNF-α). Previous 
research indeed established that peripherally produced pro-inflammatory cytokines induce 
sickness behaviour (Johnson, 2002; Dantzer, 2009). Regarding the discrepancy between the 
hypothesized and observed effects of DEX, it can be suggested that the inactivation of NF-κB 
occurs sooner than the inhibition of eicosanoid production, the latter being rather correlated 
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with fever development. Accordingly, binding of a glucocorticoid to its receptor results in a 
fast inhibition of NF-κB activity, while several hours of corticosteroid incubation are required 
for neutrophils to synthesize maximal lipocortin levels in vitro (Hirata, 1983; Smoak and 
Cidlowski, 2004). Overall, it can be concluded that the effects of DEX are not unambiguous. 
This is in accordance with findings in literature, as different studies on the efficacy of 
corticosteroids as (ancillary) therapy in the treatment of acute inflammatory processes have 
yielded controversial results (Christie et al., 1977; Espinasse et al., 1992; Semrad, 1993b; 
Sustronck et al., 1997; Malazdrewich et al., 2004b; Hewson et al., 2011). In this respect, the 
determination of eicosanoid concentrations, including PGE2 and TXA2, might provide an 
improved insight into the different effects of DEX observed in the present study. However, as 
these analyses require a specific sampling protocol (i.e. addition of indomethacin in order to 
prevent ex vivo artefactual eicosanoid generation), these inflammatory mediators could not 
be determined for the present experiment.  
 
5. Conclusions 
This in vivo study in 4-week-old calves demonstrated that neither GAM nor DEX fully 
exerted their hypothesized immunodulatory actions following an IV endotoxin challenge. 
Nevertheless, pre-treatment with DEX resulted in a faster recovery, consequently improving 
animal welfare. The information obtained in the present study can therefore contribute to 
the development of improved treatment combinations and strategies, and can serve as a 
basis to compare the clinical efficacy of corticosteroids and NSAIDs.  
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Abstract 
Background: Macrolide antibiotics and NSAIDs have been reported to be modulators of the 
innate immune response, irrespectively of their antimicrobial and anti-inflammatory actions. 
The macrolide gamithromycin (GAM) and the NSAID ketoprofen (KETO) are frequently used 
drugs in bovine veterinary medicine. 
Hypothesis: (1) Both GAM and KETO attenuate the acute-phase response following an 
intravenous LPS challenge in calves, resulting in a faster clinical recovery. (2) The combined 
administration of GAM and KETO is beneficial due to synergistic and/or additive effects. 
Animals: Sixteen 4-week-old Holstein-Friesian calves. 
Methods: Experimental study, based on a previously developed LPS inflammation model. 
The calves were randomized into 4 groups: LPS group (positive control) receiving no 
pharmacological treatment (n = 4), and GAM (n = 4), KETO (n = 4) and GAM-KETO (n = 4) 
group receiving the respective drugs 1 h prior to LPS challenge (0.5 µg/kg body weight). 
Clinical scoring was performed and plasma concentrations of the selected cytokines (TNF-α 
and IL-6), acute-phase protein (SAA) and PGE2 were quantified. 
Results: Pre-treatment with KETO had a remarkable effect in the LPS model, as depression, 
anorexia and fever were completely inhibited. PGE2 synthesis was significantly reduced by 
KETO, whereas the effect on TNF-α, IL-6 and SAA was not straightforward. Pre-treatment 
with GAM had no effect compared to the LPS group and the combination treatment 
provided no synergistic or additive effects in this model, neither clinically nor regarding the 
studied inflammatory mediators. 
Conclusion and clinical importance: KETO entirely inhibited fever development and 
depression, while GAM did not exert any effect in this model. The effect of KETO can be 
attributed to the complete reduction of PGE2 levels. These results promote the concomitant 
use of an antimicrobial drug and a NSAID in the treatment of calf diseases associated with 
LPS, both to enhance clinical recovery and to improve animal welfare. 
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1. Introduction 
Bacterial infections are highly common in bovine veterinary medicine, with LPS playing 
a key role in the pathogenesis of several of these clinical entities. Currently, the treatment of 
acute bacterial infections in cattle is mostly restricted to the administration of antimicrobial 
drugs (Edwards et al., 2010; Pardon et al., 2012a). However, both from the animal welfare 
and economic perspective, the concomitant use of an anti-inflammatory drug is 
advantageous as it decreases the severity of clinical symptoms and limits the negative 
consequences of inflammation (Francoz et al., 2012). In this respect, the choice between a 
NSAID and a corticosteroid remains a controversial topic in cattle practice (Lekeux and Van 
de Weerdt, 1997). Although immunosuppression is a well-known side effect of 
corticosteroids, these drugs are still commonly preferred by practitioners for their potent 
anti-inflammatory properties (Sustronck et al., 1997; Wagner and Apley, 2004; Hewson et 
al., 2011; Sipka et al., 2013). Indeed, a fast clinical effect on depression and anorexia is highly 
appreciated by farmers. Nevertheless, in our previous study in LPS challenged calves, DEX 
did not inhibit the onset of respiratory distress and fever (Plessers et al., in preparation). A 
faster recovery of the calves, on the other hand, was observed as well as reduced levels of 
the pro-inflammatory cytokines TNF-α and IL-6 and the acute-phase protein SAA. 
From this point of view, NSAIDs might exert a more pronounced influence on the LPS-
induced acute-phase response in comparison with corticosteroids. Indeed, COX-inhibitors 
directly block the enzymatic production of prostanoids. As a result, the production of 
prostaglandins and thromboxanes ceases, consequently resolving fever and pulmonary 
effects (Lekeux and Van de Weerdt, 1997; Lees et al., 2004). In addition to these COX-
dependent actions, certain NSAIDs have been established to modulate the innate immune 
response, including the inhibition of NF-κB-related gene transcription (Tegeder et al., 2001; 
Bryant et al., 2003). In bovine veterinary medicine, KETO is a commonly used NSAID, exerting 
anti-inflammatory, antipyretic and analgesic effects (Lees et al., 2004; Pardon et al., 2012a). 
Particularly with respect to the treatment of bovine respiratory disease, the 
combination of an antimicrobial agent with a NSAID (including carprofen, flunixin 
meglumine, KETO and meloxicam) has been demonstrated to be superior to the 
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administration of an antimicrobial alone (Lockwood et al., 2003; Elitok and Elitok, 2004; 
Friton et al., 2005). In this context, GAM is a recently developed azalide that has been 
approved for the treatment of bovine respiratory disease (Huang et al., 2010). To date, 
studies comparing the efficacy of NSAIDs and corticosteroids in cattle are rather limited, 
whereas research regarding their possible synergistic and additive effects with GAM is 
lacking.  
Therefore, the aim of this study was to investigate the immunomodulatory properties 
of KETO in a previously developed inflammation model in calves. The combined 
administration of GAM and KETO was included in the study to test for synergistic and/or 
additive effects. Besides the effect on TNF-α, IL-6, SAA and clinical signs, emphasis was 
placed on the impact on prostanoids, i.e. PGE2. 
 
2. Materials and methods 
2.1. Animal experiment 
Twenty-four healthy male Holstein Friesian calves, with a mean age of 21.1 ± 4.0 days, 
were obtained from local farms.  Upon arrival at the Faculty of Veterinary Medicine, the 
calves were housed and treated following a similar protocol as described in Plessers et al. 
(2015b). Briefly, the animals were housed in individual pens on straw with ad libitum access 
to hay and fresh water. The calves were fed milk replacer three times a day, receiving a total 
of 5 L daily. After the morning feeding, 50 g of starter mix was given to the calves. In order to 
evaluate the calves’ clinical condition, and to habituate the animals to human presence and 
contact, as well as to experimental manipulations, a one-week acclimatization period was 
set.  
The calves were weighed the day before the start of the experiment (56.1 ± 6.9 kg), 
after which a 14 G indwelling catheter (Cavafix, B. Braun, Diegem, Belgium) was placed 
aseptically in the right jugular vein. A recovery period of at least 12 h was respected. After 
this period, the 4-week-old calves were randomly divided into four groups: an LPS group (n = 
6), a GAM group (n = 6), a KETO group (n = 6) and a GAM-KETO group (n = 6). Negative 
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control animals were not included in the present study, as our previous research 
demonstrated that these animals showed no changes regarding clinical condition, nor with 
respect to cytokine and acute-phase protein concentrations (Plessers et al., 2015b). The 
clinical condition at 0 h was evaluated by determination of the rectal body temperature and 
visual inspection of the faeces. A rectal body temperature ≥ 39.5 °C was handled as an 
exclusion criterion at this time. 
Reference venous blood samples (0 h) for cytokines and SAA were drawn from the 
catheter and transferred into EDTA-containing tubes. Additionally, reference blood samples 
for PGE2 determination were collected by adding 1 mL of blood into Eppendorf tubes 
previously coated with 10 µg indomethacin (Sigma Aldrich, Diegem, Belgium) and containing 
10 IU of sodium heparine (Heparine LEO, Leo Pharma, Lier, Belgium). The indomethacin was 
added in order to prevent ex vivo artefactual eicosanoid generation (Pelligand et al., 2012). 
Briefly, 100 µL of the stock solution of indomethacin (0.1 mg/mL in ethanol (VWR, Leuven, 
Belgium)) were added per tube, and evaporated to dryness under a gentle stream of 
nitrogen (N2) at 35 °C. According to the group, the calves were subsequently either not 
treated (LPS group), treated with 6 mg/kg BW GAM (Zactran®, Merial, Diegem, Belgium) SC 
in the neck region, treated with 3 mg/kg BW KETO (Ketofen® 10%, Merial, Diegem, Belgium) 
IM in the neck region (cervical ventral serratus muscle), or treated with the combination of 
both drugs (6 mg/kg BW GAM SC and 3 mg/kg BW KETO IM). Following a one-hour interval, 
all calves were IV challenged with 0.5 µg/kg BW ultrapure LPS (500 units/kg BW, E. coli 
serotype O111:B4, LPS-EB Ultrapure, InvivoGen, Toulouse, France) via the catheter. Blood 
samples were collected at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 28, 32, 48, 54 and 72 
h p.c. At all mentioned sampling points, rectal body temperature (RT), respiratory rate (RR) 
and heart rate (HR) were recorded. Additionally, animals were clinically scored during the 
first 9 h of the experiment, including the evaluation of the presence of dyspnea, coughing, 
breathing sounds, mental state, position and appetite. Based on these observations, the 
appearance of three behavioural phases (respiratory, depression and recovery phase) 
following LPS administration was recorded (Plessers et al., 2015b). If systemic shock 
symptoms would occur, the respective calf would be humanely euthanized, and 
subsequently necropsied. The investigators were not blinded to the treatment groups. 
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All blood samples were mixed by gentle inversion and placed on ice until 
centrifugation at 1,000 × g for 15 min. Subsequently, plasma was harvested and stored in 
aliquots at ≤ -70 °C for future analysis, with a maximum of 10 months. 
 
2.2. Sample analyses for TNF-α, IL-6 and SAA 
All plasma samples were analysed in duplicate for cytokines (TNF-α and IL-6) and the 
acute phase protein (SAA) using commercially available ELISAs. As their suitability for plasma 
samples was not guaranteed by the manufacturer, the assays for cytokines (Bovine TNF-α 
DuoSet, R&D Systems Europe, Abingdon, UK; and Bovine IL-6 Screening Set, Thermo Fisher 
Scientific, Rockford, IL, USA) were validated prior to use (Plessers et al., 2015b). The SAA 
assay (Phase SAA Assay, Tridelta Development Ltd., Maynooth, Ireland) was performed 
according to the manufacturer’s protocol.  
 
2.3. Sample analyses for PGE2 
PGE2 is rapidly converted by the prostaglandin 15-dehydrogenase pathway to its inactive 
metabolite 13,14-dihydro-15-keto PGE2, which in turn is subject to further metabolism to 
13,14-dihydro-15-keto PGA2 (PGE2-met) (Fig. 3.2.1) (Hamberg and Samuelsson, 1971; 
Granström et al., 1980). The concentration of PGE2 and PGE2-met in plasma was determined 
using an in-house developed and validated ultra-performance liquid chromatography-
tandem mass spectrometry method (UPLC-MS/MS) (De Baere et al., unpublished data). 
Standards of PGE2 and PGE2-met, as well as the internal standard, deuterated PGE2 (PGE2-
d4), were obtained from Cayman Chemical Company (Ann Arbor, MI, USA). UPLC grade 
methanol, acetonitrile and water were purchased from Biosolve (Valkenswaard, The 
Netherlands). Stock solutions of 1 mg/mL of PGE2, PGE2-met and PGE2-d4 were prepared in 
UPLC methanol and stored at ≤ -70 °C. Mixed working solutions of PGE2 and PGE2-met of 0.1, 
1.0 and 10 ng/mL; and an internal standard working solution of PGE2-d4 of 10 ng/mL were 
prepared in UPLC methanol and stored at ≤ -70 °C. 
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Briefly, the sample preparation for 100 µL of plasma was performed by protein 
precipitation using 525 µL of acetonitrile, followed by centrifugation (10 min, 7825 x g, 4 °C), 
evaporation of the organic phase under N2 and analysis of a 10 µL-aliquot by UPLC-MS/MS. 
 
 
Fig. 3.2.1. Metabolism of PGE2 
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The LC system consisted of an Acquity UPLC H-Class Quaternary Solvent Manager and 
Flow-Through-Needle Sample Manager with temperature controlled tray and column oven 
from Waters. Chromatographic separation was achieved on an Acquity UPLC BEH C18 
column (50 mm x 2.1 mm i.d., dp: 1.7 µm) in combination with an Acquity BEH C18 Vanguard 
pre-column (Waters, Zellik, Belgium). The mobile phase A consisted of 0.01% formic acid in 
water, while the mobile phase B was 0.01% formic acid in acetonitrile. The UPLC column 
effluent was interfaced to a XEVO TQ-S MS/MS system, equipped with an electrospray 
ionization probe operating in the negative mode (all from Waters). A divert valve was used 
and the UPLC effluent was directed to the mass spectrometer from 2.0 to 4.9 min. MS/MS 
acquisition was performed in the multiple reaction monitoring (MRM) mode. The MRM 
transitions monitored as quantification and identification ion, respectively, were m/z = 
351.22 > 271.26 and 351.22 > 315.21 for PGE2; m/z = 355.16 > 319.28 and 355.16 > 275.27 
for PGE2-d4; m/z = 333.20 > 175.00 and 333.20 > 235.00 for PGE2-met. Data for PGE2-met 
were generated using an external standard method. 
The method was validated by a set of parameters that were in compliance with the 
recommendations defined by EU standards (Commission Decision 2002/657/EC, VICH GL49, 
Heitzman, 1994) and by Knecht and Stork (1974). In this respect, linearity, within- and 
between-run accuracy and precision, limit of quantification (LOQ), limit of detection (LOD) 
and specificity were evaluated. Linear calibration curves (r > 0.99) were constructed in a 
concentration range of 50 to 5000 pg/mL. Within- and between-run accuracy and precision 
were evaluated by analysis of independently spiked samples (n = 6) at four concentration 
levels i.e. 50, 125, 500 and 5000 pg/mL, respectively. The results fell within the accepted 
ranges for accuracy and precision (2002/657/EC; VICH GL49). The LOQ was defined as the 
lowest concentration for which the method was validated with a within-run accuracy and 
precision that fell within the specified ranges and was established at 125 and 50 pg/mL for 
PGE2 and PGE2-met, respectively. The LOD was defined as the concentration corresponding 
with a signal-to-noise ratio of 3 and was found to be 16.7 and 6.8 pg/mL for PGE2 and PGE2-
met, respectively. The specificity of the method was proven, since no peaks of endogenous 
interferences could be determined in blank samples. 
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2.4. Statistical analysis 
The results are presented as means (± SD or + SD). The effect of the LPS challenge on 
the studied parameters within the different groups was assessed using repeated measures 
ANOVA. Additionally, area under the curve (AUC0→t) values for the time course of RT 
(AUC0→24h), RR (AUC0→6h), HR (AUC0→24h) as well as TNF-α (AUC0→6h), IL-6 (AUC0→12h), SAA 
(AUC0→72h) and PGE2 (AUC0→4h) plasma concentrations were calculated, and subsequently 
analysed by single factor ANOVA (Altan et al., 2010). Pairwise comparisons of the mean AUC 
values of the different groups were performed using the Bonferroni test. For those 
parameters that were not normally distributed, an ln-transformation was executed. 
Parameters that were only recorded once in the LPS and GAM group, i.e. the duration of the 
behavioural phases, were analysed using an independent samples t-test. Differences were 
considered significant at P < 0.05. All analyses were performed using commercial statistic 
software (SPSS 22 software for Windows, IBM Corp., Armonk, NY, USA). 
 
2.5. Ethical approval 
All procedures were approved by the Ethical Committee of the Faculty of Veterinary 
Medicine and Faculty of Bioscience Engineering of Ghent University (EC 2012/189). 
 
3. Results 
The final number of calves in each of the groups was reduced from six to four. In the LPS 
group, two calves were excluded from the experiment as a rectal body temperature > 39.5 
°C was measured at 0 h (40.4 and 40.7 °C, respectively). Two calves in the GAM group were 
euthanized at 3 and 4.75 h p.c., respectively, due to severe systemic shock symptoms. The 
subsequent necropsy and histological examination revealed acute diffuse alveolar damage, 
which was comparable to the lesions observed in a euthanized calf in our previous study 
(Plessers et al., 2015b). Regarding the KETO and GAM-KETO group, two calves of each group 
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were excluded following cytokine analysis. More specifically, excessive cytokine release or 
an absent response were observed in these calves. 
 
3.1. Clinical signs 
Mean pre-LPS-challenge values for rectal body temperature, respiratory rate and heart 
rate among the different groups were 38.9 ± 0.2 °C, 32 ± 4 bpm and 80 ± 9 bpm, 
respectively. Figure 3.2.2, Figure 3.2.3, Table 3.2.1 and Table 3.2.2 demonstrate the 
unequivocal influence of pre-treatment with KETO on the clinical signs following LPS 
challenge. In this respect, fever development was completely inhibited in the KETO and 
GAM-KETO group. In the LPS and GAM group, on the other hand, a marked peak in rectal 
body temperature was observed 4 h p.c. The respiratory rate increased significantly in time 
within all groups following LPS administration (Fig. 3.2.3A), although the initial sharp rise, 
which was clearly induced in the LPS and GAM group, was absent in the KETO and GAM-
KETO group. Nevertheless, a moderate increase in respiratory rate (> 40 and ≤ 80 bpm) was 
observed 1 h p.c. in 3 out of 4 animals in the latter two groups. As can be perceived in Figure 
3.2.3B, the heart rate increased significantly in time within all groups as well, while no 
significant differences were observed between the groups.  
As expected from the results for rectal body temperature and respiratory rate, the 
three successive behavioural phases following LPS challenge, were noticeably influenced by 
KETO pre-treatment (Fig. 3.2.4). More specifically, the common sequence which was present 
in the LPS and GAM group – the respiratory, depression and recovery phase – was abolished 
in the KETO and GAM-KETO group. Firstly, as demonstrated by the respiratory rate, no 
severe respiratory distress occurred in these groups. Instead, only moderate tachypnea was 
observed in 3 out of 4 calves. This effect was not initiated simultaneously with the start of 
the respiratory phase in the LPS and GAM group, yet showed a delay of approximately 30 
minutes. Secondly, the depression phase, and consequently the recovery phase, were 
completely absent in the KETO-treated groups. The comparison of the duration of each of 
the three phases between the LPS and GAM group, on the other hand, revealed no statistical 
significant differences.  
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Figure 3.2.2. Time course of the mean rectal body temperature in 4-week-old calves after an 
IV bolus injection of 0.5 µg/kg BW lipopolysaccharide, either not preceded by drug 
administration (LPS; n = 4) or following pre-treatment with gamithromycin (GAM; n = 4), 
ketoprofen (KETO; n = 4) or the combination of both drugs (GAM-KETO; n = 4). For clarity of 
presentation, SDs are not included in this figure. However, Table 3.2.1 gives an overview of 
the full data set. 
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Figure 3.2.3. Mean (+SD) respiratory rate (A) and heart rate (B) in 4-week-old calves after an 
IV bolus injection of 0.5 µg/kg BW lipopolysaccharide, either not preceded by drug 
administration (LPS; n = 4) or following pre-treatment with gamithromycin (GAM; n = 4), 
ketoprofen (KETO; n = 4) or the combination of both drugs (GAM-KETO; n = 4). 
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Table 3.2.1. Mean (± SD) rectal body temperature (°C) after an IV bolus injection of 0.5 µg/kg BW lipopolysaccharide, either not preceded by 
drug administration (LPS; n = 4) or following a pre-treatment with gamithromycin (GAM; n = 4), ketoprofen (KETO; n = 4) or the combination of 
both drugs (GAM-KETO; n = 4).  
 
Time p.c. (h) 0 0.5 1 1.5 2 2.5 3 3.5 4 5 6 8 12 18 24 
                 
LPS  
 
 
 38.9 
(0.2) 
39.2 
(0.2) 
39.5 
(0.2) 
39.4 
(0.1) 
39.5 
(0.3) 
39.5 
(0.7) 
39.7 
(0.5) 
39.8 
(0.6) 
39.8 
(0.5) 
39.7 
(0.5) 
39.4 
(0.6) 
39.2 
(0.3) 
39.3 
(0.3) 
39.2 
(0.1) 
38.9 
(0.2) 
GAM 
 
 
 38.8 
(0.1) 
39.0 
(0.3) 
39.3 
(0.2) 
39.5 
(0.3) 
39.5 
(0.2) 
 
39.7 
(0.2) 
39.9 
(0.3) 
39.9 
(0.2) 
39.9 
(0.2) 
39.8 
(0.3) 
39.5 
(0.2) 
39.3 
(0.1) 
 
39.2 
(0.0) 
39.0 
(0.1) 
38.8 
(0.0) 
KETO 
 
 
 39.1 
(0.1) 
39.0 
(0.2) 
38.9 
(0.1) 
39.0 
(0.1) 
38.9 
(0.1) 
38.8 
(0.2) 
38.8 
(0.2) 
38.7 
(0.1) 
38.7 
(0.1) 
 
38.8 
(0.1) 
38.9 
(0.1) 
38.8 
(0.1) 
39.1 
(0.1) 
39.0 
(0.1) 
38.9 
(0.1) 
GAM-KETO 
 
 39.0 
(0.3) 
 
38.9 
(0.3) 
38.8 
(0.2) 
38.6 
(0.1) 
38.6 
(0.1) 
38.5 
(0.0) 
38.6 
(0.1) 
38.6 
(0.1) 
38.6 
(0.1) 
38.8 
(0.1) 
38.7 
(0.1) 
38.8 
(0.1) 
39.0 
(0.2) 
39.0 
(0.2) 
38.8 
(0.2) 
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Table 3.2.2. Mean (± SD) area under the curve (AUC0→t) values for the time course of the rectal body temperature (RT), the respiratory rate 
(RR), the heart rate (HR), and TNF-α, IL-6, SAA and PGE2-met plasma concentrations following an IV bolus injection of 0.5 µg/kg BW 
lipopolysaccharide, either not preceded by drug administration (LPS; n = 4) or following pre-treatment with gamithromycin (GAM; n = 4), 
ketoprofen (KETO; n = 4) or the combination of both drugs (GAM-KETO; n = 4). Within a parameter, groups sharing a superscript letter do not 
differ from one another at the 5% global significance level. N/A: not applicable, as all values were below the LOQ. 
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Figure 3.2.4. Time course of the three behavioural phases (respiratory, depression and 
recovery phase) in 4-week-old calves after an IV bolus injection of 0.5 µg/kg BW 
lipopolysaccharide, either not preceded by drug administration (LPS; n = 4) or following pre-
treatment with gamithromycin (GAM; n = 4), ketoprofen (KETO; n = 4) or the combination of 
both drugs (GAM-KETO; n = 4). This figure is based on scoring of the animals’ clinical 
condition during the first nine hours of the experiment. In general, the boxes represent the 
mean duration of the different phases, whereas the vertical lines indicate the minimum and 
maximum points in time at which the respective phase starts and ends, within a certain calf. 
The x-marks represent the time of euthanasia of the two calves in the GAM group. 
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3.2. Inflammatory mediators 
Maximal levels of TNF-α, IL-6 and SAA were attained in all groups at similar points in 
time as observed in our previous experiment (at 1, 2.5-3.5 and 24 h p.c., respectively) (Fig. 
3.2.5 and 3.2.6) (Plessers et al., in preparation). One calf of the KETO and one calf of the 
GAM-KETO group were excluded due to excessive cytokine concentrations following the LPS 
challenge (Fig. 3.2.5). The second calf in the KETO group was excluded as continuous high 
levels of TNF-α were detected during the experiment, while the cause of exclusion of the 
second calf in the GAM-KETO group was the lacking response to the challenge.  
As can be concluded from Figure 3.2.5, quite opposite effects on the cytokine release 
were observed in the KETO and GAM-KETO group. For TNF-α, the administration of merely 
KETO decreased the plasma concentrations, whereas the combination of GAM and KETO 
resulted in higher TNF-α levels compared to the LPS and GAM group (Fig. 3.2.5A). In this 
respect, a significant difference was found between the KETO and GAM-KETO group (Table 
3.2.2). Regarding IL-6, KETO on its own again reduced this cytokine’s release, whereas no 
influence was observed in the GAM-KETO group (Fig. 3.2.5B; Table 3.2.2). As shown in Figure 
3.2.6, this trend recurred with respect to SAA. Figure 3.2.7 depicts the profile of PGE2-met 
following the endotoxin challenge. The metabolite was selected, as its LOQ was lower in 
comparison with PGE2. In the LPS and GAM group, a marked increase of the levels of PGE2-
met was observed, as soon as 0.5 h p.c. The GAM group showed a tendency towards a faster 
normalization, although this was not significant (Table 3.2.2). The pre-treatment with KETO, 
on the other hand, resulted in a highly significant inhibition of PGE2 production, as no 
quantifiable concentrations were measured during the experiment in the KETO and GAM-
KETO group.  
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Figure 3.2.5. Mean (+SD) plasma concentrations of TNF-α (A) and IL-6 (B) in 4-week-old 
calves after an IV bolus injection of 0.5 µg/kg BW lipopolysaccharide, either not preceded by 
drug administration (LPS; n = 6) or following pre-treatment with gamithromycin (GAM; n = 
4), ketoprofen (KETO; n = 4) or the combination of both drugs (GAM-KETO; n = 4).  
TNF-α and IL-6 peak concentrations of the excluded calf in the KETO group were 32,844 and 
55,290 pg/mL, respectively. 
IL-6 peak concentration of the excluded calf in the GAM-KETO group was 110,524 pg/mL. 
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Figure 3.2.6. Mean (+SD) plasma concentrations of SAA in 4-week-old calves after an IV 
bolus injection of 0.5 µg/kg BW lipopolysaccharide, either not preceded by drug 
administration (LPS; n = 4) or following pre-treatment with gamithromycin (GAM; n = 4), 
ketoprofen (KETO; n = 4) or the combination of both drugs (GAM-KETO; n = 4). 
Figure 3.2.7. Mean (+SD) plasma concentrations of PGE2-met in 4-week-old calves after an IV 
bolus injection of 0.5 µg/kg BW lipopolysaccharide, either not preceded by drug 
administration (LPS; n = 4) or following pre-treatment with gamithromycin (GAM; n = 4), 
ketoprofen (KETO; n = 4) or the combination of both drugs (GAM-KETO; n = 4). Only values 
above the LOQ (50 pg/mL) were included. Ø: no quantifiable concentrations were 
determined.  
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4. Discussion 
The aim of this study was to investigate the effects of the NSAID KETO on TNF-α, IL-6, 
SAA, PGE2 and clinical signs in our previously developed LPS-induced inflammation model in 
4-week-old calves. Additionally, the combined administration of KETO and the macrolide 
GAM was studied to test for possible synergistic and/or additive effects.  
Based on the results of previous research, pre-treatment of the calves was considered 
necessary to induce a maximal immunomodulatory effect (Semrad, 1993a, 1993b). Although 
such a pre-treatment diverges from clinical settings and it was certainly not the objective to 
promote prophylactic drug use, this experiment could yield new information regarding the 
treatment of diseased animals. In this respect, all drugs were administered 1 h prior to LPS 
challenge, as this interval corresponds to the time of maximum plasma concentration of 
GAM and the S(+) enantiomer of KETO, which is the pharmacologically active form of this 
chiral compound (Huang et al., 2010; Plessers et al., 2015a). Both dosages and routes of 
administration were in accordance to the manufacturers’ recommendations (SC and IM for 
GAM and KETO, respectively).  
Despite the advantages of LPS inflammation models regarding standardization and 
reproducibility, these models know certain limitations in comparison with experimental 
bacterial infections (Olson et al., 1995; Remick and Ward, 2005). One of these limitations 
concerns the clinical significance of antimicrobial drugs (i.e. GAM). Nevertheless, the 
presence of actively invading and growing microorganisms can complicate the interpretation 
of the effect of immunomodulatory drugs. Endotoxin models can therefore provide a first 
indication of drug’s potential actions, which can subsequently be evaluated in experimental 
bacterial infection models, and under field conditions.  
Pre-treatment with KETO had a remarkable influence on the clinical signs following 
LPS-challenge. In this respect, all calves in the KETO and GAM-KETO group remained clinically 
healthy as no severe respiratory distress occurred, nor fever, depression or anorexia. 
Regarding the pulmonary response, the inhibition of COX and the consequent reduction of 
arachidonic acid metabolites, including TXA2, can be suggested (Landoni et al., 1995). 
Indeed, these inflammatory mediators have been suggested to play a major role in the early 
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hemodynamic effects after endotoxin administration, including the sharp rise in pulmonary 
arterial pressure and oedema, and the subsequent development of dyspnea (Tikoff et al., 
1966; Esbenshade et al., 1982; Olson and Brown, 1986). The inhibition of plasma 
concentrations of PGE2, measured as PGE2-met, by KETO was confirmed in our experiment 
and was additionally reflected by the absence of fever in the KETO and GAM-KETO group. 
With respect to TNF-α and IL-6, the effect of KETO was not straightforward, as the KETO 
group clearly demonstrated lower concentrations of these cytokines compared to the GAM-
KETO group. As these inconsistencies did not result in a different clinical outcome, the 
hypothesis from our previous study regarding the involvement of peripherally produced pro-
inflammatory cytokines (particularly TNF-α) in depression needs to be reconsidered 
(Johnson, 2002; Dantzer, 2009; Plessers et al., in preparation). 
Compared to the LPS group, pre-treatment with GAM had no significant influence on 
the clinical signs induced by the LPS challenge, nor on the profiles of the inflammatory 
mediators. However, it should be mentioned that two calves in the GAM group were 
euthanized due to severe systemic shock symptoms. Different reasons can be suggested to 
account for a potential synergistic influence of LPS and GAM in the GAM group and for the 
elevated cytokine levels in the GAM-KETO group. Although a local swelling can be induced 
following the SC administration of Zactran®, an additional experiment in three other calves, 
receiving merely Zactran®, demonstrated that this was not responsible for increased plasma 
levels of pro-inflammatory cytokines, nor for elevated rectal body temperatures (data not 
shown). Therefore, a second hypothesis regarding the effect on the lung can be put forward, 
given that the lung has been ascribed to be the target organ for both LPS and GAM (Tikoff et 
al., 1966; Huang et al., 2010). In this respect, PIMs, which are constitutively present in cattle, 
and PIM-related inflammatory mediators might have contributed to the observed 
differences (Winkler, 1988). Another hypothesis concerns a possible interaction following 
the intracellular accumulation of both LPS and GAM in phagocytes (Winkler, 1988; Bosnar et 
al., 2005). More specifically, a bovine ex vivo experiment confirmed KETO to reduce TNF-α 
production in LPS-stimulated whole blood samples, suggesting an inhibitory effect of KETO 
on transcription factor NF-κB (Tegeder et al., 2001; Donalisio et al., 2013). This reduced 
nuclear translocation seemed indeed to be present in the KETO group of the current study, 
while GAM appeared to counteract this influence, resulting in remarkably higher cytokine 
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levels in the GAM-KETO group. Interestingly, this hypothesis contrasts with earlier studies 
which suggest a possible suppressive effect of certain macrolides on NF-κB activation (Ianaro 
et al., 2000; Healy, 2007; Fischer et al., 2011). Due to the limited number of calves in the 
present experiment, however, further research is needed to confirm these observations. 
Overall, the results of the present study suggest a key role for PGE2 and other 
prostanoids, both with respect to fever development and depression. Additionally, these 
clinical signs have been designated to be correlated since depression deteriorates while the 
rectal body temperature increases (Plessers et al., 2015b). Blatteis et al. (2005) extensively 
reviewed the mechanisms involved in the onset of fever, and questioned the “conventional 
view”, which concerns the significance of pyrogenic cytokines. In this respect, the production 
of these cytokines and the transduction of their pyrogenic signals into fever-mediating PGE2 
requires more time than the actual start of the febrile response (Conti et al., 2004; Blatteis, 
2005; Steiner et al., 2006). Levels of PGE2-met were indeed recorded already at 0.5 h p.c. in 
the present study. Accordingly, the more recent insights in the course of fever development 
and sickness behaviour in humans and laboratory animals emphasize the importance of 
PGE2, and more specifically, COX-1 induced PGE2 (Blatteis et al., 2005; Blatteis, 2007; Pecchi, 
2009). The latter argumentation has arisen from the need for NF-κB-mediated COX-2 
transcription, which again lags the onset of fever (Yamamoto et al., 1995; Blatteis et al., 
2005). Moreover, the study of Donalisio et al. (2013) reported the preferential activity of 
KETO to bovine COX-1, the constitutive COX-isoform, mainly involved in physiological 
processes. This is in contrast with the statement that KETO is a non-selective inhibitor of 
COX-1 and COX-2, the latter being the inducible COX-isoform, upregulated as part of the 
inflammatory response (Papich, 2011). It should be mentioned, however, that the distinction 
between COX-1 and COX-2 functions is not strict, as some crossover occurs (Papich, 2011). 
From this point of view, the immediate inhibition of COX-1 in PIMs by KETO might be 
accountable for the reduced pulmonary reaction in the KETO and GAM-KETO group. This 
hypothesis may also explain the superior effect of KETO on fever development in 
comparison with DEX, which was studied in the same model (Plessers et al., in preparation). 
More specifically, the action of corticosteroids requires the de novo synthesis of lipocortin in 
order to cease the formation of arachidonic acid metabolites (Hirata, 1983). Taking the 
results of these two studies into account, it can be put forward that the administration of 
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KETO is preferable to DEX in the treatment of calf diseases that are characterized by the 
systemic involvement of LPS (inclucing pneumonia, septicemia and neonatal diarrhea), given 
the marked clinical effect of KETO on depression and fever. Furthermore, extrapolation of 
these findings to the treatment of bacterial infections in practice suggests that the 
concomitant use of an antimicrobial drug and a NSAID should be considered at all times. In 
this way, both production results and animal welfare can be enhanced.  
In conclusion, the results of the present study demonstrated the capacity of KETO to 
completely inhibit fever development and depression following an IV endotoxin challenge in 
4-week-old calves. This clinical effect was related to the inhibition of PGE2 by KETO, whereas 
the involvement of pro-inflammatory cytokines in these clinical signs was shown to be less 
prominent. GAM, on the other hand, had no influence, neither clinically nor regarding the 
studied inflammatory mediators. Furthermore, the combination treatment provided no 
synergistic or additive effects in this model. 
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Modulation of the innate immune response by drugs is the challenge of this doctoral 
thesis. In this context, the term immunomodulation differs from immunosuppression or anti-
inflammation, as it refers to the modification of the endogenous immune responses without 
impairing the normal immune or inflammatory response to defend against an infection 
(Kanoh and Rubin, 2010). Accordingly, the following parts of the innate immune response 
are frequently studied in in vitro, ex vivo and in vivo experiments: phagocytosis, respiratory 
burst, transcription and release of pro-inflammatory cytokines, chemotaxis and neutrophil 
apoptosis. Particularly the discovery that certain antimicrobial drugs exert 
immunomodulatory effects – in addition to their antimicrobial actions – has resulted in an 
enhanced interest in human medicine. In veterinary medicine, on the other hand, this 
research field is still in its infancy.  
In vivo bovine LPS inflammation models can be applied to study the 
immunomodulatory properties of e.g. antibiotics, NSAIDs and corticosteroids. More 
specifically, these models induce a marked acute-phase response in the absence of actively 
invading and growing microorganisms, which can complicate the interpretation of the drug 
effect. The results of such studies can subsequently contribute to the development of 
improved treatment strategies, including superior combination therapies. 
Based on these main principles, this doctoral thesis intended to extend the current 
knowledge on immunomodulatory drugs in bovine veterinary medicine by means of an in 
vivo LPS-challenge model. Figure Ia and Ib give an overview of the main methodologies and 
achievements of this work, respectively. Figure Ib is based on all calves included in the 
different animal experiments, by combining the results reported in the different chapters 
(LPS group: Chapter 1 and Chapter 3.2; GAM group: Chapter 3.1 and 3.2). The challenges 
that came across during this thesis will be discussed in the following sections, as well as 
some future prospects for this research area.  
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Figure Ia. Overview of the main methodologies of the present doctoral thesis   
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Figure Ib. Overview of the main results of the present doctoral thesis 
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Development of a standardized and reproducible LPS-inflammation model 
In order to mimic the dynamics and multiple interactions that occur during an 
inflammatory response, in vivo experiments can provide more reliable information than in 
vitro studies with various experimental designs (Labro, 1993). Nevertheless, prior to the 
application of an inflammation model for the pharmacodynamic study of immunomodulary 
drugs, certain requirements have to be met. In this respect, it is important to elicit a 
considerable effect on all inflammatory parameters (clinical signs, cytokines, acute-phase 
proteins and eicosanoids), without inducing (lethal) shock.  
It was previously clearly demonstrated that E. coli LPS is the most frequently used type 
of endotoxin to induce an inflammatory response. Additionally, a considerably high 
reproducibility among studies was found with respect to cytokine release following the 
administration of this type of LPS. Based on these conclusions, E. coli LPS was selected to 
elicit an acute-phase response in the present work. The use of other types of LPS, on the 
other hand, can result in a slightly altered clinical outcome. Horadagoda et al. (2002), for 
instance, used P. multocida LPS in buffalo calves. This challenge resulted in the rapid onset of 
clinical signs, characterized by dullness, sternal recumbency, elevated rectal temperatures 
and dyspnea. Additionally, excessive salivation was induced by this challenge, which is an 
important symptom of haemorrhagic septicemia caused by P. multocida serotype B:2 in 
buffalos (Horadagoda et al., 2002). These authors also reported rather high inter-animal 
variations with respect to the clinical LPS response, which might be related to the rather low 
dose of endotoxin (1 µg/kg BW) in this animal species. Regarding the release of TNF-α, on 
the other hand, peak levels were reached simultaneously with E. coli LPS challenges (1-2 h 
p.c.) (Horadagoda et al., 2002). 
Regarding the age of the calves in the present work, young calves were selected to 
avoid an extensive anamnesis with respect to Gram-negative bacteria. Nevertheless, studies 
in neonatal calves were not straightforward concerning fever development (Adams et al., 
1990; Gerros et al., 1993; Rose and Semrad, 1992; Semrad et al., 1993). From this point of 
view, 3-week-old calves were obtained, that were conventionally reared on the farm of 
origin.  
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Since calves are extremely sensitive to endotoxin, both the LPS serotype (E. coli 
serotype O111:B4) and dose (0.5 µg/kg BW or 500 units/kg BW) were carefully selected 
(Michaels and Banks, 1988). Additionally, the clinical condition of the calves at the start of 
the experiment was considered to be highly important for this type of studies. In this 
respect, the different origin of the calves and their relatively young age at arrival (3 weeks) 
might play an interfering role. In order to minimize possible influences, all calves received 
two preventive treatments, i.e. paromomycin sulphate on the farm of origin and 
enrofloxacin upon arrival. Interference with the outcome of the experiment could be 
excluded, as paromomycin sulphate is poorly absorbed after oral administration and the 
plasma half-life of elimination of enrofloxacin is rather fast in calves (6.8 ± 1.2 h following 
12.5 mg/kg BW SC) (EMA, 2000; Davis et al., 2007). Despite the paromomycin treatment, 
Cryptosporidium parvum antigen was still detected in the faeces of a number of calves. 
Certain calves indeed showed an altered faecal consistency during the acclimatization 
period, yet remained clinically healthy throughout this period. Furthermore, these animals 
only received alternating liquid electrolyte therapy until normal faecal consistency was 
regained. The single enrofloxacin treatment at the start of the 1-week acclimatization 
period, on the other hand, was found to be highly effective as none of the calves developed 
respiratory symptoms before the start of the experiment. Still, one out of 10 calves 
mentioned in the first chapter of this thesis demonstrated severe shock symptoms following 
the LPS challenge, after which euthanasia was carried out, emphasizing the sensibility of 
calves to endotoxin. 
In order to limit stress and discomfort during the frequent blood sampling, an 
indwelling catheter was placed in the jugular vein of the calves, at least 12 h prior to the 
start of the experiment. Additionally, calves were habituated to human presence and 
contact, as well as to experimental manipulations during the acclimatization period.  
Based on the results of the present work, a chronological overview of the appearance 
of clinical signs and inflammatory mediators following an LPS challenge in 4-week-old calves 
is provided in Figure II. With the exception of IL-1β, all studied parameters altered 
significantly in response to the administration of endotoxin.  
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Figure II. Chronological overview of the appearance of clinical signs and inflammatory mediators 
following an intravenous LPS challenge in 4-week-old calves: results of the present work  
(p.c.: post LPS challenge) 
 
As discussed in Chapter 1, these observations fairly correspond to the findings of other 
research groups. The developed model was therefore considered as appropriate with 
respect to the postulated aims. Nevertheless, it should be remarked that certain inter-animal 
variations in the different studied parameters were rather high, resulting in substantial 
standard deviations. Such variations were also reported by Jacobsen et al. (2005) in cows. 
With respect to the course of the rectal body temperature in Chapter 1, a distinction was 
made between early and delayed responding calves (fever peak ≤ 5 h or ≥ 6 h p.c.). As 
discussed previously, a pre-shock effect was hypothesized, with the simultaneous 
occurrence of tachycardia (Lohuis et al., 1988). Surprisingly, these two trends did not 
continue toward cytokine levels. The involvement of other mediators, including eicosanoids 
and NO, can therefore be suggested (Salvemini et al., 1990). Regarding other examples of 
individual variation, one calf in Chapter 1 recovered remarkably fast from respiratory 
distress and depression. In this respect, tolerance to LPS might have been of importance. LPS 
tolerance refers to the temporally defined reduction in the intensity of the inflammatory 
response mediators and clinical signs following repeated exposures to LPS (Lehner and 
Hartung, 2002; Wang et al., 2003). As no anamnesis on the calves was available upon arrival, 
the respective calf might indeed have overcome a Gram-negative bacterial infection at the 
farm of origin. Bieniek et al. (1998) summarized the knowledge on this transitory 
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unresponsiveness to endotoxin, which includes an early and a late tolerance. In this respect, 
the early tolerance develops 1 h after the first exposure to LPS, is mediated by cytokines, 
and is associated with a diminished capacity to produce cytokines. The late tolerance, on the 
other hand, is long-lasting, antibody-dependent and specific for the initially administered 
type of endotoxin. Nevertheless, the experiment of Bieniek et al. (1998) failed to induce 
tolerance to a second injection of LPS following a 7-day interval in 3-week-old calves. More 
specifically, the pyrogenic response and heart rates were not influenced. The release of TNF-
α, on the other hand, was significantly inhibited in comparison with the first challenge. From 
this result, the authors concluded that the rectal body temperature was not correlated to 
TNF-α production. Paradoxically, Elsasser et al. (2005) applied two subsequent LPS-
challenges to discriminate between normal or tolerant calves, and “hyperresponders”. These 
genetically burdened hyperresponders failed to develop tolerance to repeated LPS 
challenges, which was evident by the magnitude of TNF-α concentrations and the prolonged 
severity of pathological conditions. The excessive cytokine release in two calves in Chapter 
3.2 (outliers in the KETO and GAM-KETO group) might therefore be attributed to 
hyperresponsiveness. However, due to the significant effect of the NSAID, the impact on the 
clinical signs in these suspected hyperresponders could not be evaluated. Regarding the non-
responding calf in Chapter 3.2 (GAM-KETO group: neither clinically, nor regarding the 
studied inflammatory mediators), on the other hand, LPS tolerance might be too 
straightforward. In this respect, mutations in TLR4 can be hypothesized. Such mutations 
have been previously associated with endotoxin hyporesponsiveness in humans (Arbour et 
al., 2000). Also in cattle, TLR mutations were linked to natural resistance to Mycobacterium 
avium subsp. paratuberculosis infections (Mucha et al., 2009). 
Despite the unpredictable individual variations in the response to an LPS-challenge, the 
developed model can be applied with respect to the study of immunomodulatory drugs. 
After all, bovine practitioners are confronted with such variations as well. It should be kept 
in mind, however, that despite the advantages regarding standardization and reproducibility, 
the endotoxin model knows certain limitations in comparison with an experimental bacterial 
infection. One of these limitations concerns the clinical significance of antimicrobial drugs, as 
was observed in Chapter 3 for gamithromycin. 
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The fever-and-depression problem 
There is disagreement between bovine practitioners concerning the earliest sign of 
clinical entities like bovine respiratory disease. In this respect, reports on the order of 
appearance of an increased respiratory rate, coughing, fever and depression are not 
straightforward (Apley, 2006; Lorenz et al., 2011). Nevertheless, such information is highly 
important in the development of clinical scoring systems for the early detection of illness, as 
the latter allows a more effective drug use and a faster recovery. Apley (2006) even suggests 
that treatment should be initiated on recognition of depression with undifferentiated fever. 
Accordingly, important signs in the detection of depression are reduced self-grooming, 
appetite and rumination, as well as an increased time spent lying and standing inactive 
(Borderas et al., 2008). Johnson (2002) reviewed depression – and sickness behaviour in 
general – as part of a motivational state (Fig. III). More specifically, this refers to a well-
organized adaptive response by the host animal, designed to enhance disease resistance and 
facilitate recovery.  
Figure III. Sickness behaviour in cattle (adapted from Johnson, 2002) 
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From the present work, it can be concluded that depression deteriorates while fever 
develops, and that alertness is gradually regained once the maximal rectal body temperature 
is passed. This conclusion emphasizes the importance of depression detection, and 
consequently supports the view of Apley (2006). 
 
Selection of drugs to be tested in the inflammation model 
Based on the literature overview on the immunomodulatory properties of drugs in 
bovine in vitro, ex vivo and in vivo experiments, three drugs were selected for further in vivo 
studies.  
With respect to an antimicrobial drug, the choice for a macrolide was the most 
obvious, relying on the accumulating evidence from human medicine. Zarogoulidis et al. 
(2012), for instance, reviewed the clinical application of macrolides in respiratory diseases in 
humans, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. 
As mainly 14- and 15-membered macrolides have been suggested to exert 
immunomodulatory properties, the 15-membered semi-synthetic macrolide gamithromycin 
was selected for the present work (Kanoh and Rubin, 2010). This relatively recently 
developed azalide is only registered for use as a single SC administration in view of the 
treatment of bovine respiratory disease (Huang et al., 2010). Although no 
immunomodulatory effects were observed in our inflammation model (Chapter 3), a 
beneficial influence of this antibiotic, or other macrolides, in a bacterial infection model 
would be more likely. Moreover, immunomodulatory effects of macrolides have been 
reported to be time- and dose-dependent (Buret, 2010).  
The NSAID ketoprofen was selected for its beneficial effect on TNF-α in the ex vivo 
experiment of Donalisio et al. (2013) and on the clinical score following an IV endotoxin 
challenge (Semrad, 1993a). Due to the direct inhibition of COX by ketoprofen, the enzymatic 
production of prostanoids ceases. This block explains the anti-inflammatory and antipyretic 
properties of this drug, which were clearly demonstrated in the present work (Chapter 3.2). 
With respect to its immunomodulatory properties, ketoprofen reduced the levels of TNF-α 
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and IL-6 following the LPS challenge (KETO-group in Chapter 3.2), which indeed corresponds 
to the reports of Donalisio et al. (2013).  
The corticosteroid dexamethasone was included as a positive control 
immunomodulatory drug in the present work. As described in the general introduction, this 
choice was based on the reported results from several bovine studies (Ohtsuka et al., 1997a; 
Kiku et al., 2002; Malazdrewich et al., 2004a). Dexamethasone indeed confirmed its 
immunomodulatory capacities with respect to the release of pro-inflammatory cytokines, 
while its clinical effect following an IV endotoxin challenge was rather limited (Chapter 3.1). 
The latter observation was somewhat surprising, as other studies demonstrated a clear 
effect of this corticosteroid on the cardiopulmonary response and fever development during 
an inflammatory response (Olson and Brown, 1986; Lohuis et al., 1989). Additionally, it must 
be mentioned that in the animal trial described in Chapter 3.1 no extra positive control 
group was included, receiving merely LPS. Nevertheless, the calves of the LPS-group in 
Chapter 1 and Chapter 3.2 showed relatively similar profiles of all studied parameters, 
demonstrating the reproducibility of the developed inflammation model.  
 
Selection of the time of drug administration 
It was concluded that the administration of the drug after the challenge could not 
significantly influence the inflammatory response (Semrad, 1993a, 1993b). In this respect, 
pre-treatment of the calves was considered necessary to induce a maximal 
immunomodulatory effect. Although such a pre-treatment diverges from clinical settings and 
although it was certainly not the objective to promote prophylactic drug use, this 
experimental design could yield new information with respect to the treatment of diseased 
animals. 
The time of pre-treatment with gamithromycin and ketoprofen was based on their PK 
properties. More specifically, the time of maximum plasma concentration of the drugs (tmax) 
was taken into account as a maximal effect of the drugs was expected at this time. As PK 
data were lacking for the racemic mixture of ketoprofen following the frequently applied IM 
administration, an additional study was performed in calves (Chapter 2). In this respect, 
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plasma concentrations of the R(‒) and S(+) enantiomer were quantified separately, since the 
S(+) enantiomer is the pharmacologically active form of this chiral compound (Cabré et al., 
1998). Based on the results of the latter study (tmax of S(+) ketoprofen at 0.98 ± 0.18 h) and 
the study of Huang et al. (2010) concerning gamithromycin (tmax at 1.0 ± 0 h), the interval to 
the LPS-challenge was set at 1 h for both drugs. The distinct results from Chapter 3.2 
demonstrate that this interval was appropriately chosen for ketoprofen: cytokine release 
was reduced and the clinical effect of the LPS challenge was completely blocked following 
pre-treatment with this NSAID. As no influence of gamithromycin on the immune response 
was observed following LPS administration at tmax, both the applied interval and dose can be 
questioned, due to the time- and dose dependency of the immunomodulatory effects of 
macrolides (Buret, 2010). 
The administration of dexamethasone 1 h prior to the challenge was based on the 
study of Ohtsuka et al. (1997a) in calves. Similarly to the findings of these authors, a clear 
influence on TNF-α release was found in the present work (Chapter 3.1). The selected 
interval can therefore be considered as suitable for this positive control immunomodulatory 
drug. Nevertheless, one hour was most likely insufficient to induce high levels of lipocortin. 
This protein is required for the inhibition of PLA2, which in turn ceases the formation of 
arachidonic acid metabolites. From this point of view, the experimental design from Olson 
and Brown (1986), with two pre-treatments (18 and 1 h prior to the LPS challenge), may 
have exerted a more pronounced influence on the pulmonary and febrile response. 
 
The potential contradictory effect of gamithromycin 
The animal experiments revealed a notable effect of gamithromycin on the clinical 
outcome of an endotoxin challenge. In Chapter 3.1, this was related to the delayed 
responding fever profile (peak at 12 h p.c. in comparison with the average at 5 h p.c.), while 
in Chapter 3.2, two calves were euthanized at 3 and 4.75 h p.c. These observations might be 
both related to the induction of shock. Also in pigs, the administration of GAM prior to an IV 
LPS challenge has been described to result in a delayed recovery (Wyns et al., 2015a). The 
effects of gamithromycin observed in the present work were not reflected by cytokine 
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responses, as no significant differences could be observed between the GAM and LPS 
groups. Nevertheless, the group that received both gamithromycin and ketoprofen (Chapter 
3.2) demonstrated clearly higher concentrations of TNF-α and IL-6 compared to the group 
that received merely the NSAID. The beneficial clinical effect of the ketoprofen-treatment, 
on the other hand, was not affected in this combination group. Conversely, such an effect on 
cytokine levels was not present following the combined administration of gamithromycin 
and dexamethasone (Chapter 3.1), suggesting that the corticosteroid-related repression of 
NF-κB is more pronounced compared to the NSAID.  
As discussed in Chapter 3.2, different reasons can be suggested for the remarkable 
influence of gamithromycin. An effect of the formulation was ruled out following an 
additional experiment, whereas the role of PIMs and the consequences of the intracellular 
accumulation of both LPS and gamithromycin in phagocytes need further elucidation. The 
involvement of PIM-related inflammatory mediators – including TXA2 – has been suggested 
to contribute to the more severe symptoms in the gamithromycin-treated group, particularly 
since the lung has been ascribed to be the target organ for both LPS and gamithromycin 
(Tikoff et al., 1996; Huang et al., 2010). Furthermore, due to the high volume of distribution 
of gamithromycin (24.9 L/kg), high intracellular concentrations of this macrolide are reached 
following parenteral administration (Winkler, 1988; Bosnar et al., 2005; Huang et al., 2010). 
In this respect, it can be hypothesized that the presence of both gamithromycin and LPS in 
phagocytes results in an interaction. Moreover, Labro (1993) stated that intracellular drug 
concentrations may indeed alter certain phagocyte functions. It should be remarked, 
however, that the number of animals in the present work was rather limited, and that 
additional research is needed to confirm the reported observations.  
 
Cytokines or PGE2? 
With respect to the involvement of cytokines and PGE2 in sickness behaviour and fever 
development, several authors hold on to the unequivocal role of pro-inflammatory cytokines 
(“the conventional view”), while others suggest a more important contribution of PGE2 
(Johnson, 2002; Blatteis et al., 2005; Dantzer, 2009; Pecchi et al., 2009). As previously 
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discussed, the results of the in vivo studies (Chapter 3) rather support the idea of the major 
involvement of PGE2, in both sickness behaviour and the onset of fever. Initially, in Chapter 
3.1, the association between depression and cytokines was hypothesized, since pre-
treatment with dexamethasone resulted in a faster recovery from the challenge and 
remarkably lower levels of TNF-α and IL-6. The results of Chapter 3.2 subsequently conflicted 
with this hypothesis as the calves in the GAM-KETO group demonstrated no behavioural 
changes, despite high levels of the pro-inflammatory cytokines. The importance of the 
inhibition of PGE2 production – and other prostanoids – could therefore be put forward with 
respect to reduced sickness behaviour (Pecchi et al., 2009). Teeling et al. (2007) also 
demonstrated a key role for prostaglandins in this context, as low grade inflammation was 
observed to impact on the brain, independently of peripheral cytokine production. 
The role of PGE2 in fever development was already proposed in Chapter 3.1. Since the 
dexamethasone-induced inhibition of cytokines had no prominent influence on the febrile 
response following the LPS challenge, the involvement of prostanoids was suggested, based 
on the rather slow action of corticosteroids. However, as their analysis requires a specific 
sampling protocol (i.e. addition of indomethacin in order to prevent ex vivo artefactual 
eicosanoid generation), these inflammatory mediators could not be determined in Chapter 
3.1. In Chapter 3.2, the hypothesis concerning the involvement of PGE2 in fever was then 
confirmed by the direct inhibition of COX by ketoprofen. In this respect, the calves in the 
KETO and GAM-KETO group demonstrated no quantifiable PGE2 concentrations, nor any 
changes regarding the course of the rectal body temperature. The inhibition of PGE2 
synthesis by ketoprofen in inflammatory exudate was also demonstrated in the study of 
Landoni and Lees (1995b), following the injection of carrageenan in SC implanted tissue 
cages in calves.  
The important role of PGE2 can also be established from the chronological overview of 
the appearance of clinical mediators following the challenge (Fig. II). More specifically, high 
levels of PGE2 were already detected 0.5 h p.c., whereas concentrations of TNF-α and IL-6 
were still relatively basal or absent at this time. The early release of PGE2 was clearly 
associated with the pulmonary response, which started on average 18 min p.c., and which 
was linked to the presence of LPS-clearing PIMs in the lung (Winkler, 1988). Additionally, the 
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onset of the febrile response preceded the peak of the pyrogenic cytokine IL-6 (at 3.5 h p.c.). 
As previously discussed, the occurrence of depression and fever are thought to be 
correlated, suggesting a key role for PGE2 and other prostanoids in sickness behaviour as 
well. Overall, these observations emphasize that the “conventional view” with respect to 
fever development and clinical signs needs to be reconsidered. The quantification of 
prostanoids in bovine plasma can definitely contribute to this research. Although the 
development of a specific and accurate ultra-performance liquid chromatography (UPLC)-
tandem mass spectrometry (MS/MS) method is quite challenging, such a method can 
provide several advantages compared to ELISAs. More specifically, the specificity of ELISAs in 
the analysis of eicosanoids can be questioned, due to the abundant presence of isomers, 
which can possibly cross-react (Mesaros et al., 2009). An LC-MS/MS method, on the other 
hand, is characterized by a very high specificity and sensitivity, which allows the 
quantification of rather low concentrations of the eicosanoids of interest. 
 
NSAID or corticosteroid? 
The choice between a NSAID and a corticosteroid as an ancillary therapy in the 
treatment of acute bacterial infections in cattle remains a vexed question. Both practitioners 
and farmers aim at a fast clinical response, rather than taking the side effects of 
corticosteroids in account. Nevertheless, the results of the present work demonstrate that 
ketoprofen is capable to exert an outstanding effect on the clinical condition of the animal, 
with complete suppression of depression and fever, while the influence of dexamethasone 
was rather limited (Chapter 3). A similar conclusion was formulated by Bednarek et al. (2003) 
following the comparative study of meloxicam and flumethasone – both in combination with 
oxytetracycline – for the treatment of enzootic bronchopneumonia in calves. More 
specifically, a significantly faster improvement of the clinical score was observed following 
the treatment with meloxicam. However, in contrast to the results of the present work, both 
meloxicam and flumethasone reduced the mean rectal body temperature in these naturally 
infected calves. It should be mentioned that the body temperature was only determined 24 
h after the treatment with the anti-inflammatory drugs, and that higher lipocortin levels 
were presumably reached during this prolonged time interval, in comparison with the 
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treatment 1 h prior to LPS. Also in the meeting abstract of Olaerts et al. (1995), a significant 
effect on the febrile response by ketoprofen as well as dexamethasone – without the 
concurrent administration of an antimicrobial drug – was reported. Nevertheless, in this 
model of experimentally induced pasteurellosis in calves, dexamethasone could not inhibit 
hyperpnea and a higher frequency of macroscopic lung lesions was observed following the 
treatment with this corticosteroid. From this point of view, these authors suggested 
ketoprofen to be more appropriate in the modulation of lung inflammation. Indeed, the 
attenuation of pulmonary inflammation can prevent severe dysfunctions and lesions, which 
can be responsible for irreversible lung damage or death (Lekeux, 2006). 
Whereas experimental and field tests with respect to corticosteroids as (ancillary) 
therapy in the treatment of acute inflammatory processes have yielded conflicting results, 
the conclusions of such studies using NSAIDs were notably more straightforward. Christie et 
al. (1977), for instance, reported a poorer response to treatment, a higher relapse rate and a 
slower recovery from disease when dexamethasone was used as ancillary therapy for bovine 
respiratory disease treatment. Conversely, Sustronck et al. (1997) found a superior effect of 
the combination of flumethasone and sodium ceftiofur to the antibiotic alone in 
experimental pasteurellosis in calves. This was characterized by a faster recovery and a 
decreased mortality rate. Finally, Espinasse et al. (1992) could not demonstrate a beneficial 
effect from the additional administration of prednisolone compared to the treatment with 
merely ceftiofur in experimental M. haemolytica bronchopneumonia in calves. With respect 
to NSAIDs, on the other hand, all studied drugs (carprofen, flunixin meglumine, ketoprofen, 
meloxicam and tolfenamic acid) have been shown to be effective as ancillary therapy in the 
treatment of bovine respiratory disease (Deleforge et al., 1994; Balmer et al., 1997; 
Lockwood et al., 2003; Elitok and Elitok, 2004; Friton et al., 2005; Guzel et al., 2010). Even 
the administration of merely carprofen significantly decreased clinical scores and pulmonary 
lesions following an experimental infection with M. haemolytica (Wallemacq et al., 2007). 
Based on the results of the present work and the findings in literature, it can be 
concluded that NSAIDs can be preferred to corticosteroids as an ancillary therapy, 
particularly in the treatment of calf diseases that are characterized by the systemic 
involvement of LPS. The NSAID does not only improve animal welfare, but also exerts 
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beneficial long-term effects regarding production results. In this respect, Friton et al. (2005) 
reported a significantly higher mean daily weight gain and mean carcass weight following the 
concomitant administration of meloxicam and oxytetracycline for the treatment of bovine 
respiratory disease, as well as significantly less lung lesions at slaughter. Nevertheless, the 
risk for (gastrointestinal) side effects of non-selective NSAIDs should be taken into account 
as well. The combined administration of an NSAID and a corticosteroid, on the other hand, 
should be avoided at all times, as this combination results in a higher incidence of 
gastroenteritis, gastrointestinal ulcerations and gastrointestinal perforations compared to 
NSAIDs (Curry et al., 2005). Moreover, corticosteroids have been associated with illegal 
growth promoting effects.  
 
Perspectives on the use of immunomodulatory drugs in cattle practice 
As previously reported, data on the immunomodulatory properties from bovine in vivo 
studies are much scarcer than those from in vitro studies. The extrapolation from in vitro to 
in vivo situations, however, is not feasible as the results from in vitro studies are in some 
cases inconsistent, and dependent on the experimental protocol. Nevertheless, in vitro 
experiments can provide an indication of certain immunomodulatory actions. In this respect, 
Fischer et al. (2011) studied the effect of tulathromycin on bovine neutrophil apoptosis both 
in vitro and in vivo. A significant increase was found in both experiments, although it should 
be mentioned that the in vivo experiment included an experimental infection with M. 
haemolytica in calves. A more recent study of the same authors also demonstrated the 
inhibition of the chemoattractant LTB4 by tulathromycin in vitro and in vivo, the latter in a 
nonbacterial model of pulmonary inflammation (Fischer et al., 2014). Additionally, bovine 
studies using tilmicosin and tulathromycin have confirmed the inhibition of PGE2 by both 
macrolides in vitro, ex vivo as well as in vivo (Lakritz et al., 2002; Fischer et al., 2014). These 
results are clearly in accordance with the reports on the immunomodulatory properties of 
macrolides from human medicine, and emphasize their potential added value in the 
treatment of diseased animals.  
GENERAL DISCUSSION 
 
 
155 
 
In contrast to the reports of the former bovine studies, gamithromycin exerted no 
immunomodulatory effects in the inflammation model developed in the present doctoral 
thesis. In this respect, the reduced nuclear translocation of NF-κB that was observed for 
tulathromycin did not continue toward gamithromycin, as the release of pro-inflammatory 
cytokines in LPS-challenged calves was not influenced. Pre-treatment with gamithromycin 
did not reduce PGE2 synthesis either, suggesting the absence of an influence of the 
macrolide on COX expression and/or PLA2 activity, as described by Fischer et al. (2014). 
Ketoprofen, on the other hand, reduced plasma levels of TNF-α, IL-6 and PGE2. Also from this 
point of view, the concomitant use of a NSAID and an antimicrobial drug can be 
recommended. Nevertheless, this combination did not result in a more pronounced 
beneficial clinical effect in the inflammation model, compared to the exclusive 
administration of ketoprofen (Chapter 3.2). On the contrary, higher concentrations of the 
studied pro-inflammatory cytokines were measured following the combined administration 
of gamithromycin and ketoprofen, though without affecting the clinical outcome. Levels of 
PGE2, on the other hand, remained below the limit of quantification of the UPLC-MS/MS 
method. Overall, these findings suggest the beneficial effect of the combination of 
gamithromycin and ketoprofen in experimental bovine bacterial infection models, which 
should subsequently be studied under field conditions in bacterial diseases. 
 
Extrapolation to other NSAIDs 
The distinct influence of ketoprofen on the clinical outcome of an LPS challenge raises 
the question whether all NSAIDs are capable to exert such an effect. Although the general 
action of NSAIDs concerns the direct inhibition of COX, certain aspects should be taken into 
consideration.  
As previously reported in this doctoral thesis (Chapter 3.2), the more recent insights 
with respect to fever development and sickness behaviour have suggested a key role for 
PGE2, and more specifically COX-1 induced PGE2 (Blatteis et al., 2005; Blatteis, 2007; Pecchi, 
2009). This constitutive COX-isoform would be responsible for the immediate release of 
prostanoids in response to the IV administration of endotoxin. The transcription of COX-2, 
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on the other hand, is upregulated as part of the inflammatory response, and consequently 
induces a delay regarding the synthesis of PGE2. This view provides an explanation for the 
remarkable effect exerted by ketoprofen in the present work: although this NSAID is 
generally referred to as a non-selective COX-inhibitor, the ex vivo study of Donalisio et al. 
(2013) reported a preferential action of ketoprofen to bovine COX-1. In this respect, other 
NSAIDs showing a preference for bovine COX-1 can be of particular interest. Flunixin 
meglumine, for instance, can be put forward since the study of Donalisio et al. (2013) 
demonstrated similar effects as observed for ketoprofen: a significant inhibition of TNF-α as 
well as a preferential activity versus COX-1. Additionally, Semrad (1993a, 1993b) reported a 
reduction of the clinical score following an in vivo LPS-challenge in calves by flunixin 
meglumine. As mentioned before, however, the risk for gastrointestinal side effects of these 
COX-1-preferring NSAIDs should be taken into consideration as well.  
Also in other animal species, ketoprofen and flunixin meglumine are considered 
important mainstays in the treatment of endotoxemia (Kelmer, 2009; Peters et al., 2012; 
Wyns et al., 2015a). Nevertheless, extrapolation of drug effects to other animal species 
needs to be performed with caution, as several factors can interfere. These factors include 
anatomical, biochemical and physiological differences, which can result in species-specific 
pharmacokinetics (PK) and pharmacodynamics (PD) (Lees et al., 2004). More specifically, 
each of the pharmacokinetic processes (absorption, distribution, metabolism and excretion) 
can differ between animal species, with variations in drug metabolism being the major factor 
accounting for species differences in PK and PD (Toutain et al., 2010). In this respect, the 
production of active or toxic metabolites can result in divergent clinical outcomes. 
Additionally, a number of side effects of NSAIDs have been demonstrated to be more 
pronounced in certain species (Rainsford et al., 2003). Regarding oral porcine ketoprofen 
preparations, for instance, the drug leaflets mention a high risk for gastric ulcers. 
Accordingly, these porcine preparations were retrieved from the Belgian market. 
Besides the formerly mentioned influencing factors, the formulation of the drug can 
also affect the clinical outcome. Firstly, non-active substances, including excipients, can 
induce side effects (Golightly et al., 1988). Secondly, as the formulation plays a critical role in 
drug absorption, it can influence the onset and duration of action of the drug (Grady and 
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Stahl, 2012). The preparation of dexamethasone used in the present work, for example, was 
formulated as a phosphate ester prodrug and consequently needs to be hydrolysed after 
administration, possibly delaying its activity. 
Overall, these conclusions suggest that each formulation of each drug should be 
investigated on a species-by-species basis to guarantee its effective and safe use. 
   
GENERAL DISCUSSION 
 
 
 
 
Future perspectives 
Based on the results from the present doctoral thesis, the following perspectives can be 
formulated with respect to the developed in vivo inflammation model: 
- Enclosure of other eicosanoids in the UPLC-MS/MS method, including TXA2 and LTB4. 
Particularly TXA2 was frequently mentioned in this work with respect to its 
contributing role to the pulmonary response following an endotoxin challenge. 
Additionally, the determination of proresolving lipoxins might be of interest. In cattle, 
the promoting effect of tulathromycin on lipoxin A4 release has already been 
confirmed (Fischer et al., 2014).  
- Study of the effect of dexamethasone on PGE2 levels in the inflammation model 
following a single treatment as well as following repeated treatments. Knowledge on 
the profile of this prostanoid could provide valuable information regarding the 
observed febrile response in dexamethasone-treated calves. However, the specific 
sampling protocol using indomethacin should be taken into consideration. 
- Optimization of the use of PGE2 and other eicosanoids, determined by the UPLC-
MS/MS multi-method, as end-points for efficacy testing of NSAIDs. 
- Evaluation of the immunomodulatory properties of other antimicrobial drugs, NSAIDs 
and corticosteroids in the developed LPS inflammation model. In this respect, the 15-
membered macrolide tulathromycin might be of interest, based on the results of 
Fisher et al. (2011, 2013, 2014). Regarding NSAIDs, on the other hand, flunixin 
meglumine can be put forward for its preferential activity to COX-1 (Donalisio et al., 
2013).  
- Assessment of the studied drugs in experimental bacterial infection models (including 
M. haemolytica and P. multocida), with emphasis on the effect of the concomitant 
use of antimicrobial drugs and NSAIDs.  
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As part of the outer membrane of Gram-negative bacteria, lipopolysaccharide (LPS) is 
involved in several clinical entities in cattle, and particularly in calves, including neonatal 
diarrhea, pneumonia and septicemia. The exogenous administration of LPS has been widely 
applied in veterinary research to study diverse aspects of the acute-phase response. 
Moreover, it has been established that such LPS inflammation models can be used to study 
the immunomodulatory properties of drugs. In this context, immunomodulation refers to 
the relatively recent research field aiming to modify the innate immune responses to benefit 
the host in the treatment of diseases. Consequently, immunomodulation does not strictly 
refer to immunosuppression or anti-inflammation. Studies in humans and laboratory animals 
demonstrated that certain antimicrobial drugs (including macrolide antibiotics), non-
steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids possess immunomodulatory 
properties, irrespectively of their direct pharamacodynamic effects. In cattle, on the other 
hand, reports on this topic are rather limited. Nevertheless, this information can contribute 
to the development of improved treatment strategies for LPS-associated diseases, resulting 
in economic, public and animal benefits. 
Therefore, the GENERAL AIM of this doctoral thesis was to evaluate the 
immunomodulatory properties of the macrolide antibiotic gamithromycin (GAM), the 
corticosteroid dexamethasone (DEX) and the NSAID ketoprofen (KETO) alone, as well as their 
two-drug combinations (GAM-DEX and GAM-KETO) in a standardized LPS inflammation 
model in calves, with emphasis on the acute-phase response.  
In the GENERAL INTRODUCTION, an overview of the reported bovine in vivo LPS 
inflammation models was provided with respect to the LPS-induced acute-phase response. 
More specifically, the release of pro-inflammatory cytokines (tumor necrosis factor (TNF)-α, 
interleukin (IL)-1β and IL-6) and acute-phase proteins (serum amyloid A (SAA) and 
haptoglobin (Hp)) was highlighted, as well as the clinical signs following the challenge: 
pulmonary response, fever, tachycardia and behavioural changes including depression and 
anorexia. Additionally, the results from bovine in vitro, ex vivo and in vivo studies regarding 
the immunomodulatory properties of antibiotics, NSAIDs and corticosteroids were 
discussed.   
SUMMARY 
 
 
190 
 
In CHAPTER 1, the development and characterization of an LPS inflammation model in 4-
week-old calves was described. In this respect, a single intravenous dose of 0.5 µg/kg body 
weight ultrapure Escherichia coli LPS was selected to induce an acute-phase response. This 
bolus administration resulted in the following clinical signs: tachypnea (on average 20 min 
post challenge (p.c.)), decubitus (30 min p.c.), general depression (1.75 h p.c.), fever (5 h 
p.c.) and tachycardia (5 h p.c.). Subsequent to the recovery from respiratory distress, general 
depression was prominent, which deteriorated when fever increased. Once the maximal 
rectal body temperature was passed, alertness and appetite were gradually regained. The 
calves recovered on average within 6 h p.c. With respect to the induced inflammatory 
mediators, peak plasma concentrations of TNF-α, IL-6, SAA and Hp were detected at 1, 3.5, 
24 and 18 h p.c., respectively. 
In CHAPTER 2, the pharmacokinetic properties of KETO were determined following 
intramuscular (IM) administration in calves. Due to possible enantioselective disposition 
kinetics and chiral inversion, the plasma concentrations of the R(‒) and S(+) enantiomer 
were quantified separately. The results demonstrated a distinct predominance of the S(+) 
enantiomer, as well as significantly different pharmacokinetic parameters between R(‒) and 
S(+) KETO. The time to maximal plasma concentration (tmax) of S(+) KETO, the 
pharmacologically active form of this chiral compound, was found to be 0.98 ± 0.18 h. 
In CHAPTER 3, the immunomodulatory properties of GAM, DEX and KETO, as well as 
their two-drug combinations were assessed in our standardized LPS inflammation model. 
DEX was selected as a positive control immunomodulatory drug. Based on the work of other 
research groups, pre-treatment was considered necessary in order to elicit a maximal effect 
of the drug on the immune response. Therefore, all drugs were administered 1 h prior to the 
LPS challenge, either subcutaneously (GAM) or IM (DEX and KETO). This interval was in 
accordance with the tmax of these drugs in calves. Two studies were performed (CHAPTER 3.1 
and CHAPTER 3.2), using a similar study design in both chapters. However, Hp was only 
included in Chapter 3.1, whereas prostaglandin E2 (PGE2) concentrations were only 
determined in Chapter 3.2.  
GAM alone had no significant effect on the production of TNF-α, IL-6, SAA, Hp and 
PGE2, nor on the clinical signs induced by the LPS challenge. This was in contrast to previous 
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reports on other macrolides. DEX, on the other hand, inhibited cytokine levels and resulted 
in a faster recovery, whereas the onset of respiratory distress and fever were not altered by 
this corticosteroid. KETO exerted the most pronounced effects in our inflammation model, 
as the calves remained clinically healthy throughout the experiment: fever, depression and 
anorexia were completely counteracted. Moreover, cytokine and SAA concentrations were 
reduced and PGE2 levels were absent following KETO pre-treatment. Regarding the two-drug 
combinations, no synergistic or additive effects were observed in this model. Conversely, the 
GAM-KETO group demonstrated higher cytokine levels compared to the KETO group, though 
without affecting the clinical outcome.  
In CONCLUSION, we developed a standardized and reproducible LPS inflammation model 
in calves to evaluate the immunomodulatory properties of drugs. KETO inhibited all studied 
aspects of the acute-phase response: cytokine, SAA and PGE2 levels, fever, depression and 
anorexia. GAM, on the other hand, had no effect, while DEX exerted an intermediate 
influence. Overall, these findings suggest that prostaglandins outweigh pro-inflammatory 
cytokines with respect to LPS-induced sickness behaviour. As a consequence, this doctoral 
thesis emphasizes the beneficial effect of the concomitant use of an antibiotic and a NSAID 
in the treatment of acute bacterial infections.  
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Lipopolysaccharide (LPS) is een onderdeel van de buitenste membraan van Gram-
negatieve bacteriën en speelt een belangrijke rol bij verschillende aandoeningen in de 
rundveesector. Vooral bij het kalf zijn LPS-gerelateerde ziektebeelden veel voorkomend, 
zoals neonatale diarree, pneumonie en septicemie. De experimentele toediening van LPS 
aan dieren werd reeds veelvuldig toegepast om de verschillende aspecten van de acute fase 
reactie te bestuderen. Dergelijke LPS inflammatiemodellen worden bovendien geadviseerd 
om de immunomodulerende eigenschappen van geneesmiddelen na te gaan. 
Immunomodulatie duidt in deze context op een relatief recent onderzoeksdomein waarin 
getracht wordt om de aangeboren immuunrespons zodanig te moduleren dat het herstel 
van het dier bevorderd wordt. Bijgevolg betreft het niet louter een immunosuppressief of 
anti-inflammatoir effect. Studies bij zowel de mens als laboratoriumdieren bevestigden 
reeds de immunomodulerende eigenschappen van bepaalde antimicrobiële geneesmiddelen 
(waaronder macrolide antibiotica), niet-steroïdale anti-inflammatoire geneesmiddelen 
(NSAIDs) en corticosteroïden, onafhankelijk van hun directe farmacodynamische effecten. Bij 
runderen daarentegen staat dit onderzoeksonderwerp nog in zijn kinderschoenen. Nochtans 
kan informatie over dergelijke eigenschappen van geneesmiddelen bijdragen tot de 
ontwikkeling van geoptimaliseerde behandelingsstrategieën voor LPS-geassocieerde 
aandoeningen, die op hun beurt voordelen hebben met betrekking tot productieresultaten 
en dierenwelzijn. 
De ALGEMENE DOELSTELLING van dit doctoraatsonderzoek was daarom het bestuderen van 
de immunomodulerende eigenschappen van het macrolide gamithromycine (GAM), het 
corticosteroïd dexamethasone (DEX) en het NSAID ketoprofen (KETO), alsook hun 
combinaties (GAM-DEX en GAM-KETO), in een gestandaardiseerd LPS inflammatiemodel bij 
het kalf. De nadruk lag hierbij op de acute fase reactie. 
In de ALGEMENE INLEIDING werd een overzicht gegeven van de beschreven in vivo LPS 
inflammatiemodellen bij het rund. Hierbij lag de focus op de LPS-geïnduceerde acute fase 
respons, met vrijstelling van pro-inflammatoire cytokines (tumor necrosis factor (TNF)-α, 
interleukine (IL)-1β en IL-6) en acute fase eiwitten (serum amyloid A (SAA) en haptoglobine 
(Hp)) en het optreden van volgende symptomen: acuut longfalen, koorts, tachycardie en 
gedragsveranderingen zoals depressie en anorexie. Daarnaast werden de resultaten van 
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boviene in vitro, ex vivo en in vivo studies met betrekking tot de immunomodulerende 
eigenschappen van antibiotica, NSAIDs en corticosteroïden besproken. 
In HOOFDSTUK 1 werd de ontwikkeling en karakterisatie van een LPS inflammatiemodel 
bij 4-weken-oude kalveren beschreven. Bij deze dieren werd een acute fase respons 
geïnduceerd via een intraveneuze toediening van ultra-zuiver Escherichia coli LPS aan een 
dosis van 0.5 µg/kg lichaamsgewicht. Deze challenge gaf aanleiding tot volgende 
symptomen: tachypnee (gemiddeld 20 min post challenge (p.c.)), decubitus (30 min p.c.), 
algemene depressie (1.75 h p.c.), koorts (5 h p.c.) en tachycardie (5 h p.c.). Na het 
normaliseren van de ademhalingssymptomen volgde een periode van algemene depressie, 
waarbij de depressie toenam met stijgende lichaamstemperatuur. Eenmaal de koortspiek 
voorbij was, werden de dieren geleidelijk aan terug alert en nam hun eetlust toe. Een 
volledig herstel werd na gemiddeld 6 h bereikt. Maximale plasmaconcentraties van de 
inflammatoire mediatoren TNF-α, IL-6, SAA en Hp werden gedetecteerd na 1, 3.5, 24 en 18 
h, respectievelijk. 
In HOOFDSTUK 2 werden de farmacokinetische eigenschappen van KETO bepaald na 
intramusculaire (IM) toediening aan kalveren. Aangezien enantioselectieve dispositiekinetiek 
en chirale inversie beschreven werden voor dit NSAID werden de plasmaconcentraties van 
R(‒) en S(+) KETO afzonderlijk gekwantificeerd. De resultaten toonden duidelijk hogere 
concentraties van het S(+) enantiomeer aan, alsook significant verschillende 
farmacokinetische parameters tussen R(‒) en S(+) KETO. Het tijdstip waarop maximale 
concentraties (tmax) van het S(+) enantiomeer – de farmacologisch actieve vorm – bereikt 
werden, was 0.98 ± 0.18 h. 
In HOOFDSTUK 3 werden de immunomodulerende eigenschappen van GAM, DEX en 
KETO, en hun respectievelijke combinaties bestudeerd in ons gestandaardiseerde LPS 
inflammatiemodel. DEX werd hierbij gebruikt als positieve controle. Gebaseerd op studies 
van andere onderzoeksgroepen kon besloten worden dat voorbehandeling nodig was om 
een maximaal effect op de immuunrespons uit te oefenen. Om deze reden werden alle 
geneesmiddelen 1 h voor de LPS challenge toegediend, overeenkomstig met de tmax bij 
kalveren. De toediening van GAM gebeurde subcutaan, voor DEX en KETO was dit IM. Twee 
studies met een identiek proefopzet werden uitgevoerd (HOOFDSTUK 3.1 en HOOFDSTUK 3.2), 
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hoewel Hp enkel in Hoofdstuk 3.1 bepaald werd, en prostaglandine E2 (PGE2) enkel in 
Hoofdstuk 3.2. 
Niettegenstaande de resultaten van eerdere studies met macroliden had GAM geen 
invloed op de productie van TNF-α, IL-6, SAA, Hp en PGE2, noch op de klinische symptomen 
na LPS. In tegenstelling tot GAM, inhibeerde DEX de vrijstelling van cytokines en resulteerde 
het in een sneller herstel van de dieren. De ademhalingssymptomen en de 
koortsontwikkeling werden daarentegen niet beïnvloed door het corticosteroïd. KETO 
vertoonde de meest uitgesproken effecten in het inflammatiemodel, aangezien de kalveren 
gezond bleven gedurende het experiment: het optreden van koorts, depressie en anorexie 
werd volledig onderdrukt. Bovendien lagen de cytokine en SAA concentraties lager na 
voorbehandeling met KETO, en was PGE2 niet detecteerbaar. In de combinatiegroepen 
werden geen synergistische of additieve effecten vastgesteld. In de GAM-KETO groep 
daarentegen werden zelfs hogere cytokineconcentraties teruggevonden, hoewel deze geen 
invloed hadden op het klinische beeld. 
Samengevat kan gesteld worden dat we een gestandaardiseerd en reproduceerbeer 
LPS inflammatiemodel ontwikkeld hebben bij kalveren voor de studie van de 
immunomodulerende eigenschappen van geneesmiddelen. KETO inhibeerde alle 
bestudeerde aspecten van de acute fase reactie: cytokine, SAA en PGE2 concentraties, 
koorts, depressie en anorexie. GAM daarentegen had geen invloed, terwijl DEX een 
intermediair effect uitoefende. Deze bevindingen suggereren dat prostaglandines een 
belangrijkere rol spelen bij het induceren van LPS-gerelateerde ziektesymptomen in 
vergelijking met pro-inflammatoire cytokines. Bijgevolg beklemtoont dit 
doctoraatsonderzoek de voordelen van het gecombineerd gebruik van een antimicrobieel 
geneesmiddel en een NSAID voor de behandeling van acute bacteriële infecties bij runderen.  
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Na het onderzoeksgerelateerde werk rest er me – op de verdediging na natuurlijk – nog één 
“challenge”: het dankwoord. Moest u zich afvragen waarom ik het woord “challenge” hier 
gebruik, zou ik u aanraden om te starten met lezen aan het begin van deze thesis, in plaats 
van hier achteraan . 
Moest u toch onmiddellijk verderlezen, volgt nu mijn poging om iedereen die heeft 
bijgedragen aan dit werk oprecht te bedanken. In de eerste plaats zijn dit uiteraard mijn 
promotoren, want zonder hen was er geen sprake geweest van dit proefschrift! 
Prof. dr. Croubels, Siska, ik herinner me nog goed ons telefoontje van een goede 6 jaar 
geleden waarin ik informeerde naar de inhoud van de nieuwe assistentenplaats. Het 
onderwerp van het doctoraatsonderzoek sprak mij onmiddellijk aan, en dat is ook altijd zo 
gebleven. Ik wil u dan ook enorm bedanken voor uw vertrouwen, en voor het feit dat u, 
ondanks uw overvolle agenda, steeds snel tijd vrijmaakte voor mijn vragen over moeilijke 
tox-cases, voor het bespreken van resultaten, voor het nalezen van allerhande draft-
versies... Het is ongelooflijk hoe u al uw activiteiten zo efficiënt weet te combineren!  
Prof. dr. De Backer, ik ben heel blij dat ik de afgelopen 6 jaar aan uw vakgroep heb kunnen 
werken, aan een onderwerp dat mij zodanig interesseert. Uw kennis en ervaring hebben 
meermaals nieuw licht geworpen op mijn onderzoek en ik heb er dan ook zeer veel van 
bijgeleerd. 
Graag wil ik ook de leden van de lees- en examencommissie bedanken. Prof. dr. Deprez, 
Prof. dr. Bols, Prof. dr. Cox, Prof. dr. Meyer, dr. Meyns en dr. Pardon, bedankt voor jullie 
suggesties, waardevolle opmerkingen en opbouwende kritiek! Prof. Deprez, ik had nooit 
gedacht dat de promotor van mijn Masterproef ook de voorzitter van de examencommissie 
van mijn doctoraat zou zijn! Verder wil ik u heel erg bedanken dat mijn dierproeven steeds 
aan uw vakgroep konden doorgaan, en voor uw interesse in mijn onderzoek, onder meer ’s 
ochtends in de stallen. Prof. Bols, hartelijk dank dat u op Siska’s vraag bent ingegaan om deel 
uit te maken van mijn lees- en examencommissie! Prof. Cox, ik ben blij dat u als lid van mijn 
begeleidingscommissie me al vroeger heeft kunnen bijsturen over een 
onderzoeksonderwerp waar u zelf ook veel ervaring in heeft! Varkens of kalveren, LPS blijft 
LPS... Evelyne, u was reeds vanaf het sollicitatiegesprek betrokken bij mijn onderzoek! Ook 
door de link met Heidi bleven onze wegen elkaar kruisen. Graag wil ik u bedanken voor uw 
interesse in mijn dierproeven, ELISAs, resultaten... en het recept van de tarte tatin! Tom, 
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heel erg bedankt om altijd snel op mijn vele vragen te antwoorden! En dank aan Merial voor 
de gedeeltelijke sponsering van mijn onderzoek. Bart, jouw enthousiasme over onderzoek in 
het algemeen werkt aanstekelijk! Als copromotor van mijn Masterproef al wist je me enorm 
te motiveren, en dat heeft er ook toe bijgedragen dat ik graag verder wilde in deze richting. 
Een hele dikke merci dat ik steeds bij jou terecht kon met (statistische) vragen en voor al 
jouw hulp bij dit werk: de katheters, de opvolging van de kalfjes, je input bij het schrijven... 
Dankzij jouw vroege tussenkomst als lid van mijn begeleidingscommissie werd bovendien de 
link met de praktijk veel concreter, en daar ben ik heel blij om! 
En dan natuurlijk de collega’s! Zonder hen zouden die 6 jaar er heel anders uitgezien 
hebben! Erg saai, en dierproeven en labo-analyses zouden zeker niet gelukt zijn. 
Op de eerste plaats komen natuurlijk Heidi en Anneleen. Onze band bestond al van voor dat 
we mekaar echt leerden kennen aan de vakgroep: we waren namelijk samen afgestudeerd. 
Daarna werd onze band nog sterker, omdat we alle 3 behoorden tot het enige echte “LPS-
team”. (Ik ging initieel deze term proberen te vermijden, na de slechte herinneringen aan de 
combinatie LPS-team en dankwoord, maar ik kon het toch niet laten .) En uiteindelijk zijn 
we dan vriendinnen geworden, met de daaraan gekoppelde DDD’s! Ik kan me echt geen 
betere collega’s voorstellen!  
Heidi, of het nu om kreeften of blind typen gaat, we komen supergoed overeen. Zowel 
tijdens onze proeven (als vaste scoorders) als na onze verhuis naar de “schrijvers-bureau” 
hadden we heel veel aan mekaar, zeker omwille van het feit dat we 2 eeuwige twijfelaars 
zijn ;-) Het was even wennen toen ik op 1 juni in een lege bureau binnenkwam... Gelukkig 
waren er nog de telepathische koffiepauzes! Ik wens je heel veel geluk toe in alles wat je 
doet, samen met je nieuwe gezinnetje!  
Anneleen, je optimisme is fenomenaal! Ik ben blij dat we mekaar na de verhuis van bureau 
(en nadat onze onderzoekswegen scheidden ;-)) niet uit het oog verloren zijn op het werk, en 
ik steeds bij jou terecht kan voor recentelijk onder meer ook kind-gerelateerde vragen! Voor 
jou komt het einde nu ook héél dichtbij. Heel veel succes met de laatste loodjes, en geniet 
nog van je (b)engeltjes en Stijn! 
Jelle, we hebben meer dan één ding gemeen: op dezelfde dag beginnen werken aan de 
vakgroep, de toxicologie, onze liefde voor paarden, middagmalen die doorgaans uit 
boterhammen bestaan en in de keuken geconsumeerd worden...  Bedankt voor de vele 
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hulp in het labo, zowel voor de toxicologie als bij mijn proeven! En natuurlijk ook voor de 
leuke buitenritjes vorig jaar! Ik wens je in toekomst GEEN onbekende pieken meer toe, en 
verder heel veel geluk in jullie hoevetje, met je 2 prachtige paarden, hond én kat! 
Sophie, exact 2.5 jaar geleden kwam je ons als mycotoxiner vergezellen in de LPS-bureau. 
Bedankt om de toxicologie over te nemen in de finale fase van mijn doctoraat! Binnenkort 
krijg je weer versterking!  Veel succes nog met de combinatie toxicologie/doctoraat! En 
uiteraard ook op het thuisfront! 
Jorien, ongelooflijk hoe je klaarstaat om te helpen! Ik herinner me nog goed dat je speciaal 
was gestopt op de faculteit om me die polsbrace te lenen... Nogmaals een dikke merci 
daarvoor! Ik wens je nog heel veel geluk met je doctoraat, en ik kijk alvast uit naar een 
eerste foto van jullie puppy!  
Elke G., mijn naamgenoot!  Als thesisstudent kreeg je een plaatsje in onze bureau, en niet 
zoveel later werd mijn ex-bureau jouw vaste plaats! Jammer dat we niet meer samen naar 
het werk kunnen fietsen... Veel succes met de toekomstige varkentjes, en al de stalen die nu 
in de diepvries zitten. En natuurlijk ook met de bouwplannen in Laarne! 
Siegrid, Ann. S. en Kris, jullie waren mijn allereerste bureaugenoten, lang, lang geleden . 
Siegrid, zonder jouw kennis over analysemethoden lag dit boekje er nu niet! De PGE2-
methode op de Xevo was de kers op taart! Heel erg bedankt voor alles! Ann S., bedankt voor 
de juwelenmiddagen en de ambiance aan de keukentafel! Maar des te serieuzer neem je je 
QA-verantwoordelijkheid: GLP-approved! Kris, jouw uitgebreide kennis heeft me meer dan 
één keer op weg geholpen! Toxicologie, interpretatie van PK-resultaten, 
computerproblemen... Je bent van alle markten thuis! Een dikke merci!  
Nermin, Joren en Jonas, met jullie heb ik tijdelijk de bureau gedeeld. Bedankt voor de 
aangename weken, en een bijzonder woordje van dank voor Nermin, voor je hulp tijdens 
mijn vervanging! Ik wens jullie alle 3 een heel voorspoedige carrière als doctoraatsstudent! 
Joske, ook wij hebben een bureau gedeeld – dezelfde tafel zelfs – al was het niet op 
hetzelfde moment . Succes met je onderzoek!  
An, jij verdient een speciaal plaatsje in mijn dankwoord. Niet alleen voor de aangename 
samenwerking op de werkvloer, maar ook voor de goede zorgen voor onze Trippel! Bedankt 
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(ook aan Nacho) voor de vele keren dat hij bij jou op logé is mogen komen, en mijn excuses 
voor zijn slechte manieren . 
En dan zijn de intussen “ancien” mannen aan de beurt. Mathias, jouw carrière aan de 
vakgroep begon al als student. Gelukkig heb je met Prof. De Backer en Siska een goed 
voorbeeld! Gunther, jouw doctoraat is pas ingediend. Dus nu op naar jouw verdediging (en 
dan die van Bonnie)! Nathan, ook voor jou komt het dichterbij! En dan is er weer tijd om te 
reizen ;-) Thomas, ongelooflijk hoeveel van die potjes er door jouw handen gepasseerd zijn! 
Maar binnenkort zal je de resultaten hiervan ook kunnen presenteren. Veel succes nog 
allemaal en bedankt voor de hulp bij mijn dierproeven! 
Marc, naast Jelle ben je steeds om 12u present in de keuken! Ik vraag me trouwens af 
hoeveel leveringen ik de laatste jaren niet aan jou heb overhandigd om op te volgen... Mijn 
oprechte excuses hiervoor, en tegelijkertijd bedankt!  
Filip, het nieuwste personeelslid van onze vakgroep! En onmiddellijk het aanspreekpunt voor 
de hele vakgroep... Geen evidente job, maar je weet van aanpakken! Veel succes nog, 
meneer de secretaris! 
En dan ben ik aan de overkant van de gang terecht gekomen: bij de biochemici. Kristel, je 
hebt me wegwijs gemaakt in de wondere wereld van de ELISAs. Bedankt dat ik met al mijn 
vragen bij jou terecht kon, en voor je positieve kijk op alles! Koen, jouw verdediging is al een 
paar maanden achter de rug. Maar even gemotiveerd blijf je verderwerken. Veel succes nog 
met je onderzoek!  
Tijdens de afgelopen 6 jaar heb ik van veel collega’s afscheid moeten nemen. Ook zij 
verdienen uiteraard een woordje van dank!  
Nathalie, je hebt een hele tijd alles in goede banen geleid aan onze vakgroep. Bedankt dat ik 
altijd mocht binnenvallen met de meest uiteenlopende vragen! En voor het helpen 
ontcijferen van de facturen van Verdifarm ;-) Heel veel succes met je nieuwe job!  
Eva, heel kort hebben we een bureau gedeeld. Toen zat jij in de fase waarin ik me nu bevind 
. Ik ben heel blij dat mekaar nog af en toe zien tijdens onze DDD’s! Succes met de bouw en 
geniet nog samen van Elmer! 
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En dan de ex-leden van de koekjespauze... Ann O., daar stonden we op 1 september 2009: 
klaar om aan ons doctoraatsonderzoek te beginnen. Lang geleden, en toch lijkt het als 
gisteren! Ik mis in ieder geval de ritjes met de vrachtwagen ;-) Joline en Anja, een 
superteam! Bedankt om de stalmomenten zo aangenaam te maken! Jella, succes met de 
sollicitatie binnenkort! ;-) Donna, bedankt voor de leuke babbels! Ik kan nog wat leren van 
jouw directheid: “Pas!” ;-) Virginie, mijn grote voorbeeld voor de toxicologie. Bedankt voor 
de fijne samenwerking!  
Sandra, jouw doctoraat heb ik nog vaak in mijn handen gehad! LPS was inderdaad een 
uitdagende molecule...  
Maggy, ik zie je nog elke ochtend langs onze deur passeren, met de bijbehorende, 
welgemeende “goeiemorgen”! Jouw passie voor de toxicologie was inspirerend! Geniet nog 
van je pensioen! 
Jolien en Laurence, bedankt voor jullie bijdrage aan dit werk! Ik wens jullie veel geluk in jullie 
verdere carrière! Dankjewel ook aan alle studenten die meegeholpen hebben met de 
dierproeven, voor jullie hulp met de katheters, en de goede zorgen voor de kalfjes!  
Dan zijn er nog de 60 kalfjes die ik zeker niet mag vergeten te bedanken voor hun 
medewerking aan dit doctoraat! Mijn oprechte excuses dat ik jullie eruit gepikt heb... Graag 
wil ik dan ook mijn cover aan jullie opdragen!  
En dan wil ik nog iedereen bedanken die me vanaf de zijlijn heeft bijgestaan tijdens het tot 
stand komen van dit boekje! Meer in het bijzonder zijn dit de volgende personen: 
Vanessa, bedankt voor het beantwoorden van al mijn (kalver-gerelateerde) vragen, vaak op 
de meest onmogelijke momenten! Veel succes met je praktijk! 
Delphine, Emily, Kaat, Kim R., Kim VDW en Kristel, bedankt voor de vele diergeneeskundige 
reünies! Ik kijk alvast uit naar de volgende! Kim R., binnenkort nog eens tijd voor een lunch 
in Merelbeke? ;-) 
Tine, Ralph, Linde, Katleen, Sofie, Kris en Gert, ook al heeft de afstand Bree-Wetteren ervoor 
gezorgd dat we minder kunnen afspreken, ik ben blij dat we dit toch nog geregeld doen! 6C 
& friends zijn OK! ;-) 
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Michelle, mijn beste vriendinneke . Ook al zien me mekaar niet zo meer vaak, het is nog 
steeds zoals vroeger! Bedankt voor al je steun, en voor de heerlijke wandelingen met Cocky 
en vriendin! Volgende afspraak in september! 
Godfried en Ingrid, heel erg bedankt voor jullie hulp en voor de goede zorgen voor Mathieu 
de afgelopen weekends! Kevin en Jessie, ik heb genoten van onze reis naar Andalusië vorig 
jaar! Het was een goede ontspanning voor dit alles echt begon! En Jessie, binnenkort is het 
aan jou! Veel succes nog met je doctoraat! 
Oma, altijd zo bezorgd... Bedankt voor al de kaarsjes die je voor me hebt gebrand! Ze 
hebben geholpen! 
Jan, mijn grote broer!  Ik ben heel blij dat me mekaar de laatste jaren meer zien! Bedankt 
voor de gezellige momenten! Mathieu kijkt er alvast naar uit om mee met Nomi te gaan 
wandelen! 
Ben, mijn “kleine” broer, en Heleen, bedankt voor jullie bezoekjes de afgelopen maanden! 
Anders hadden we mekaar waarschijnlijk niet zoveel gezien... Ik wens jullie nog heel veel 
geluk samen, met mooie reizen en zoveel meer! 
Mama en papa, jullie hebben me ongelooflijk gesteund de voorbije jaren, om dan nog te 
zwijgen van de laatste maanden! Ik weet niet hoe ik jullie hiervoor ooit moet bedanken... 
Wel ben ik heel fier dat ik hier vandaag mijn onderzoek aan jullie mag voorstellen, dat in 
feite een mix is van jullie levens!   
En dan natuurlijk nog mijn 2 mannen... Sven, je hebt véél van mij moeten verdragen de 
laatste jaren/maanden... Gelukkig was je daar altijd met je humor om me toch te doen 
lachen op de meest moeilijke momenten . Je betekent zó veel voor mij! Mathieu, mijn 
kleine, vrolijke schat, je bent nog maar zo kort in ons leven, en het is met geen woorden te 
beschrijven hoe graag we jou zien! Bedankt ook om te wachten tot 28 februari om geboren 
te worden, zodat je mama dit boekje al grotendeels kon afwerken . Nu kijk ik er naar uit 
om met ons drietjes verder de wijde wereld in te trekken... 
Bedankt! 
Elke 
